M1 and M4 Muscarinic Acetylcholine Receptor Regulation of Neurotransmission and Cell Excitability in Rodent Hippocampus and Prefrontal Cortex by Shirey-Rice, Jana Kristin
M1 AND M4 MUSCARINIC ACETYLCHOLINE RECEPTOR REGULATION OF 
NEUROTRANSMISSION AND CELL EXCITABILITY IN RODENT               
HIPPOCAMPUS AND PREFRONTAL CORTEX 
By 
 
Jana Kristin Shirey-Rice 
 
Dissertation 
Submitted to the Faculty of the 
Graduate School of Vanderbilt University 
in partial fulfillment of the requirements 
for the degree of 
 
DOCTOR OF PHILOSOPHY 
in 
Pharmacology 
May, 2010 
Nashville, Tennessee 
Approved: 
                                                 Professor P. Jeffrey Conn 
                                                 Professor Ariel Y. Deutch 
                                                 Professor Danny G. Winder 
                                                 Professor C. David Weaver 
ABSTRACT 
 
 Muscarinic acetylcholine receptors (mAChRs), specifically M1 and M4 subtypes, 
provide viable targets for the treatment of multiple central nervous system disorders. 
However, highly selective activators of either M1 or M4 have not been available, making 
it difficult to determine the in vivo effects of selective activation of these receptors.  We 
have used cheminformatics and medicinal chemistry to develop new, highly selective M1 
and M4 positive allosteric modulators (PAMs). VU10010 potentiated the functional M4 
response to acetylcholine while having no activity at other mAChR subtypes.  Whole-cell 
patch clamp recordings revealed that VU10010 increased carbachol-induced depression 
of transmission at excitatory but not inhibitory synapses at the Schaffer collateral-CA1 
(SC-CA1) synapse in the hippocampus.  Chemical optimization of VU10010 afforded 
two centrally penetrant analogs, VU0152099 and VU0152100, which are also potent, 
selective M4 PAMs. Interestingly, these compounds reversed amphetamine-induced 
hyperlocomotion in rats, a model that is predictive of clinical antipsychotic efficacy in 
humans.   
 A growing body of literature also supports M1 receptors as a viable target for 
treatment of disorders involving impaired cognitive function.  Data in this thesis reports 
the molecular characterization of a novel compound, BQCA, which is a potent, highly 
selective PAM of the rat M1 receptor.  BQCA induced a robust inward current and 
increased spontaneous EPSCs in mPFC layer V pyramidal cells, effects which were 
absent in acute slices from M1 receptor knockout mice.  Furthermore, multiple single-unit 
recordings were obtained from the mPFC of rats which showed that BQCA increased 
ii 
 
firing of pyramidal cells in vivo.  BQCA also restored discrimination reversal learning in 
a transgenic mouse model of AD and regulated non-amyloidogenic APP processing in 
vitro. 
 Together, these studies provide compelling evidence while M4 inhibits excitatory 
transmission at the SC-CA1 synapse, M1 receptor activation induces a dramatic excitation 
of PFC neurons.  Newly developed highly selective ligands that activate or potentiate M1 
and M4 provide exciting tools that will be useful in further delineating the individual roles 
of these receptors in the efficacy of drugs like acetyl cholinesterase inhibitors and 
xanomeline. 
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CHAPTER I 
 
INTRODUCTION 
 
Cholinergic biosynthesis and neuroanatomy 
 A detailed understanding of cholinergic synthesis and neurotransmission is now 
available as a result of diverse research techniques, including biochemical analysis, 
molecular genetics, and microscopy (Fig. 1) (Krnjevic, 1969; Csillik, 1975).  In the 
presynaptic terminal, acetylcholine (ACh) is synthesized from its precursors acetyl 
coenzyme A (acetyl CoA) and choline by the enzyme choline acetyltransferase (ChAT). 
ACh is packaged into synaptic vesicles by the vesicular acetylcholine transporter 
(VAChT) and subsequently released into the synaptic cleft.  Synaptic vesicles containing 
the neurotransmitter can bind and activate pre- and post-synaptic acetylcholine receptors 
only for a brief time until it is degraded by acetylcholinesterase (AChE).  Following 
degradation, the precursor choline is taken up into the presynaptic axon terminal by a 
high affinity choline transporter (CHT). This reuptake process is the rate limiting step in 
acetylcholine biosynthesis. 
Cholinergic nuclei in the basal forebrain, a group of structures in the medial and 
ventral telencephalon, contain large numbers of neurons that project to the hippocampus, 
amygdala, and cerebral cortex and provide the majority of cholinergic innervation to 
these areas (Mufson et al., 2000).  The basal forebrain is divided into several distinct 
regions that send bundles of axons to their respective targets.  Projection cholinergic 
neurons in the medial septum and the diagonal band of Broca project to the hippocampus, 
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while neurons in the nucleus basalis of Meynert project broadly to the neocortex as well 
as to the amygdala.  These cholinergic projections provide one of the most crucial 
neuromodulatory inputs to the forebrain in humans and other mammals. Cholinergic 
interneurons in the striatum also release ACh within local circuits where muscarinic 
receptors modulate the activity of medium spiny neurons.  Cholinergic neurons are 
distinguished among other features by the presence of ChAT, the enzyme that is 
responsible for ACh biosynthesis these neurons. 
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Figure 1.  Schematic model of cholinergic biosynthesis and neurotransmission in the 
central nervous system.  Acetylcholine (ACh) is synthesized in presynaptic nerve 
terminals by the enzyme choline acetyltransferase (ChAT), packaged into synaptic 
vesicles by the vesicular acetylcholine transporter (VAChT), and released into the 
synaptic cleft. Intact ACh can bind and activate nicotinic and muscarinic acetylcholine 
receptors on both pre- and post-synaptic membranes until it is degraded by the enzyme 
acetylcholinesterase (AChE). The biosynthetic precursor choline is then taken up into the 
presynaptic terminal by the high affinity choline transporter (CHT) with choline reuptake 
being the rate-limiting step in ACh synthesis. 
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Acetylcholine Receptors 
 ACh, the first neurotransmitter to be identified, activates two families of receptors 
that mediate its action in target tissues: nicotinic receptors, which function as ligand-
gated cation channels that participate in rapid postsynaptic neurotransmission, and 
muscarinic receptors (mAChR), which are members of family A G-protein coupled 
receptors (GPCRs) and play a role in modulating the activity of many circuits within the 
CNS.  These two classes of receptor families were originally named for their specific 
activation by nicotine and muscarine, respectively, but have been extensively 
characterized since that time on a molecular basis.  This thesis will focus on muscarinic 
acetylcholine receptor subtypes.  The diversity and complexity of muscarinic cholinergic 
signaling is facilitated in part by five distinct receptor subtypes, M1-M5, the genes for 
which were cloned in the mid to late 1980s (Bonner et al., 1987; Peralta et al., 1987; 
Bonner et al., 1988).  These intronless genes encode muscarinic receptor proteins that 
have the typical structural features of the seven transmembrane helix GPCR superfamily, 
the largest family of cell-surface receptors and key regulators of a wide variety of 
physiological processes (Lefkowitz, 2007).  In general, when the receptor is activated 
GDP is converted to GTP on the G protein resulting in its dissociation from the receptor.  
Subsequently, the G protein dissociated into α and βγ subunits, which both activate 
downstream signaling cascades. 
 
Muscarinic acetylcholine receptor subtypes, signaling, and function  
 The five receptor subtypes are highly homologous in the ACh binding domain; 
their signaling properties are quite different, however.  M1, M3, and M5 preferentially 
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couple to Gαq proteins to activate phospholipase C (PLC) and cause a subsequent release 
of calcium from intracellular stores as well as an increase in phosphatidylinositol 
turnover and activation of protein kinase C (PKC) (Wess, 1996).  The major mechanism 
of calcium release from endoplasmic reticulum stores in CA1 pyramidal neurons is via 
production of inositol 1,4,5-triphosphate (IP3) induced by mAChR activation.  In addition 
M1, M3 and M5 receptors have also been shown to activate phospholipase A2 (PLA2), 
phospholipase D (PLD) and tyrosine kinases (Wess, 1996).  M2 and M4 receptors couple 
predominantly to Gαi/o proteins to inhibit adenylate cyclase and cause a decrease in cyclic 
AMP levels.  Activation of Giβγ subunits by M2 and M4 subtypes also modulate a variety 
of ionic channels including voltage-gated calcium channels as well as inwardly rectifying 
potassium channels.  All subtypes of muscarinic receptors have been shown to activate 
extracellular signal related kinase (ERK), a signaling protein involved in cell growth, 
differentiation and survival (Hulme (a) et al., 2003). 
In situ hybridization experiments following the cloning of mAChR subtype genes 
revealed that individual subtypes were expressed in partially overlapping tissues, with 
some regions, including the hippocampus, expressing all five mAChR subtypes (Buckley 
et al., 1988; Weiner et al., 1990).  A series of studies using subtype-selective antibodies 
has illustrated the distinct neuroanatomical localization of the mAChR subtypes in brain 
and have provided important clues as to their function in neural circuits (Levey et al., 
1991; Mrzljak et al., 1993; Levey et al., 1994; Hersch and Levey, 1995; Levey et al., 
1995b; Rouse and Levey, 1996; Rouse et al., 1998; Rouse et al., 2000b). 
 The M1 receptor is expressed at very high levels in multiple brain regions 
including cortex, hippocampus, and striatum (Wess, 2003).  In the cortex, M1 is localized 
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to pyramidal cells and is prominent in the neuropil of layers II/III and VI (Levey et al., 
1991).  M1 is expressed broadly throughout the hippocampus, including in pyramidal 
neuron cell bodies and dendritic processes in the stratum radiatum and stratum oriens, 
and in the molecular layer and granule cells of the dentate gyrus (Levey et al., 1995b).  In 
the striatum, M1 is found in the majority of dopamine-2 receptor (D2)-expressing medium 
spiny neurons as well as in the neuropil.  At the electron microscopy level, M1 can be 
visualized at the postsynaptic density of asymmetrical synapses, suggesting a role in 
modulating excitatory neurotransmission (Hersch et al., 1994).  Studies using knockout 
mice have suggested a role for M1 in learning and memory, and it has been demonstrated 
that M1 potentiates NMDA receptor currents (Marino et al., 1998) and is the sole mAChR 
responsible for muscarinic activation of extracellular signal-regulated kinase (ERK 1/2) 
in the hippocampus, a protein involved in synaptic plasticity (Berkeley et al., 2001; 
Hamilton and Nathanson, 2001).  M1 knockout mice are less susceptible to pilocarpine-
induced seizures and have a phenotype that is similar to that seen in animal models of 
psychosis, including hyperactivity, increased dopamine release, and a heightened 
response to amphetamine (Gerber et al., 2001; Miyakawa et al., 2001).  Interestingly, M1 
knockout mice perform as well as their wild-type littermates in the Morris water maze, a 
paradigm commonly used to assess hippocampal-dependent spatial memory; however, 
performance was impaired under certain experimental conditions in the eight-arm radial 
maze and in fear conditioning studies (Miyakawa et al., 2001).  These animals only 
exhibited a mild reduction in hippocampal long-term potentiation (LTP), an 
electrophysiological phenomenon associated with learning and memory (Anagnostaras et 
al., 2003).  The profound hyperactivity phenotype of these animals (Gerber et al., 2001; 
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Miyakawa et al., 2001) makes it unclear whether some of the behavioral impairments are 
actually due to cognitive impairments.  This caveat aside, M1-/- mice display significant 
impairments in non-matching-to-sample working memory and consolidation 
(Anagnostaras et al., 2003), implicating these receptors in cortical memory function and 
tasks requiring prefrontal cortical signaling (Hamilton and Nathanson, 2001).  Based on 
these studies using genetically altered mice as well as a growing body of clinical and pre-
clinical data, the M1 receptor subtype is viewed as one of the most exciting therapeutic 
targets for the treatment of neurological disorders such as Alzheimer’s disease (AD) and 
schizophrenia (Fisher, 2008b; Conn et al., 2009b). 
 M2 is the most widespread mAChR subtype in brain; it is expressed 
predominantly on presynaptic terminals and has been shown to function as an 
autoreceptor controlling ACh release in the hippocampus and cerebral cortex but not in 
striatum (Zhang et al., 2002a).  M2 has a distinct laminar distribution in the cortical 
neuropil of layer IV and the junction between layers V/VI, and is also present on 
interneuron cell bodies (Levey et al., 1991).  Close inspection revealed that M2 is 
expressed both pre-and post-synaptically (Mrzljak et al., 1993).  In the hippocampus, M2 
localizes to discrete bands of cell bodies and processes along the oriens/alveus border, 
and is also found in processes along the pyramidal cell layer, most prominently in the 
CA3 region (Levey et al., 1995b).  There is a high expression level of M2 in the basal 
forebrain, in both cholinergic and noncholinergic cells, as well as in the neuropil (Levey 
et al., 1995a).  M2 also mediates parasympathetic decreases in the force of contraction 
and in the rate of cardiac contraction by inhibiting voltage-gated calcium channels and 
activating inwardly rectifying potassium channels (Caulfield and Birdsall, 1998).  Studies 
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in M2 knockout mice have demonstrated a physiological role for this protein in 
locomotion, regulation of body temperature, and response to pain (Gomeza et al., 2001).  
These mice have deficits in behavioral flexibility and working memory as well as in 
passive avoidance (Seeger et al., 2004; Tzavara et al., 2004). 
 The M3 receptor is expressed at relatively low levels in brain, accounting for only 
5-10% of total mAChRs in various brain regions (Levey et al., 1994).  By 
immunohistochemistry, M3 can be seen to localize to multiple brain regions, including 
cortex, hippocampus, olfactory bulb, amygdala, striatum, thalamus, and pons.  
Subcellularly, M3 appears in cell bodies and proximal dendrites, suggesting a 
postsynaptic localization, and also as a diffuse, punctate reaction product in the neuropil 
that may reflect presynaptic terminals or dendritic processes.  In the CNS, M3 helps 
regulate the release of several neurotransmitters, including dopamine in the striatum, 
GABA and glycine in the dorsal horns of the spinal cord, and endocannabinoids (Zhang 
et al., 2002a; Ohno-Shosaku et al., 2003; Zhang et al., 2006; Zhang et al., 2007).  Studies 
in M3 knockout mice have also implicated this subtype in multiple peripheral and 
autonomic functions, including arterial vasodilation, insulin release, glandular secretion 
(including salivation), weight gain, and smooth muscle contraction in the stomach, 
trachea, and urinary bladder (Matsui et al., 2000; Yamada et al., 2001b; Duttaroy et al., 
2004; Khurana et al., 2004).  It is believed that activation of peripheral M3 receptors leads 
to severe side effects such as excess salivation and GI distress induced by cholinergic 
agonists and AChE inhibitors used to treat AD. 
 The M4 receptor is expressed at somewhat lower levels than other mAChR 
subtypes in cortical laminae, and is localized to discrete layers in the hippocampus, 
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including the stratum radiatum and stratum oriens in CA1 and the inner molecular layer 
of the dentate gyrus.  In the striatum where M4 is most highly expressed, dense patches of 
receptor expression are observed that correspond to postsynaptic sites on medium spiny 
neurons.  Analogous to the autoinhibitory role that M2 plays in the hippocampus and 
cortex, M4 is the major autoreceptor in the striatum responsible for feedback regulation of 
ACh release from the presynaptic terminal (Zhang et al., 2002b).  M4 has been shown to 
participate in regulating dopaminergic signaling and release, and M4 knockout mice show 
increased basal and dopamine-regulated locomotor responses (Gomeza et al., 1999; 
Zhang et al., 2002a).  These animals are hypersensitive to agents that disrupt prepulse 
inhibition of the acoustic startle response, a measure of sensorimotor gating which is also 
disrupted in schizophrenic patients (Felder et al., 2001).    In vivo microdialysis studies 
revealed that M4 knockout mice also have elevated basal dopamine levels in the nucleus 
accumbens and that these mice show heightened dopamine efflux in response to 
psychostimulants like D-amphetamine and phencylidine (Tzavara et al., 2004).     
            Levels of the M5 receptor approach the lower limits of specific detection in brain 
as determined by quantitative immunoprecipitation and immunohistochemistry, although 
M5 mRNA is detectable in multiple brain tissues.  M5 knockout mice have revealed roles 
for M5 in dilation of cerebral blood vessels and in reward and reinforcement behaviors, 
specifically in response to drugs of abuse such as morphine and cocaine (Yamada et al., 
2001a; Basile et al., 2002; Thomsen et al., 2005).  Further support for the role of M5 in 
drug addiction came with the finding that these animals exhibit less severe withdrawal 
symptoms after chronic morphine exposure as well as decreased cocaine conditioned 
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place preference and reduced acute cocaine self-administration (Fink-Jensen et al., 2003; 
Thomsen et al., 2005).  
 
Muscarinic regulation of hippocampal physiology and function 
The hippocampus is a key cortical structure that plays an important role in a 
number of normal physiological processes, including processing of complex spatial and 
temporal patterns and formation of short- and long-term memory.  In addition, the 
hippocampus is a primary site of pathology in certain neurological disorders, such as AD 
and temporal lobe epilepsy.  Because of this, much effort has been directed at developing 
a detailed understanding of the synaptic organization of the hippocampus as well as the 
cellular mechanisms involved in regulation of synaptic transmission in this structure (see 
(Brown and Zador, 1990) for review).  Glutamate is the primary neurotransmitter at each 
of the three major excitatory synapses in the hippocampal formation.  In addition, 
neuromodulators from extrinsic afferents (ie. acetylcholine, serotonin, norepinephrine) 
regulate transmission through the hippocampus by activating GTP-binding protein-linked 
receptors.  Regulation of hippocampal function by these neuromodulators dramatically 
influences net transmission through the hippocampus and participates in a variety of 
different physiological and pathological conditions. 
The hippocampus is commonly viewed as a relatively simple circuit consisting of 
three major excitatory synapses.  The primary input to the hippocampus is from the 
entorhinal cortex which sends excitatory afferents to the dentate gyrus (DG) via the 
perforant path; the entorhinal cortex collects polymodal information from other cortical 
areas and relays this information to dentate granule cells.  Mossy fibers from the dentate 
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granule cells project to area CA3 of the hippocampus which in turn sends afferents via 
the Schaffer collateral to hippocampal area CA1.  Afferents from CA1 pyramidal cells 
then provide the major output of the hippocampus. Each subregion of the hippocampus 
also has intrinsic circuits and connections within (associational) and between 
(commissural) hippocampi.  Glutamate is the excitatory neurotransmitter at each of the 
three major excitatory synapses in the hippocampal formation.  In addition, 
neuromodulators from extrinsic afferents (ie. acetylcholine, serotonin, norepinephrine) 
regulate transmission through the hippocampus by activating GTP-binding protein-linked 
receptors.  Regulation of hippocampal function by these neuromodulators dramatically 
influences net transmission through the hippocampus and participates in a variety of 
different physiological and pathological conditions. 
 One of the major neuromodulatory inputs to the hippocampus is a large bundle of 
cholinergic projections from the medial septum and the diagonal band of Broca (Brown 
and Zador, 1990), and these cholinergic projections make synaptic contact with 
widespread but highly specific targets in the hippocampus.  A large number of animal 
and human studies suggest that cholinergic projections to the hippocampus play a critical 
role in memory and attention mechanisms.  For instance, blockade of muscarinic 
receptors or lesions of the septo-hippocampal projections produce memory and 
attentional deficits (Drachman and Leavitt, 1974; Bartus et al., 1982; Dekker et al., 1991; 
Fibiger et al., 1991; Nilsson et al., 1992; Callahan et al., 1993).  Also, the theta rhythm, 
an electroencephalographic measure of the arousal response in the hippocampus which 
may be involved in attention and filtering of sensory information, is regulated by 
cholinergic septal input and can be induced by muscarinic agonists and abolished by 
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muscarinic antagonists (Colom et al., 1991; Vinogradova et al., 1993).  Furthermore, 
abundant evidence suggests that the clinical syndrome associated with AD results, at least 
in part, from failed neurotransmission at cholinergic synapses in the hippocampus and 
neocortex.  The basal forebrain neurons that provide the majority of cholinergic 
innervation of the neocortex and hippocampus degenerate with AD (Whitehouse et al., 
1982; Arendt et al., 1983) and this is accompanied by a depletion of presynaptic 
cholinergic markers in these brain regions (Bowen et al., 1976; Davies and Maloney, 
1976; Perry et al., 1978; Whitehouse et al., 1982).  Furthermore, lesions of basal 
forebrain neurons or pharmacological blockade of muscarinic receptors, experimentally 
in animals (Dunnett, 1985; Dekker et al., 1991; Fibiger, 1991; Voytko et al., 1994) or 
naturally in humans (Drachman and Leavitt, 1974; Drachman, 1977; Bartus et al., 1982; 
Damasio et al., 1985), impairs learning, memory, and attention.  Evidence suggests that 
cholinergic transmission in the hippocampus is mediated primarily by mAChRs and 
thatthese receptors are likely to mediate the cholinergic involvement in learning and 
memory (Coyle et al., 1983; Brown and Zador, 1990; Fibiger, 1991). 
 
Electrophysiological effects of mAChR activation in the hippocampus 
 Multiple mAChR subtypes are expressed in the hippocampus (Hulme et al., 1990; 
Caulfield, 1993; Levey et al., 1995b) where they are involved in regulating various 
aspects of hippocampal physiology.  Early studies showed that mAChR activation 
induces a number of direct excitatory effects on hippocampal pyramidal cells and reduces 
both excitatory (Hounsgaard, 1978; Segal, 1982; Dutar and Nicoll, 1988; Sheridan and 
Sutor, 1990; Williams and Johnston, 1990; Burgard et al., 1993) and inhibitory (Krnjevic 
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et al., 1981; Bilkey and Goddard, 1985) synaptic transmission in the hippocampus.  
Another well characterized electrophysiological effect of muscarinic receptor activation 
in hippocampal pyramidal cells using the intracellular recording technique is a slow post-
synaptic potential (Cole and Nicoll, 1984a); repetitive electrical stimulation of 
cholinergic fibers terminating in stratum oriens evokes a series of membrane potential 
changes.  First is a series of fast excitatory postsynaptic potentials (EPSPs) followed by 
an inhibitory postsynaptic potential (IPSP); these are followed by a slow EPSP that lasts 
on the order of 20-30 seconds.  The slow EPSP could be induced by ionophoretic 
application of ACh and was blocked by atropine and was dependent on action potential 
firing and calcium (Cole and Nicoll, 1984a).   
 Muscarinic receptors modulate a large number of ionic conductances in pyramidal 
neurons through both direct and indirect biochemical interactions; the conductances 
known to be modulated by mAChRs in hippocampal pyramidal cells include several 
potassium currents (IM, the muscarine sensitive K+ current; IAHP, the Ca2+-activated K+ 
current underlying spike frequency adaptation; Ileak, the background leak current) 
(Halliwell, 1990).  Exogenously applied muscarinic agonists induce a pronounced 
membrane potential depolarization and increased membrane resistance (Cole and Nicoll, 
1984b), and direct electrical stimulation of cholinergic afferents in the hippocampus 
causes a similar mAChR-dependent membrane potential depolarization (Segal, 1982; 
Cole and Nicoll, 1984b; Madison et al., 1987; Pitler and Alger, 1990; Morton and Davies, 
1997).  This response often results in a sustained action potential discharge, in part 
arising from a pronounced reduction in spike frequency adaptation (Cole and Nicoll, 
1984b).  Activation of mAChRs increases cell firing and depresses the IAHP that is due to 
14 
 
a calcium-activated potassium conductance, as mentioned above.  It is thought that this 
conductance, at least in part, is responsible for a dampening of action potential discharge 
during depolarizing current injections.  These excitatory effects of ACh are mediated by 
mAChRs because they are completely blocked by atropine, a non-selective muscarinic 
antagonist, but not by nicotinic antagonists.  mAChR activation also potentiates two 
mixed cation currents (Ih, the hyperpolarization-activated cation current; Icat, the Ca2+-
dependent non-specific cation current) (Halliwell, 1990; Colino and Halliwell, 1993) and 
modulates the activity of both voltage-dependent Ca2+ currents and several ligand-gated 
receptors including N-methyl-D-aspartate (NMDA) receptors (Markram and Segal, 
1990b, a, 1992; Harvey et al., 1993; Marino et al., 1998; Sur et al., 2003).  In addition, 
mAChR agonists increase pyramidal cell excitability indirectly by reducing GABA-
mediated synaptic inhibition (Krnjevic et al., 1981; Bilkey and Goddard, 1985).  
Presynaptically, activation of mAChRs inhibits excitatory afferents, reducing the release 
of glutamate through inhibition of voltage-gated calcium channels (Qian and Saggau, 
1997; Fernandez de Sevilla et al., 2002; Fernandez de Sevilla and Buno, 2003).  More 
recently, muscarinic agonists have also been shown to inhibit L-type calcium currents in 
superior cervical ganglion (SCG) neurons (Liu et al., 2006) and enhance R-type, but not 
T-type, Ca2+ currents in hippocampal CA1 pyramidal neurons, an effect that required 
PKC activation (Tai et al., 2006). 
 Subsequent studies examining specific mAChR subtypes involved in some of 
these electrophysiological effects have shown that depolarization of hippocampal 
pyramidal neurons is likely mediated, at least in part, by the M1 receptor subtype as 
inward currents recorded in voltage clamp mode from CA3 pyramidal cells were 
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markedly reduced in M1 knockout mice as compared to wild-types (Fisahn et al., 2002).  
The muscarinic potentiation of ICAT contributes to the depolarization of pyramidal 
neurons.  Muscarine caused an increase in magnitude of Ih in wild-type but not M1 
knockout mice, indicated that the M1 subtype is responsible for this effect in CA3 cells; 
conversely, there was no effect of muscarinic agonists on IM in the M1 knockout 
supporting data by Rouse et al. (Rouse et al., 2000a) indicating a lack of M1 modulation 
of this current in CA1 pyramidal cells. 
 
Muscarinic modulation of GABAergic transmission in the hippocampus  
 Extrahippocampal γ-aminobutyric acid  (GABA)ergic afferents originating from 
the medial septum and diagonal band of Broca innervate the hippocampus and target 
solely hippocampal interneurons and cholinergic afferents which in turn target both 
pyramidal cells and interneurons (Frotscher and Leranth, 1985).  Acetylcholine is a 
powerful presynaptic modulator of synaptic transmission at both excitatory glutamatergic 
and inhibitory GABAergic synapses with modulation being both cell type and pathway 
specific. Furthermore, GABAergic interneurons can inhibit cholinergic release 
presynaptically through GABAB receptors (Morton et al., 2001).  The role of mAChRs in 
modulating activity of GABAergic inhibitory neurons is complex; studies have shown 
that mAChR activation of individual interneurons in the hippocampus yields differential 
effects on resting membrane potential (McQuiston and Madison, 1999a, b).  Among 
several subpopulations of GABAergic interneurons, muscarinic receptor activation 
produces a pure hyperpolarizing response, a biphasic response in which an initial 
hyerpolarization is followed by a secondary depolarizing phase, a slow membrane 
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potential oscillatory response, or no response.  Immunocytochemical findings suggested 
cell type-specific localization of mAChRs in different subtypes of interneurons (Levey et 
al., 1995b) which likely explains the variable muscarinic effects observed in these cells.  
This diversity of interneuron responses also likely reflects a highly heterogeneous 
population of GABAergic interneurons with respect to their connectivity and 
neurochemistry.  A more recent study investigated mAChR function in a morphologically 
identifiable class of stratum oriens interneurons, the stratum oriens-lacunosum moleulare 
(O-LM) interneurons; they exhibit a muscarinic-induced afterdepolarization that is 
associated with the inhibition of several potassium conductances and the activation of 
ICAT (Lawrence et al., 2006).  In these interneurons, muscarine abolished the 
afterhyperpolarization (AHP) current and induced a switch in firing frequency from 
accommodating to accelerating during the depolarizing current injection.  The AHP was 
replaced by a prominent afterdepolarization in the presence of muscarine.  In another set 
of cells that exhibited strong spike frequency accommodation and broad rebound spikes, 
mAChR activation was accompanied by a reduction in input resistance and shunting of 
firing.  Finally, muscarinic receptor activation increases the frequency and amplitude of 
spontaneous IPSCs but depresses monosynaptically evoked IPSCs and the frequency of 
miniature IPSCs (Behrends and ten Bruggencate, 1993). 
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NMDAR modulation by mAChRs 
 As previously stated, one of the most prominent effects of mAChR activation in 
the hippocampus and other forebrain regions is potentiation of currents through the 
NMDA subtype of ionotropic glutamate receptor (Markram and Segal, 1990b; Harvey et 
al., 1993; Calabresi et al., 1998; Marino et al., 1998; Lu et al., 1999; Marino and Conn, 
2002).  The M1 receptor likely enhances currents through NMDARs through a PKC-
dependent activation of the non-receptor tyrosine kinase (Src) signaling cascade 
(Calabresi et al., 1998; Lu et al., 1999).  The NMDA receptor plays a critical role in 
regulating hippocampal and cortical function and is thought to be important for the 
cognition-enhancing and attention-promoting effects of mAChR activation.  In addition, 
the NMDA receptor may play an important role in regulation of circuits that are disrupted 
in schizophrenia and other psychotic disorders (Coyle et al., 2002; Marino and Conn, 
2002; Tsai and Coyle, 2002).  Competitive and non-competitive antagonists of the 
NMDA receptor can induce a psychotic state that closely resembles that seen in 
schizophrenic patients.  Furthermore, co-agonists at the NMDA receptor, such as glycine 
and D-cycloserine produce improvements in the symptoms of schizophrenic patients.  
Thus, a large number of clinical and animal studies have led to the hypothesis that 
potentiation of NMDA receptor currents in these regions could have an antipsychotic 
action.  Based on this, it is possible that mAChR-induced potentiation of NMDA receptor 
function plays important roles in the therapeutic efficacy of mAChR activation in 
psychotic disorders. 
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Presynaptic M2 and M4 receptors may regulate excitatory and inhibitory synaptic 
transmission 
   
 Many studies have indicated that mAChR-induced reduction of transmission at 
excitatory synapses in the hippocampus is mediated presynaptically.  Based on early 
immunocytochemical studies, the most likely mAChRs involved in the presynaptic 
actions of mAChR agonists are M2 and M4 since both of these receptors are 
predominantly localized presynaptically in each major subsector of the hippocampus.  
Consistent with this, a large body of research suggests that presynaptic receptors involved 
in regulating neurotransmitter release are often coupled to inhibition of adenylyl cyclase, 
and M2 and M4 both couple to this effector system.  While both M2 and M4 are localized 
presynaptically, M2 immunoreactivity is not present in granule cells and pyramidal cells, 
but is highly localized in inhibitory interneurons (Levey et al., 1995b).  Since dentate 
granule cells and CA3 pyramidal cells provide the majority of excitatory input to areas 
CA3 and CA1 respectively, this makes M4 a more likely candidate for the mAChR 
involved in regulating glutamate release. In contrast, if M2 is localized on presynaptic 
terminals of inhibitory interneurons, M2 would be in an ideal position for regulating 
GABA release and thereby reducing GABA-mediated synaptic inhibition. 
 One mechanism of presynaptic inhibition of neurotransmitter release involves the 
modulation of presynaptic calcium channels that are involved in vesicle fusion and 
release.  Early indirect (Valentino and Dingledine, 1981) and more recent studies have 
shown that muscarinic inhibition of synaptic transmission in the hippocampus is 
presynaptic and relies at least in part on muscarinic blockade of N-type and P/Q-type 
voltage dependent calcium channels at the SC-CA1 synapse (Qian and Saggau, 1997) and 
in the associational-commissural fiber system of CA3 (Vogt and Regehr, 2001).  
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Activation of mAChRs with carbachol (CCh), a muscarinic agonist, increases the paired-
pulse facilitation index of evoked EPSCs at CA1 synapses and also decreased the 
coefficient of variation ratio, indicating that CCh inhibits synaptic transmission via 
activation of presynaptic mAChRs which causes a reduction in the reliability of 
glutamate release (Fernandez de Sevilla et al., 2002).  Electrical stimulation of 
cholinergic terminals in stratum oriens/alveus also causes a decrease in evoked CA1 
EPSCs by presynaptically inhibiting glutamate release via activation of mAChRs as 
indicated by parallel changes in PPF index and EPSC variance (Fernandez de Sevilla and 
Buno, 2003).  Although ACh has been shown to suppress excitatory transmission at 
mossy fiber synapses in CA3 through modulation of GABAB receptor activity (K. E. 
Vogt and W. G. Regehr, 2001), presynaptic inhibition at CA1 seems to be independent of 
GABAergic transmission (Kremin et al., 2006).  Although experiments to confirm a 
presynaptic mechanism of action were not carried out, we have found that selective 
potentiation of M4 receptors with the PAM VU10010 enhances muscarinic depression of 
evoked excitatory but not inhibitory postsynaptic currents in CA1 neurons (Chapter 
IIIa).  
 
Role of muscarinic cholinergic signaling in hippocampal LTP  
 Of particular relevance to issues of synaptic plasticity, mAChR activation 
enhances agonist-evoked currents through the NMDA subtype of glutamate receptor 
(Markram and Segal, 1990b; Harvey et al., 1993; Marino et al., 1998).  The NMDA 
receptor is known to play a critical role in several forms of hippocampal long-lasting 
synaptic plasticity which are thought to underlie learning and memory.  Consistent with 
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this, mAChR activation can also induce or enhance long term potentiation (LTP) of 
excitatory synaptic responses in the hippocampus (Blitzer et al., 1990; Burgard and 
Sarvey, 1990; Markram and Segal, 1990b; Abe et al., 1994; Auerbach and Segal, 1996; 
Shinoe et al., 2005).  Because long-term alterations in efficacy of glutamate transmission 
contribute to memory mechanisms (Bliss and Collingridge, 1993; Malenka and Bear, 
2004), induction of long-term synaptic changes by cholinergic receptors may underlies 
the cholinergic dependence of normal memory processing.  Furthermore, because of the 
postulated role of NMDA receptors and LTP in learning and memory, it has been 
suggested that the mAChR subtype that mediates these responses may be an excellent 
target for therapeutic agents useful in the treatment of AD.  
 Early studies using sharp microelectrodes revealed that ionophoretic application 
of ACh caused an initial reduction in EPSP amplitude followed by a gradual and long-
lasting facilitation of EPSP amplitude in CA1 pyramidal cells that was not associated 
with a change in input resistance (Markram and Segal, 1990b).  Atropine blocked both 
the suppressing and facilitating effects of ACh.  These studies also indicated that ACh 
enhanced the slow NMDA-mediated component of the EPSP and that responses to 
NMDA application in current clamp mode were also potently facilitated by both ACh and 
oxotremorine-M, a muscarinic agonist.  Muscarinic facilitation of both EPSP amplitude 
and NMDA responses were independent of changes in voltage or K+ conductances as the 
facilitation was not affected by clamping cells at resting membrane potentials or by the 
inclusion of cesium in recording electrodes. 
 Burgard and Sarvey (1990) showed a concentration-dependent ability of 
muscarine in the dentate gyrus to facilitate LTP induction by subthreshold titanic 
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stimulation (Burgard and Sarvey, 1990); Blitzer et al. (1990) demonstrated a significant 
depression of the CA1 field EPSP with high doses of CCh which, when controlled for, 
enhanced tetanus-induced LTP (Blitzer et al., 1990).  Subsequent reports indicated that 
bath application of 750 nM carbachol also induced a long-lasting (>45 min post drug 
washout) facilitation of intracellularly recorded EPSPs; muscarinic potentiation of field 
EPSPs was also seen and was dependent on CCh concentration and time of drug 
application (Auerbach and Segal, 1994).  Only with 20-minute CCh application was 
sustained LTP produced.  This phenomenon was termed LTPm and was completely 
blocked by atropine; when antagonist was added to the bath after the establishment of 
LTP, no effect was seen indicating that induction but not maintenance of LTPm was 
mediated by mAChRs.  These studies also indicated that LTPm requires involvement of 
intracellular calcium stores and protein kinases but is activity independent.  Interestingly, 
CCh still induced LTPm in the presence of the 10 µM NMDAR antagonist (2R)-amino-5-
phosphonopentanoate (APV), a concentration that did block tetanus-induced LTP, 
suggesting that the two mechanisms were somewhat divergent.   It was also demonstrated 
that 0.1 µM CCh (a concentration that did not induce LTP alone) facilitated LTP caused 
by a subthreshold titanic stimulus and that LTPm and tetanus-induced LTP were mutually 
occlusive phenomena.  Therefore, the mechanisms of LTPm and tetanus-induced LTP 
seemed to converge at a point downstream of NMDA receptor activation (Auerbach and 
Segal, 1994).  LTPm was later shown to not be accompanied by a change in the size of the 
afferent fiber volley or by a change in paired-pulse potentiation, consistent with a 
postsynaptic locus of CCh action (Auerbach and Segal, 1996).  Intracellular recordings 
from CA1 pyramidal cells in voltage clamp mode revealed that 0.5 µM CCh transiently 
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potentiated NMDA responses but that responses to AMPA increased gradually and 
remained potentiated after drug washout.   
 The M1 receptor is a likely candidate for the mAChR subtype involved in the 
facilitation of LTP induction.  For instance, evidence suggests that mAChR-induced 
facilitation of LTP is mediated by a postsynaptic mechanism, and depends on the release 
of calcium from intracellular stores (Auerbach and Segal, 1994).  The M1 receptor is the 
most abundant postsynaptically localized mAChR subtype in CA1 pyramidal cells.  
Furthermore, M1 is coupled to phosphoinositide hydrolysis and activation of this receptor 
leads to release of intracellular calcium.  Thus, it seemed plausible that the mAChR-
induced facilitation of LTP induction is mediated by the M1 receptor.  Recent studies 
have indicated that M1 is indeed the subtype most likely mediating cholinergic 
modulation of synaptic plasticity in the mouse hippocampus.  Experiments focusing on 
enhancement of electrically induced LTP by low concentrations of CCh or by repetitive 
stimulation in the stratum oriens, which presumably trigger release of endogenous ACh 
from cholinergic terminals, revealed that the enhancing effect was abolished in M1 
knockout but not in M3 knockout mice (Shinoe et al., 2005).  While concentrations of 500 
nM to 5 µM CCh induced a transient depression of field excitatory postsynaptic 
potentials (fEPSPs) at the SC-CA1 synapse, 50 nM had no effect alone on fEPSPs.  This 
is in contrast to what had been reported in rat where low doses of CCh induced LTP.  
This could be a result of differences in mAChR expression and receptor density between 
species; as shown in Chapters IIIa and IV, we have also seen a difference in potency of 
CCh on various electrophysiological responses between rat and mouse.  Regardless, 
Shinoe et al. reported that 50 nM CCh significantly increased LTP elicited by high 
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frequency stimulation (HFS, 100 Hz for 1 sec) of SC afferent fibers.  Stimulation of 
stratum oriens thirty seconds prior to the HFS to cause endogenous ACh release also 
potentiated the degree of LTP.  While HFS-LTP remained intact in both M1 and M3 
knockout animals, CCh-induced enhancement of LTP was absent in only the M1 
knockout supporting a role for M1 in mediating this effect.  The same was shown to be 
true after stratum oriens stimulation (Shinoe et al., 2005). 
 One recent set of studies by Fernández de Sevilla et al. (2008) revealed that a 
brief puff of ACh applied at the apical dendritic shaft of a CA1 pyramidal cell induces a 
postsynaptic calcium elevation and LTP of excitatory postsynaptic currents (EPSCs) 
evoked by stimulation of SC-CA1 afferents.  Because changes in postsynaptic responses 
can be mediated by a change in α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate 
receptor (AMPAR) density at the postsynaptic membrane, the content of recombinant 
tagged GluR1 and GluR2, subtunits of AMPARs, was analyzed before and after ACh 
treatment using two-photon microscopy.  Indeed, ACh induced an increase in GluR1 and 
GluR2 containing AMPARs at the spine surface without a change in spine volume.  
Results also suggested that LTP induced by ACh was mediated through a postsynaptic 
mechanism as shown by a lack of effect of ACh on the paired-pulse ratio or the fiber 
volley of fEPSPs evoked by Schafer Collateral (SC) stimulation, and LTP in this case 
was NMDA independent.  Because levels of ACh released from the medial septum rise 
during tasks that require attention, it could be postulated that this form of plasticity could 
be induced in vivo.  Tetanic stimulation of the medial septum using chronically implanted 
stimulating electrodes did in fact induce a long-lasting synaptic enhancement of fEPSPs 
at CA1 synapses in vivo (Fernandez de Sevilla et al., 2008).  A key difference between 
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the ACh-induced LTP reported by Fernández de Sevilla et al. and the synaptic 
enhancement induced by CCh in earlier studies (Auerbach and Segal, 1994, 1996) is a 
dependence on NMDAR activity.   
 
Muscarinic modulation and induction of LTD in the hippocampus  
 Interestingly, M1 activation also seems to induce a novel form of long-term 
depression (LTD) often termed mLTD (Scheiderer et al., 2006).  At hippocampal CA3-
CA1 synapses, bath application of a high concentration of CCh (50 µM) elicits a robust 
transient depression of the dendritic fEPSP which is followed by LTD after agonist 
washout.  This mLTD was prevented by atropine, by the M1 toxin MTx-7 (Potter, 2001), 
and by pirenzepine but not by the nAChR antagonist methyllycaconitine.  The expression 
of mLTD was independent of GABAA receptor activity and appeared to be via a 
postsynaptic mechanism.  It was also postulated that the acute presynaptic depression and 
mLTD involve separate mechanisms and that the presynaptic depression is not required 
for mLTD induction.  Lastly, similar to LTPm described by Auerbach and Segal (1994), 
mLTD was blocked in the presence of the NMDAR antagonist D,L-APV (Auerbach and 
Segal, 1994).  In contrast to LTPm however, mLTD is activity dependent; mLTD requires 
presynaptic activity because cessation of stimulation of presynaptic afferents during CCh 
application prevented induction of plasticity when CA3 cell bodies were removed from 
the slice.  Thus mLTD is both activity- and NMDAR-dependent.  Interestingly, this 
Hebbian form of LTD is lost after medial septal lesioning but is rescued by sympathetic 
sprouting of noradrenergic fibers from the superior cervical ganglia into hippocampus.  
This sprouting of sympathetic fibers appears to stimulate cholinergic reinnervation as 
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indicated by new VAChT-positive fibers in the hippocampus, and the appearance of these 
new fibers correlates with the rescue of mLTD. 
 In a subsequent publication, McCutchen et al. (2006) found that mLTD did not 
affect subsequent electrical induction of LTP; mLTD was also able to depotentiate LTP.  
That is, application of CCh could cause a population of CA1 pyramidal cells exhibiting 
LTP after high frequency stimulation to undergo an acute depression and then return to 
the baseline fEPSP slope level (McCutchen et al., 2006).   
 Electrical induction of LTD using low frequency stimulation (LFS-LTD) is both 
activity- and NMDA receptor dependent; since both LFS-LTD and mLTD share those 
characteristics, occlusion studies were performed to confirm a shared mechanism 
between the two types of LTD.  Not surprisingly, prior saturation of LFS-LTD occluded 
induction of mLTD by CCh application.  Unexpectedly, however, when the converse 
experiment was performed, saturating levels of mLTD did not occlude further depression 
induced by subsequent LFS.  In other words, even after multiple CCh applications to 
insure saturated mLTD, application of LFS induced roughly 25% more depression of the 
fEPSP.  Further studies revealed that CCh treatment prior to LFS caused LFS-LTD to 
become independent of NMDARs at hippocampal CA1 synapses but not in layer IV-layer 
II/III synapses in visual cortex where LFS-LTD is also normally NMDA-dependent.  The 
fact that the switch in LFS-LTD does not occur in visual cortex suggests that this may be 
a cholinergic mechanisms specific to hippocampal synapses and that there is perhaps 
more flexibility in the induction mechanisms available to mediate hippocampal LTD 
(McCoy and McMahon, 2007).  Finally, induction of mLTD seems to require ERK 
activation; application of U0126, a MEK inhibitor, before and during CCh treatment 
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completely blocks mLTD.  Induction of this form of synaptic plasticity also required 
activity of Src kinase but not PLC (Scheiderer et al., 2008). 
  
Muscarinic modulation of hippocampal physiology: conclusions 
 It is likely that these cellular actions of mAChR activation are directly related to 
the behavioral effects of activation of hippocampal mAChRs.  For instance, the combined 
reduction of excitatory synaptic transmission with an increase in excitability of pyramidal 
cells could increase the signal to noise ratio of signaling through the hippocampus.  Such 
modulation of signal to noise ratio occurs with some other neurotransmitters and has been 
proposed to play an important role in regulation of attentiveness to sensory stimuli 
(Madison and Nicoll, 1986).  In addition, selective potentiation of NMDA receptor 
responses could critically modulate synaptic plasticity that is involved in learning and 
memory.  Consistent with this, mAChR activation modulates LTP and LTD of excitatory 
synaptic responses in the hippocampus. A complete understanding of the roles of 
mAChRs in both normal and pathological hippocampal function will require a detailed 
understanding of the cellular mechanisms involved in these responses as well as the 
specific mAChR subtypes that mediate each of these responses.  While preliminary 
studies using mice lacking each of the individual mAChR subtypes have provided 
important clues about the function of these subtypes in mediating many of the 
electrophysiological effects described above, we now have selective activators of M1 and 
M4 that will be described further in subsequent chapters.  It will be important to confirm 
initial findings in knockout mice as well as to further delineate the roles of these two 
receptor subtypes in modulating hippocampal physiology.  Studies using the M4 positive 
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allosteric modulator VU10010 (see Chapter IIIa) revealed that this mAChR subtype is 
involved in modulation of excitatory but not inhibitory transmission at the SC-CA1 
synapse in rats and mice.  
 
Prefrontal cortical physiology and function 
An important projection from the hippocampus is to the prefrontal cortex (PFC), a 
cortical region that integrates information from multiple other brain regions; PFC 
function is the target of many neuromodulators including acetylcholine.  The PFC 
receives glutamatergic inputs from the thalamus and primary sensory cortices, from the 
brainstem, and from the hippocampus (Groenewegen and Uylings, 2000; Dalley et al., 
2004; Vertes, 2006), and this merging of information in the PFC is implicated in higher 
executive functioning.  Cholinergic input to the PFC regulates attention (Muir et al., 
1992; Hasselmo, 1995), memory (DeSousa et al., 1994), and anxiety induction processes 
(Berntson et al., 1998).  Dysfunction of mAChRs and muscarinic-mediated signaling 
pathways has been linked to Fragile X mental retardation (Volk et al., 2007), AD (Fisher, 
2008b), and aging (Joseph et al., 1993).  Lesions of the medial PFC (mPFC) result in 
cognitive deficits that resemble symptoms of schizophrenia and Alzheimer’s disease 
(Kolb, 1984, 1990; Heckers et al., 1998).  
 Among a number of glutamatergic afferents projecting to the PFC, the afferents 
originating in the hippocampus are especially crucial in supporting memory and cognitive 
function.  Previous work has shown that the CA1 and subiculum of ventral hippocampus 
send ipsilateral, unidirectional projections that terminate on neurons in the mPFC (Jay 
and Witter, 1991; Jay et al., 1992).  This hipocampal-mPFC pathway has been described 
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as projecting anteriorly through the fornix, and it ultimately ascends dorsally to terminate 
on neurons within the nucleus accumbens and a region of the mPFC that includes the 
infralimbic and prelimbic cortices.  The functional integrity of the hippocampal-mPFC 
network and the flow of information between these two brain regions are critical to the 
proper functioning of the mPFC in memory formation (O'Donnell and Grace, 1995; 
O'Donnell et al., 2002; Goto and O'Donnell, 2003).    
 
Role of mAChRs in the mPFC 
 Cholinergic afferents to the prelimbic and infralimbic cortices, the major 
components of the medial prefrontal cortex (mPFC), originate primarily in the basal 
forebrain nucleus basalis magnocellularis, the diagonal band of Broca, and the 
mesopontine laterodorsal nucleus (Lehmann et al., 1980; Satoh and Fibiger, 1986; 
Gaykema et al., 1990).  Cholinergic input to the cortex plays a vital role in supporting 
processes requiring arousal, attention, memory, and learning (Phillis, 2005); in addition 
to being released from inputs from the basal forebrain nuclei, ACh is also released from 
local circuit neurons in the mPFC, and ACh release increases during performance of 
attentional tasks (Passetti et al., 2000).  In contrast, lesions of cholinergic nuclei that 
project to the mPFC impair cue detection and attentional performance whereas 
augmentation of cholinergic transmission enhances behavioral arousal and locomotor 
activity (Day et al., 1991; McGaughy et al., 2002; Parikh et al., 2007).  Of the five 
mAChR subtypes, M1 and M2 are the predominant subtypes expressed in the mPFC with 
M1 mainly localizing postsynaptically at asymmetrical (glutamatergic) synapses and M2 
localizing both pre- and postsynaptically (Volpicelli and Levey, 2004).  Activation of 
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mAChRs results in an array of effects on the excitability and firing properties of cortical 
neurons, and these effects involve different cellular mechanisms.  In addition, mAChRs 
play a role in modulating long-term strengthening and weakening of synaptic 
transmission in this brain region which appears to be input-specific.  Modulation of 
electrophysiological behavior and plasticity of cortical circuits, particularly in the PFC, 
by ACh is thought to play a critical role in attention and memory (Gill et al., 2000; 
Passetti et al., 2000; Anagnostaras et al., 2003; Sarter et al., 2005). 
 
Postsynaptic effects of mAChRs in cortical neurons 
 Similar to the effects seen in hippocampal pyramidal cells, ACh causes a marked 
depolarization and increase in membrane excitability and repetitive spiking in cortical 
pyramidal cells (Benardo and Prince, 1982; Andrade, 1991; Krnjevic, 2004; Carr and 
Surmeier, 2007).  Many ionic currents have been implicated in mediating this 
depolarization; one of these is a voltage-dependent nonselective cation current (Haj-
Dahmane and Andrade, 1996; Klink and Alonso, 1997; Fisahn et al., 2002).  Studies in 
hippocampal and sensorimotor cortices have indicated this increase in excitability can be 
attributed to the inhibition of three main potassium currents: the calcium-activated 
potassium current underlying the afterhyperpolarization (IAHP), a voltage-dependent leak 
potassium current (Ileak), and the voltage-dependent M-current (IM).  The involvement of 
a potassium current-mediated mechanism was supported by the increase in input 
resistance and a dependence on membrane potential; barium and tetraethylammonium 
(TEA), potassium channel blockers, also reduced CCh-induced inward currents (Haj-
Dahmane and Andrade, 1996).  However, the CCh-induced current did not reverse at the 
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reveral potential of potassium (EK) but persisted as an inward current at membrane 
potentials 10-20 mV negative to the predicted EK for potassium.  Intracellular cesium, 
which blocks a wide range of potassium channels, also did not inhibit the CCh-induced 
inward current.  These results indicated that another ion conductance was likely involved 
in this muscarinic effect.  Subsequent studies implicated the involvement of a non-
selective cation current in muscarinic depolarization of mPFC layer V neurons (Haj-
Dahmane and Andrade, 1996).  Similar findings in entorhinal cortex did not support a 
role for potassium conductances in this effect but rather a calcium-dependent cationic 
conductance largely permeable to sodium (Klink and Alonso, 1997).  Conflicting data 
support the involvement of an inwardly rectifying potassium current through a channel 
containing Kir2 subunits; these channels are open at the resting membrane potential and 
help set the resting membrane potential in PFC pyramidal neurons and also play a role in 
integration of excitatory synaptic inputs (Day et al., 2005).  Carr and Surmeier (2007) 
found the CCh-induced inward current to be sensitive to barium and cesium that block 
Kir2 channels, and showed that mAChR activation reduces Kir2 channel currents by 
depleting membrane phosphatidylinositol 4,5-bisphosphate (PIP2) as this modulation was 
blocked by PLC but not PKC inhibitors (Carr and Surmeier, 2007). 
 The calcium-dependent non-selective cation current mentioned above has also 
been shown to contribute to the fast afterdepolarization (fADP) that follows an action 
potential triggered by depolarizing current injection (Haj-Dahmane and Andrade, 1997).  
This fADP is prominently displayed by pyramidal neurons of layer V in rat PFC.  
Interestingly, these cells also exhibit a muscarinic-induced slow afterdepolarization 
(sADP) (Haj-Dahmane and Andrade, 1998).  Buffering of intracellular calcium prevented 
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the mAChR-induced sADP, and ion substitution experiments implicated the flow of 
sodium ions into the cell but not the flux of potassium or chloride.  The muscarinic sADP 
therefore is likely mediated by a calcium- and voltage-sensitive nonselective cation 
current and could represent a mechanism by which mAChRs modulate neuronal 
excitability in the PFC.  Due to the calcium-dependence of the sADP, the involvement of 
calcium channel modulation by mAChRs has been investigated.  A recent study has 
implicated TRPC (transient receptor potential) ion channels in the muscarinic sADP (Yan 
et al., 2009); these channels allow calcium flux into cells in response to a variety of 
stimuli usually linked to phosphatidylinositol signal transduction pathways.  Data 
indicates that the current underlying the sADP induced by mAChR activation is carried 
through TRPC channels containing TRPC5 or TRPC6 subunits and occurs through a 
mechanism involving Gαq and PLCβ1 signaling. 
 Pyramidal cells normally respond to a sustained current injection with a high 
initial firing rate followed by a slowing of this rate.  The voltage-sensitive potassium 
current (IM) and voltage-dependent calcium influx which activates a calcium-sensitive 
potassium current (IAHP) are both thought to underlie this accommodation or adaptation in 
cell firing rate by pyramidal cells in response to sustained depolarization.  Activation of 
mAChRs decreases both of these potassium currents which, in turn, allows neurons to 
fire in a more sustained manner in response to sustained afferent input.  Cholinergic 
agonists also cause a strong increase in the firing rate of cortical neurons, and this 
increase in firing rate was demonstrated to result from a slow depolarization of cortical 
pyramidal cells due at least in part to blockade of potassium currents (Krnjevic et al., 
1971; Hasselmo and McGaughy, 2004).  The muscarinic inhibition of the calcium-
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dependent potassium currents underlying afterhyperpolarization also supports a role of 
mAChRs in modulating voltage-dependent calcium channels.  Indeed, mAChR 
modulation of L-, N-, P/Q- and R-type calcium channels pre- and postsynaptically in both 
hippocampal and cortical neurons occurs through G-protein dependent mechanisms 
(Perez-Burgos et al., 2008). 
 In accordance with the excitatory effects of selective M1 receptor activation in rat 
and mouse layer V mPFC pyramidal cells described in this thesis, a recent study using M1 
knockout mice shows that activation of this receptor subtype mediates cholinergic 
modulation of excitability in these neurons (Gulledge et al., 2009).  Interestingly, short 
focal application of ACh near the soma of the recorded neuron produced a 
hyperpolarization and pronounced inhibition of spiking followed by spike acceleration 
when ACh was delivered during periods of action potential generation by depolarizing 
current injection in layer V but not as robustly in layer II/III neurons.  This effect was 
abolished in slices from M1 knockout but not M3 or M5 knockout mice.  Tonic 
cholinergic excitation using bath-applied CCh depolarized layer V neurons and also 
suppressed the afterhyperpolarization in addition to generating a slow afterdepolarization, 
effects that were also absent in M1 knockout slices (Gulledge et al., 2009). 
 
Cholinergic modulation of cortical neurotransmission 
 Despite a consistent reporting of increases in cortical neuronal excitability in 
response to cholinergic agonists, many discrepancies exist in studies examining the 
effects of cholinomimetic drugs on glutamatergic transmission; data suggests that the 
effect of ACh on synaptic transmission is region- and input specific (Hasselmo and 
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Bower, 1992; Gil et al., 1997; Gulledge et al., 2007; Eggermann and Feldmeyer, 2009; 
Gulledge et al., 2009).  In addition, varying concentrations of ACh induce either 
depression or facilitation of glutamatergic transmission; this principle holds true when 
examining the effects of CCh on long-term changes in synaptic transmission as discussed 
below.  By employing stimulation of either layer Ia or Ib in rat piriform cortex slices, 
Hasselmo and Bower found that CCh, muscarine, and ACh strongly reduced responses 
stimulated from intrinsic fibers in layer Ib but not from afferent fibers from layer Ia; this 
suggested that mAChR activation decreases excitatory transmission within intracortical 
circuits but not from afferent inputs (Hasselmo and Bower, 1992).  In slices containing 
somatosensory cortex and ventrobasal thalamus, muscarine depressed EPSPs at both 
thalamocoritcal (TC) and intracortical (IC) synapses onto layer III pyramidal cells 
whereas nicotine selectively enhanced responses from TC synapses and had no effect on 
IC synapses.  Muscarine increased the paired-pulse ratio at both TC and IC synapses, 
suggesting a presynaptic mechanism of action (Gil et al., 1997).  In addition, GABA 
released by an intracortical stimulus selectively suppresses transmitter release from IC 
synapses but not TC synapses by activating presynaptic GABAB receptors.  Taken 
together, these results indicate that cholinergic receptors selectively modulation of 
intrinsic versus afferent synapses.     
 Acetylcholine also modulates activity and GABA release from cortical 
GABAergic interneurons differentially depending on cell subtype (Kawaguchi, 1997).  
Despite the relatively low abundance of inhibitory neocortical interneurons, these cells 
have profuse axonal arborizations such that a single GABAergic interneuron can control 
hundreds of excitatory pyramidal cells (Kruglikov and Rudy, 2008).  Recordings from 
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these interneurons revealed that ACh induces inhibitory postsynaptic potentials in 
neocortical cells indirectly through cortical GABAergic cells; CCh also induces an 
increase in spontaneous IPSC in frontal cortical pyramidal cells, an effect that was 
dependent on action potential firing as it was suppressed by the fast sodium channel 
blocker tetrodotoxin (TTX).  While fast-spiking and late-spiking GABAergic cells were 
not depolarized by CCh, this muscarinic agonist did appear to depolarize somatostatin-
immunoreactive and vasoactive intestinal peptide (VIP)-positive GABAergic cells 
(Kawaguchi, 1997) indicating that muscarinic modulation of inhibitory interneurons is 
cell-type specific.  Paradoxically, muscarine and oxotremorine decrease the amplitude of 
electrically evoked inhibitory postsynaptic currents in layer II/II neurons in rat auditory 
cortex (Salgado et al., 2007) and in the mouse layer V somatosensory cortex (Kruglikov 
and Rudy, 2008) via a presynaptic mechanism.  Furthermore, mAChR activation 
potentiates GABAA currents in acutely dissociated PFC neurons, an effect that required 
pretreatment with insulin.  This effect was blocked by inhibitors of PKC, broad-spectrum 
protein tyrosine kinase, and Src inhibitors (Ma et al., 2003).  This array of muscarinic 
effects on GABAergic release and transmission likely results from the cortical expression 
of multiple mAChR subtypes both pre- and postsynaptically where they have both 
excitatory and inhibitory effects on different populations of inhibitory neurons. 
 Of particular relevance to muscarinic modulation of prefrontal cortical signaling 
in AD, a relationship between beta amyloid (Aβ), ACh, and GABAergic signaling has 
been established.  Exposure of cortical slices to fibril Aβ peptides activated PKC and 
CamKII in addition to inducing action potential firing and enhancing spontaneous EPSCs 
in mPFC layer V neurons; these effects were blocked by oxotremorine.  In addition, 
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mAChR activation caused a PKC-dependent increase in spontaneous IPSC amplitude and 
frequency (Gu et al., 2003).  Interestingly, this muscarinic modulation of sIPSCs was 
impaired in an APP mutant mouse model of AD (Zhong et al., 2003).  These authors also 
showed that persistent spiking of layer V neurons induced by CCh was independent of 
PKC activation and was intact in APP transgenic mice, suggesting that muscarinic 
modulation of inhibitory transmission is selectively impaired in these animals. 
 
mAChRs modulation of long-term changes in cortical synaptic strength 
 Cholinergic receptors have been shown to play a role in cortical synaptic 
plasticity in a number of cortical regions.  Similar to the cholinergic activity-dependent 
long-term depression of EPSPs observed in hippocampus (Scheiderer et al., 2006), 
carbachol induces LTD of synaptic responses when paired-pulse stimulation is delivered 
to layer IV and field EPSPs were recorded from layer III of rat visual cortex (Kirkwood 
et al., 1999).  A key difference is that in hippocampus, agonist treatment alone without 
any low-frequency stimulation induced LTD; a paired pulse stimulation protocol was 
required to reveal muscarinic LTD in visual cortex.  Therefore CCh, in conjunction with 
paired-pulse stimulation, induces an activity-dependent and homosynaptic form of LTD.  
CCh also facilitated LTD induction using a low-frequency stimulation protocol in visual 
cortex.  Muscarinic-induced LTD required NMDAR activity as it was blocked in the 
presence of AP5. 
 Subsequent studies have shown that mLTD in visual cortex has a postsynaptic 
locus of expression as indicated by the fact that there was no change in the paired pulse 
ratio during expression of the long-lasting depression induced by CCh (McCoy and 
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McMahon, 2007).  A change in PPR is usually indicative of a presynaptic locus of 
expression, whereas no change indicates a postsynaptic locus.  In contrast to results 
reported by Kirkwood et al. (1999), these authors found no effect of the NMDA 
antagonist APV in mLTD induction or maintenance.  They did however show that the L-
type Ca2+ blocker nifedipine inhibited mLTD whereas picrotoxin had no effect which 
indicates that mLTD induction is not due to an increase in inhibitory transmission but 
requires activity of L-type Ca+2 channels.  McCoy and McMahon also found that mLTD 
in visual cortex was independent of PKC but was partially dependent on PLC activation.  
A prominent signaling cascade downstream of M1 receptor activation is the Src tyrosine 
kinase which leads to the phosphorylation and activation of MEK which subsequently 
phosphorylates and activates ERK1/2 (Chan et al., 2005).  The Src inhibitor PP2 
completely blocked mLTD as did the ERK1/2 inhibitor U0126, indicating that activation 
of the MEK/ERK1/2 cascade is required for this form of plasticity to occur.  In the 
hippocampus, Src activation has also been implicated in muscarinic modulation of 
NMDA currents (Lu et al., 1999); since mLTD in visual cortex may or may not require 
NMDAR activity, it is unclear whether there is a link between these two phenomena.  
Lastly, the maintenance of mLTD in visual cortex which can last on the order of 2.5 
hours can be blocked by protein synthesis inhibitors (McCoy and McMahon, 2007).  
Translation of new proteins is not required for the induction of mLTD but for 
maintenance of the depression long-term.  Inhibiting transcription of mRNAs had no 
effect on either the induction, expression, or the long-term maintenance of mLTD. 
Reduction of cortical cholinergic innervations produces a shift from LTP to LTD 
that can be prevented by exogenous application of ACh (Kuczewski et al., 2005); this 
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suggests a regulatory action of ACh on the direction of synaptic plasticity (LTP vs. LTD).  
In a recent study by Origlia et al. (2006), an approach using mAChR knockout mice 
indicated that M2/M4 receptors were necessary for TBS-induced LTP whereas M1/M3 
receptors were necessary for LFS-LTP in visual cortex.  Interestingly, this group showed 
that in the absence of any muscarinic agonist, atropine was able to fully block TBS-
induced LTP and LFS-LTD in layer II/III of visual cortex after stimulation of layer IV.  
This data indicates that mAChR activity, unlike in hippocampus, is required for induction 
of LTP and LTD using standard electrical stimulus protocols.  Furthermore, theta-burst 
stimulation failed to induce LTP in M2/M4 double knock-outs, and LFS failed to induce 
LTD in but instead induced LTP in M1/M3 double knock-outs.  In single knockout 
studies, M2 and M4 knockouts exhibited normal LTP after TBS whereas the M3 knockout 
showed no LTD after LFS and the M1 knockout actually exhibited LTP after a low 
frequency stimulation protocol that induces LTD in wild-type animals.  Application of 
the PLC inhibitor U73122 had a similar effect on the response to LFS as when M1 
receptors were absent; in other words, blocking PLC caused LTP to be induced by the 
LFS protocol.  Similarly, treatment of slices with pertussis toxin blocked the ability of 
TBS to induce LTP supporting the idea that activation of M2/M4 receptors and the 
downstream activation of Gi/o proteins underlie LTP induction.  These studies indicate 
that the direction of synaptic plasticity in visual cortex depends on the combined activity 
of different mAChR subtypes (Origlia et al., 2006).  It could be postulated that if there 
was a loss or decrease in particular mAChR subtype expression or function, this would 
tip the balance of muscarinic modulation of LTP and LTD and induce a bias in one 
direction or another. 
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More directly relevant to the studies described in this thesis is the finding that 
mAChR activation also induces very robust LTD in layer V pyramidal cells of the mPFC 
(Huang and Hsu, 2009).  Whole cell patch clamp studies in voltage clamp mode revealed 
that CCh induces a dose-dependent acute depression of EPSCs evoked by stimulation of 
layer V apical dendrites, and that the acute depression is followed by a long-lasting 
depression of excitatory transmission.  Very high concentrations of CCh were used (10, 
50, and 100 µM), but the short- and long-term effects of 50 µM CCh were completely 
blocked by 1 µM atropine and 100 nM pirenzepine, indicating that the depression is 
indeed mediated by mAChRs.  CCh also transiently depressed monosynaptic IPSCs in 
the presence of 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) and APV, but IPSCs 
returned to baseline levels upon agonist washout indicating that mLTD is selective for 
excitatory synaptic transmission.  This depression of excitatory synaptic transmission still 
occurred in the presence of NMDA antagonist D-APV indicating that mLTD is NMDAR 
independent, a finding similar to what was observed in the visual cortex by McCoy and 
McMahon (2007).  In contrast to mLTD at CA1 and visual cortical synapses, however, 
this form of plasticity in layer V mPFC is activity independent; if electrical stimulation 
ceased during CCh addition, mLTD was still induced when stimulation resumed.  
Activation of ionotropic and metabotropic glutamate receptors was also not required for 
induction of mLTD.  GDPβS which disrupts G protein-coupled signaling blocked the 
long-term but not the acute depression induced by CCh, suggesting that the acute 
depression is likely presynaptic whereas the LTD requires postsynaptic G protein 
activation.  mLTD also required activation of PLC, PKC, and IP3 receptors.  Intriguingly, 
as opposed to mLTD in visual cortex (McCoy and McMahon, 2007) and hippocampus 
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(Scheiderer et al., 2008), long-term depression induced by CCh in layer V mPFC 
pyramidal cells was not blocked by Src kinase and MEK inhibitors PP2 and U0126, 
respectively (Huang and Hsu, 2009).  Another discrepancy was seen with the use of the 
L-type Ca2+ blocker nimodipine which inhibited mLTD in visual cortex but not in mPFC.  
mLTD in the mPFC appeared to have a presynaptic locus of expression that did not 
require postsynaptic clathrin-mediated endocytosis of AMPARs.  Data indicated that 
activation of postsynaptic mAChR signaling suppresses glutamatergic synaptic 
transmission through a presynaptic effect on neurotransmitter release; it was therefore 
hypothesized that a retrograde messenger was involved in the expression of mLTD.  The 
nitric oxide synthase (NOS) inhibitor L-NAME blocked mLTD induction; inhibitor 
studies also showed that mLTD was dependent on activation of presynaptic sGC/PKG 
signaling pathway initiated by postsynaptic nitric oxide (NO) production.  Finally, to 
ascertain whether endogenous ACh release, as opposed to exogenously applied CCh, can 
modulate LTD, a paired-pulse LFS (PP-LFS) protocol was used to induce a stable form 
of LTD measured using field EPSPs.  The magnitude of PP-LFS-LTD was significantly 
reduced by atropine and pirenzepine and enhanced by the cholinesterase inhibitor eserine.  
These results indicate that endogenous ACh does in fact play and critical role in LTD in 
these neurons.  Occlusion experiments also showed that PP-LFS-LTD and mLTD share a 
common mechanism (Huang and Hsu, 2009). 
Also of particular interest in relation to our findings in mPFC layer V neurons is 
the finding that mAChRs modulate excitatory afferents from the hippocampus which 
project to the mPFC (Wang and Yuan, 2009).  Parent et al. (2009) identified a bundle of 
afferent fibers that project to the mPFC from the ventral hippocampus in acute slice 
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preparations; in vivo track tracing and optic studies revealed that the afferent bundle did 
not include contributions from the mediodorsal nucleus of the thalamus, amygdala, or 
lateral hypothalamus/medial forebrain bundle (Parent et al., 2009).  Although there have 
been numerous studies examining the result of hippocampal monosynaptic projections to 
the mPFC in vivo (Laroche et al., 1990; Degenetais et al., 2003; Romcy-Pereira and 
Pavlides, 2004), the majority of electrophysiological studies examining 
neurotransmission in vitro in acute slices of the mPFC have employed placement of a 
stimulating electrode in different layers of the mPFC. This is possible due to the fact that 
pyramidal neurons in this brain region have elaborate dendrites that extend into both deep 
and superficial layers of the cortex.  The mPFC, like other cortical regions, not only 
contains local circuits but receives innervations of afferents that are not spatially 
resolved.  Therefore synaptic responses resulting from general laminar stimulation are a 
product of stimulating mixed populations of axonal fibers, and this type of stimulation 
often results in polysynaptic responses.  Studies by Parent et al. (2009) indicate that 
hippocampal afferent fibers can be identified and stimulated in modified coronal mouse 
brain slices containing the mPFC, and that stimulation of these fibers produces 
monosynaptic responses that undergo bidirectional plasticity in response to patterned 
stimulation.  This finding provides an exciting opportunity to further explore 
neurotransmission and informational flow from the hippocampus to the mPFC and the 
ways in which mAChRs may contribute to and modulate this flow. 
Employing this modified coronal slice preparation, Wang and Yuan (2009) 
recorded monosynaptic EPSPs in current clamp mode from mPFC layer II/III and layer V 
pyramidal cells during stimulation of afferents from the ventral hippocampus.  They 
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found that bath application of 20 µM CCh for 10 min depressed EPSP slope and that this 
depression lasted >45 min after agonist washout; this muscarinic effect was evident in 
recordings from both layer II/II and layer V.  In other words, muscarinic LTD occurs not 
only in hippocampus and visual cortex but also in mPFC neurons, and this mLTD can be 
induced by CCh application after stimulation of deep or superficial cortical layers or after 
stimulation of newly proposed hippocampal afferents to the mPFC.  It was also shown 
that mLTD at hippocampal-mPFC glutamatergic synapses was not affected by GABAA 
and GABAB antagonists (Wang and Yuan, 2009).  It is important to note that when layer 
I was stimulated and whole cell EPSPs recorded in layer II/III, CCh induced an acute 
depression but not a long-lasting one; Huang and Hsu (as described above, 2009) saw 
confounding results when stimulating and recording from layer V or when stimulating 
layer II/III and recording in layer V.  In both scenarios, mLTD could be induced.  One 
critical difference is that Wang and Yuan used slices from mice whereas studies from 
Huang and Hsu employed rat slices.  This may go to show, however, that the stimulation 
and recording location within the mPFC have quite an impact on plasticity phenomena 
and that a more consistent, direct examination of the hippocampal-mPFC pathway may 
yield more reliable data. 
Paired pulse facilitation studies indicated that mLTD upon stimulation of 
hippocampal afferents was induced via a presynaptic mechanism, and interruption of 
electrical stimulation during CCh application prevented mLTD which indicated activity 
dependence (Wang and Yuan, 2009).  Acute and long-term depression of EPSPs by CCh 
were both intact in the presence of NMDAR antagonist APV but not with the addition of 
the L-type Ca2+ blocker nifedipine indicating that mLTD at hippocampal-mPFC synapses 
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is NMDA independent but relies on Ca2+ influx through voltage gated L-type calcium 
channels.  Upon the observations that mAChR antagonists AF-DX 116 and pirenzepine 
induced differential modulation of mLTD and that the mechanism of depression seemed 
presynaptic, the authors concluded that presynaptic M2 receptors mediated mLTD.  These 
antagonists are not selective, however, and evidence presented by Huang and Hsu (2009) 
supporting a role for the retrograde signaling molecule nitric oxide seems much more 
conclusive (Huang and Hsu, 2009).  This scenario would explain the involvement of a 
post-synaptic Gq-coupled mAChR as well as presynaptic inhibition of glutamate release 
seen by both sets of researchers. 
 
mAChR modulation of cortical physiology: conclusions 
 Acetylcholine release in cortical areas of the brain results in a multi-faceted array 
of electrophysiological responses in both pyramidal neurons and GABAergic 
interneurons by activating both mAChRs and nAChRs.  ACh is a powerful modulator of 
numerous ion channels that contribute to the excitability and firing patterns of cortical 
neurons both at rest and in response to intracortical and afferent inputs from multiple 
brain regions including the thalamus and hippocampus.  The diversity of cholinergic 
receptor subtypes and layer-specific expression contributes to the complex cell type- and 
input-dependent consequences of mAChR activation.  In this thesis, we show that the 
selective activation of the M1 receptor induces an inward current and an increase in 
spontaneous EPSCs in layer V pyramidal neurons in rat and mouse mPFC, a cortical 
region implicated in attentional processes and cognition.  These effects are decreased in 
M1 knockout mice.  Potentiation of M1 also increases the firing rate of rat mPFC neurons 
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in vivo.  Finally, the selective M1 PAM BQCA reverses impairments in a form of 
learning that requires normal functioning of the PFC in a mouse model of AD.  These 
studies lend further support for a critical role of M1 in supporting normal function of the 
PFC. 
 
Pharmacology of muscarinic receptors 
  Our lack of understanding of the physiological roles of specific mAChRs is largely 
due to the historical lack of pharmacological agents that are highly selective for individual 
subtypes.  Previous efforts have failed to develop highly selective traditional (orthosteric) 
agonists of the individual muscarinic receptors.  This is likely due to the high conservation 
of the orthosteric (primary) ACh binding region across muscarinic receptor subtypes 
(Eglen, 2005), making it difficult to develop subtype selective ligands that bind to this site 
(Felder et al., 2000).  However, in recent years, we and others have been highly successful 
in developing allosteric modulators and agonists of GPCRs.  These compounds provide 
unprecedented selectivity for the intended receptor and can have behavioral effects in vivo 
that are very similar to those of direct acting agonists. 
 
Models of receptor activation 
  The binding of an agonist to the receptor can be theoretically modeled.  One type 
of model, the two-state model also referred to as the ternary model of binding posits that 
the receptor exists in two conformations; an inactive conformation and an active 
conformation (Gether, 2000).  In this model, the agonists are able to bind to receptors in the 
active conformation and thus shift the equilibrium toward that of activated receptors.  
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Antagonists bind to both the inactive and active conformations, resulting in no change in 
equilibrium.  In contrast, inverse agonists bind to the inactive form of the receptor resulting 
in a shift in equilibrium towards inactive receptors (Gether, 2000).  This is quantified by 
the cooperativity factor α, which is based on the affinity of the ligand for the active state of 
the receptor compared to the affinity for the inactive state (Christopoulos and Kenakin, 
2002; Hulme (a) et al., 2003).  This model is expanded further in the extended ternary 
complex model to incorporate binding of G proteins to the receptor (Hulme (a) et al., 
2003).  In this case, the receptor again exists in inactive and active conformations.  
However, the receptor in the active state (either bound or unbound by ligand) now binds to 
the G protein (Hulme (a) et al., 2003).  It should be noted that the G protein could also bind 
to the inactive form of the receptor (Christopoulos and Kenakin, 2002).  In this model it is 
also possible that multiple G proteins have the ability to bind to the active receptor 
conformation, which would allow for potential specificity in receptor signaling (Kenakin, 
2003). 
  Molecules bind to the receptor in a specific manner to activate (agonists), block 
(antagonists) or decrease (inverse agonists) receptor activation.  Agonists have both affinity 
and intrinsic efficacy for the receptor, whereas antagonists possess only affinity; an inverse 
agonist has negative efficacy (Christopoulos and El-Fakahany, 1999).  The action of an 
agonist is dependent on the system that it is being studied, thus it can only be defined as a 
partial or full agonist for the system in which the response is measured.  When a system has 
spare receptors this means that only a fraction of the receptors need to be activated to get a 
maximal response. Additionally, it is important to note that a receptor saturating 
concentration of a drug in one system may not be saturating in a different system. 
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  There are different classes of allosteric modulators; positive allosteric modulators 
or potentiators are thought to result in a conformation change at the orthosteric site that 
results in higher affinity for the orthosteric ligand.  Allosteric agonists result in increased G 
protein coupling irrespective of the action on the orthosteric site; and allosteric antagonists 
result in a decrease in receptor affinity and/or make the G protein less likely to couple to 
the receptor (Christopoulos and Kenakin, 2002; Wess, 2005). 
  Furthermore, ligands that bind in an allosteric manner can induce conformational 
changes in the receptor which can result in the modulation of receptor activity 
(Christopoulos, 2002).  In allosteric interactions the binding of one ligand affects the ability 
of another ligand to bind.  This occurs in a reciprocal manner between the two ligands 
(Birdsall et al., 1996).  Changes in receptor conformation can result in change in receptor 
affinity. While positive cooperativity results in an increase in affinity, negative 
cooperativity results in a decrease in affinity and neutral cooperativity results in no change 
in affinity (Christopoulos, 2002).  The action of a particular allosteric modulator may also 
be ligand specific.  Thus, it may be possible to get some degree of subtype selectivity based 
in cooperativity rather than affinity (Lanzafame et al., 2006). 
 
Allosteric ligands of mAChRs 
  Despite tremendous efforts by multiple industry and academic scientists, previous 
efforts have failed to produce highly selective traditional (orthosteric) agonists of the M1 
muscarinic receptor.  This is likely due to the fact that the ACh binding site is highly 
conserved, making it difficult to develop agonists at M1 that are devoid of activity at the 
other mAChR subtypes.  In addition to the difficulty in developing M1 agonists that are 
46 
 
highly selective, there are a number of problems associated with the use of direct acting 
agonists as drugs.  These include adverse effects associated with excessive activation of the 
receptor, greater receptor desensitization than may occur with more indirect approaches, 
and loss of activity dependence of receptor activation.  Another approach to achieving 
receptor activation that has been highly successful for ligand-gated ion channels is 
development of allosteric modulators of receptor function.  Allosteric ligands do not bind 
to the orthosteric neurotransmitter binding site and do not directly activate the receptor but 
bind to another site on the receptor and potentiate the effects of a orthosteric agonist.  A 
classical example of this approach is the use of benzodiazepines to potentiate GABAA 
receptor function (Mohler et al., 2002).  Because allosteric potentiators require the 
endogenous agonist for activity, they maintain activity-dependence of receptor activation.  
This is thought to reduce adverse effects that can be associated with direct-acting agonists 
and may also reduce the level of desensitization.  In recent years, we (Marino et al., 2003; 
O'Brien et al., 2003; Lindsley et al., 2004; O'Brien et al., 2004; Galici et al., 2005; Kinney 
et al., 2005; Brady et al., 2008; Shirey et al., 2008; Bridges et al., 2009; Marlo et al., 2009) 
and others (Christopoulos, 2002; Gasparini et al., 2002; Rees et al., 2002; Soudijn et al., 
2002; Waelbroeck, 2003) have been highly successful in developing allosteric potentiators 
of GPCRs.  In many cases, these compounds provide unprecedented selectivity for the 
intended receptor and can have behavioral effects in vivo that are very similar to those of 
direct acting agonists.  In the case of mAChRs, a major goal has been to develop allosteric 
ligands that selectively increase the activity of M1 or M4 receptors.  Allosteric activators 
can also include allosteric agonists, which act at a site removed from the orthosteric site to 
directly activate the receptor in the absence of ACh, in contrast to positive allosteric 
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modulators (PAMs), which do not activate the receptor directly but potentiate activation of 
the receptor by the orthosteric agonists. Lastly, it is possible for a single molecule to have 
both allosteric potentiator and allosteric agonist activity (May et al., 2007; Conn et al., 
2009a). 
  As stated earlier, previous attempts to develop orthosteric agonists that are highly 
selective for individual mAChR subtypes have failed because of the high degree of 
conservation of the orthosteric ACh-binding site.  Although there have been reports of 
subtype-selective M1 agonists in the patent and primary literature, subsequent studies 
across multiple systems have revealed that previous orthosteric agonists are not highly 
selective when evaluated across multiple systems.  A reason for this is that the claims of 
selectivity of these agents were based on functional efficacy rather than selective binding to 
individual mAChR subtypes.  Because of this, a weak partial agonist at multiple mAChR 
subtypes might seem to be selective in cell lines in which there is little or no receptor 
reserve but might have robust agonist activity at these same mAChR subtypes in native 
systems that have high receptor reserve.  Because high receptor reserve is common for 
mAChRs in native tissues, these agents often activate multiple mAChR subtypes in animal 
models and humans (Felder et al., 2000; Wess et al., 2007; Langmead et al., 2008b).  A 
recent example, AF267, was suggested to have selective agonist activity at M1 but displays 
a similar selectivity profile to previous orthosteric agonists and activates multiple mAChR 
subtypes (i.e. M1, M3 and M5) (Jones et al., 2008). As discussed further elsewhere in this 
introduction, the muscarinic agonist developed by Eli Lilly, xanomeline, suffers from this 
same lack of selectivity across multiple mAChR subtypes (Langmead et al., 2008b).  These 
studies do not rule out the possibility that highly selective agonists of individual mAChR 
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subtypes will eventually be developed but do raise a need for also considering other 
strategies for identifying agents that selectively activate individual subtypes of this receptor 
family. 
 
Development of early allosteric ligands of mAChRs 
  Work by several laboratories (Jakubik et al., 1997; Lazareno et al., 1998; Fawzi et 
al., 2001; Lazareno, 2004) identified a diverse array of chemotypes that possess PAM 
activity at the M1 and M4 mAChR subtypes.  The first mAChR PAM reported was brucine 
(Jakubik et al., 1997; Lazareno et al., 1998), which acts as an allosteric potentiator at M1.  
Brucine is a weak M1 PAM requiring high micromolar concentrations for activity and 
induces only a two-fold increase in ACh affinity at the M1 receptor.  However, brucine is 
relatively selective for M1 and this provided an important proof of concept that it would be 
possible to develop selective PAMs for this important mAChR subtype.  Equilibrium and 
non-equilibrium radioligand-binding studies with brucine, the mAChR antagonist 
radioligand [3H]-N-methyl-scopolamine ([3H]NMS) and unlabeled ACh were consistent 
with a ternary allosteric model in which both the orthosteric and allosteric ligands bind to 
the receptor simultaneously and modify the affinities of each other. 
  Discovery of brucine was followed by the discovery of thiochrome as an M4 PAM 
(Lazareno et al., 2004) and SCH-202676 as a PAM of multiple GPCR subtypes including 
M1 (Fawzi et al., 2001; Lanzafame and Christopoulos, 2004).  Thiochrome was especially 
interesting in that it provided M4 subtype selectivity.  This compound increases the affinity 
of ACh three- to fivefold at M4 and increased ACh potency in activating M4 in functional 
assays but has no effect on ACh affinity at M1, M2 or M5 (Lazareno et al., 2004).  
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Interestingly, thiochrome has no effect on the equilibrium binding of [3H]-NMS to the five 
human mAChRs (M1–M5) but inhibits the [3H]NMS dissociation from M1–M4.  This 
indicates that the selectivity of thiochrome for M4 is due to selective cooperativity rather 
than selective interactions with this single mAChR subtype. 
 Another major breakthrough in mAChR pharmacology came when Spalding et al. 
(2002) identified AC42 as the first in a novel class of compounds that bind to a secondary 
ectopic site on the M1 receptor (Spalding et al., 2002).  AC42 acts at a site that is clearly 
distinct from the orthosteric ACh site and involves transmembrane domains one and seven 
(but not three, five, and six, which contribute to the orthosteric site).  AC42 is an allosteric 
agonist rather than an allosteric potentiator in that it activates the receptor directly rather 
than potentiating the response to ACh.  This compound fully activates the M1 receptor and 
is highly selective for M1 relative to other mAChR subtypes.  As with allosteric 
potentiators, this selectivity is likely to be achieved by targeting a site distinct from the 
orthosteric ACh binding site.  Mutations that render the receptor insensitive to ACh 
agonists do not alter activity of AC42.  Also, activity of AC42 can be eliminated by 
mutations that do not alter activation of the receptor by ACh (Spalding et al., 2002).  
      Unfortunately, brucine, AC-42 and other early mAChR allosteric agonists and 
PAMs lacked the pharmacological profiles and physicochemical properties required to be 
useful tools to probe the effect of allosteric activation of mAChRs in more complex native 
systems.  For instance, these compounds have off-target activities at other receptors and 
have relatively low potencies at M1 or M4.  This, combined with poor solubility in 
physiological buffer systems, prevented their use for studies in tissue or animal model 
systems.  However, discovery of these early compounds provided an important advance in 
50 
 
establishing the potential of developing more selective activators of M1 and other mAChR 
subtypes by targeting allosteric sites. 
 
New ligands are highly selective for the M4 mAChR subtype 
  Another major breakthrough came with the discovery of a novel highly selective 
allosteric potentiator of M4, LY2033298, by Felder and coworkers at Eli Lilly (Chan et al., 
2008).  This compound does not activate M4 directly but induces a robust potentiation of 
the M4-mediated response to ACh.  This compound is highly selective at M4 and has no 
discernable activity at the other mAChR subtypes.  Site-directed mutagenesis studies 
revealed that residue D432 in the third extracellular loop (o3) of the receptor is involved in 
the potentiating effects of LY2033298.  When co-administered with a low dose (0.1 – 0.3 
mg/kg) of oxotremorine, LY2033298 attenuated conditioned avoidance responding (CAR) 
and reversed apomorphine-induced disruption of the prepulse inhibition (PPI) of the 
acoustic startle response.  Potentiation of M4 also augmented oxotremorine-stimulated 
dopamine (DA) release in dialysate from prefrontal cortex but not nucleus accumbens 
supporting a role for M4 in modulating mesocortical but not mesolimbic DA levels.  
Authors reported a diminished potency of this compound at the rat M4 (rM4) receptor 
compared to the human receptor (hM4), and this statement was based on the ability of 
LY2033298 to enhance binding of [3H]-oxotremorine-M to CHO hM4 cell membranes and 
rat striatal membranes in a dose-dependent manner.  The lack of effect of the PAM when 
administered alone on CAR, PPI, and DA release was therefore postulated to be due to this 
species difference (Chan et al., 2008).  Functional data using recombinant cell lines 
expressing rM4 or hM4 wild-type and mutant receptors indicated that the response to ACh 
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was similar between species, but no data examining potentiation by LY2033298 in this 
assay was shown.    
  Employing a cheminformatics approach based on LY2033298, coupled with 
medicinal chemistry, we identified a new series of ligands that interact with an allosteric 
site on the M4 receptor (no displacement of [3H]-NMS in binding assays) which not only 
potentiate the receptor, but also confer complete subtype selectivity versus M1, M2, M3 and 
M5 (Shirey et al., 2008).  The lead compound in this series, VU100010, possesses an EC50 
for potentiation of ~400 nM and shifts the functional ACh response curve 47-fold to the 
left.  As described further in this thesis in Chapter IIIa, binding studies indicate that 
VU100010 exerts its allosteric potentiation of M4 by increasing the affinity of the receptor 
for ACh and downstream coupling to G proteins.  Electrophysiological studies indicate that 
VU100010 modulates hippocampal synaptic transmission at excitatory but inhibitory CA1 
synapses in acute slices (Shirey et al., 2008). 
  Despite this notable advance in mAChR pharmacology, VU10010 suffered from 
poor physiochemical properties (logP~4.5) and in vivo studies proved infeasible because 
we were unable to formulate VU10010 into a homogeneous solution in any acceptable 
vehicle, regardless of salt form or particle size.  Several nonhomogenous suspensions were 
prepared and dosed i.p., but VU10010 was not found to be centrally active.  In order to 
evaluate the role of selective M4 activation in vivo, VU10010 required further chemical 
optimization.  The subsequent development and characterization of two novel analogs of 
VU10010 that are CNS penetrant following systemic administration are described in 
Chapter IIIb of this thesis (Brady et al., 2008).  VU0152099 and VU0152100 were 
identified as M4 PAMS with EC50 values for potentiation of the response to ACh of 
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approximately 400 nM.  These novel modulators maintained the high degree of mAChR 
subtype selectivity shown by VU10010 and also showed functional selectivity in a screen 
of 15 other GPCRs that are highly expressed in the CNS.  Similar to the binding profile of 
VU10010, VU0152099 and VU0152100 did not compete for orthosteric [3H]NMS binding 
but increased M4 receptor affinity for ACh.  The most exciting finding in this series of 
studies was that VU0152099 and VU0152100 exhibited improved physiochemical and 
pharmacokinetic properties as compared to VU10010; in contrast, to the high logP of 
VU10010 (4.5), both VU0152099 and VU0152100 possessed logPs of 3.65 and 3.6, 
respectively, a full order of magnitude less lipophilic than VU10010.  As a consequence, 
both VU0152099 and VU0152100 displayed improved physiochemical properties and 
afforded homogeneous dosing solutions in multiple vehicles acceptable for in vivo studies.  
Furthermore, both compounds exhibited substantial systemic absorption and brain 
penetration after systemic dosing with the PK profile of VU0152100 being superior as 
shown by a higher AUC (0-∞) value, a measurement of bioavailability.  Subsequent studies 
in an animal model used to predict antipsychotic efficacy showed that both novel M4 
PAMS substantially reduced amphetamine-induced hyperlocomotion (Brady et al., 2008).  
It will be of critical importance to further evaluate these compounds and their efficacy in 
other animal models of psychosis and cognition to yield a deeper understanding of the role 
of this receptor subtype in human diseases like schizophrenia and AD. 
 
Advances in the development of novel selective activators of M1 
  Over the past few years, several novel selective M1 agonists and allosteric 
potentiators have been identified.  These compounds are providing important new tools to 
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evaluate the potential utility of selective activators of M1 for treatment of AD and other 
CNS disorders.  For instance, TBPB (Jones et al., 2008) and 77-LH-28-1 (Langmead et al., 
2008b; Thomas et al., 2008) have been reported as agonists of M1.  Since the discovery of 
AC42, Acadia has developed a number of related compounds that have unprecedented 
selectivity for M1 relative to other mAChR subtypes, are orally bioavailable, and readily 
cross the blood brain barrier.  These compounds provide an exciting new approach for 
developing therapeutic agents to selectively activate M1.  In addition, they provide new 
tools that can be used to determine the physiological roles of M1 in the central nervous 
system and test the hypothesis that activation of M1 has effects that would predict 
antipsychotic efficacy in humans.  Both of these compounds are systemically active and are 
proving to be useful for in vivo studies of M1 activation. 
  TBPB selectively activates M1 in cell lines and has no agonist activity at any other 
mAChR subtypes.  Mutations that reduce the activity of orthosteric agonists have no effect 
on the response to TBPB, and Schild analysis of the blockade of TBPB effects with the 
orthosteric antagonist atropine reveals that TBPB does not interact with the orthosteric site 
in a competitive manner.  These data are consistent with the predictions of an allosteric 
ternary complex model for the actions of two molecules that interact with distinct sites 
(May et al., 2007; Conn et al., 2009a) and are consistent with the hypothesis that TBPB 
acts as an allosteric M1 agonist.  However, recent studies have shown that TBPB acts as an 
antagonist at M2-M5 receptors (Lebois et al., 2009) and also has off-target activity at D2 
receptors (Jones et al., 2008).  Despite the fact that TBPB does not significantly occupy D2 
sites at doses that produced efficacy in vivo, these findings do complicate data 
interpretation from studies using this compound. 
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  Interestingly, TBPB induces M1-dependent potentiation of NMDA currents in 
hippocampal pyramidal cells, an action that is thought to be important for the cognition-
enhancing effects of mAChR activation.  By contrast, TBPB does not reduce inhibitory or 
excitatory synaptic transmission in these neurons, effects thought to be mediated by M2 and 
M4 mAChRs, respectively (Jones et al., 2008).  Of particular relevance to AD pathology, 
early studies in cell lines indicate that TBPB induces an increase in processing of the 
amyloid precursor protein (APP) towards the non-amyloidogenic pathway and decreased 
Aβ production in vitro (Jones et al., 2008).  This is consistent with previous extensive 
studies indicating that mAChR activation has favorable effects on amyloid precursor 
protein processing in animal models and in humans (Nitsch et al., 2000; Fisher, 2008a; 
Caccamo et al., 2009) and provides further support to the hypothesis that selective 
activation of M1 might have disease-modifying effects in the treatment of AD in addition to 
its potential efficacy in acutely enhancing cognition in patients suffering from this disorder.  
TBPB is systemically active and crosses the blood–brain barrier, making this a useful tool 
for studies of cognition-enhancing effects of M1-selective agonists.  These encouraging 
results provide strong support for the utility of M1 allosteric agonists in activating this 
crucial mAChR subtype in the CNS without inducing the adverse effects associated with 
less selective mAChR agonists. 
  A second systemically active M1 agonist, 77-LH-28-1 was discovered as a 
structural analog of AC-42 (Langmead et al., 2008b; Thomas et al., 2008). 77-LH-28-1 is 
somewhat selective for M1 relative to other mAChR subtypes but does have weak agonist 
activity at M3 at higher concentrations.  Interestingly, in contrast to the effects of atropine 
on the response to TBPB, the orthosteric antagonist scopolamine induces parallel rightward 
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shifts in the 77-LH-28-1 concentration–response relationship (Langmead et al., 2008b). 
Consistent with this, recent radioligand-binding studies reveal that 77-LH-28-1 binds to the 
orthosteric site in a competitive manner (Thomas et al., 2008).  However, extensive 
mutagenesis studies combined with functional studies and analysis of the effects of 77-LH-
28-1 on binding of an orthosteric antagonist are consistent with an allosteric mode of 
agonist action of this compound.  These studies raise the possibility that 77-LH-28-1 might 
be what has been referred to as a ‘bi-topic’ ligand that binds to a site that overlaps with the 
orthosteric site but also includes an allosteric site that modulates orthosteric-site affinity 
(Lebon et al., 2009).  Electrophysiological studies indicated that 77-LH-28-1 increased 
activity of hippocampal CA1 pyramidal cells in vitro and in vivo and also induced 
synchronous network activity in the gamma and/or theta frequency bands in the 
hippocampus (Langmead et al., 2008b).  Interestingly, 77-LH-28-1 selectively activates the 
coupling of M1 to Gαq and Gαs signaling without activating the coupling of M1 to Gαi in 
Chinese hamster ovary cells (Thomas et al., 2008); this indicates that this compound might 
preferentially activate different responses to M1 activation.  Such differential effects of 
allosteric agonists on various responses to M1 activation could prove to be crucially 
important in determining the in vivo and ultimately therapeutic potential of allosteric M1 
agonists. 
  None of the novel M1 allosteric agonists described above are entirely selective for 
the M1 subtype and have properties that limit their use in determining the roles of M1 in 
native systems; an exciting development in the field of muscarinic pharmacology has been 
the recent discovery of M1 allosteric agonists VU0184670 and VU0357017 (Lebois et al., 
2009). These compounds are chemically optimized analogs of M1 allosteric agonists 
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identified in a primary high-throughput screen in the Vanderbilt Screening Center for 
GPCRs, Ion Channels and Transporters, initiated and supported by the NIH Molecular 
Libraries Roadmap.  A diversity-oriented synthesis/iterative screening approach was used 
to rapidly explore structure-activity relationships (SAR) of novel compounds with the goal 
being to improve potency while maintaining subtype selectivity.  Neither initial hits from 
the primary screen (VU0207811, VU0177548) nor the two chemically optimized analogs 
(VU0184670, VU0357017) displayed any agonist or antagonist activity at M2-M5, and the 
optimized leads also possessed an exceptionally clean ancillary pharmacology profile when 
assessed in a Panlab lead profiling screen of sixty-eight GPCRs, ion channels, and 
transporter targets (Lebois et al., 2009).  Thus, these newer generation M1 allosteric 
agonists represent a major breakthrough and are much more highly selective and have 
improved physiochemical properties compared to previous allosteric or orthosteric M1 
agonists.  Mutagenesis studies revealed that residues located in the extracellular loop three 
(o3) and the first helical turn of transmembrane seven (TM7) of the M1 receptor were 
critical for activity of VU0184670.  This same region of M4 was also implicated in the 
actions of M4 PAM LY2033298 (Chan et al., 2008).  Both M1 allosteric agonist lead 
compounds were found to possess a high degree of solubility in aqueous solutions and were 
centrally penetrant after systemic administration with VU0184670 possessing a superior 
pharmacokinetic profile. Similar to what was found with TBPB, VU0184670 also 
potentiates NMDAR currents evoked by NMDA application in hippocampal CA1 
pyramidal cells.  An exciting finding was that acute i.p. administration of VU0357017 
reversed cognitive deficits induced by the orthosteric mAChR antagonist scopolamine in a 
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contextual fear conditioning paradigm, a measure of hippocampal dependent learning 
(Lebois et al., 2009). 
  In addition to the discovery of novel M1-selective allosteric agonists, exciting 
progress has been made in the discovery of novel M1 PAMs that serve as allosteric 
potentiators of this receptor. For instance, multiple M1 allosteric potentiators have recently 
been identified in a high-throughput functional-screening campaign (Marlo et al., 2009).  
These molecules belong to several structurally distinct chemical scaffolds and include 
compounds that are selective for M1 relative to other mAChR subtypes.  None of the 
compounds identified had agonist activity but each behaved as a pure PAM and induced 
parallel leftward shifts in the ACh concentration–response relationships.  None of the novel 
M1 PAMs competes for binding at the orthosteric ACh-binding site.  The two most 
selective compounds, VU0090157 and VU0029767, were studied in detail and induced 
progressive shifts in ACh affinity at M1 that are consistent with their effects in a functional 
assay; this indicates that they mechanistically enhance M1 activity by increasing ACh 
affinity.  However, these compounds were strikingly different in their ability to potentiate 
responses at a mutant M1 receptor that exhibits decreased affinity for ACh and in their 
ability to affect responses of the allosteric M1 agonist TBPB.  Furthermore, VU0090157 
induced similar potentiation in M1 activation of PLC and PLD activity, whereas 
VU0029767 potentiated activation of PLC but not PLD signaling.  This provides another 
example of an ability of novel M1 PAMs to differentially regulate coupling of the receptor 
to different signaling pathways.  Based on this, it is possible that different M1 PAMs will 
have different actions on different responses to M1 activation in native systems. 
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  In a recent publication, researchers reported an encouraging advance in the 
discovery of benzyl quinolone carboxylic acid (BQCA) as a highly selective and 
efficacious allosteric potentiator for M1 (Ma et al., 2009).  As with VU0090157 and 
VU0029767, BQCA has no direct agonist activity but induces a robust leftward shift of the 
concentration–response relationship of ACh at activating M1.  BQCA has no activity at M2, 
M3, M4, or M5.  This compound markedly increased two markers of neuronal activation, c-
fos and arc, in multiple brain regions including cortex in wild-type but not M1 knockout 
mice as detected by in situ hybridization.  Similar to data from studies in our lab, BQCA 
did not compete for orthosteric [3H]NMS binding but increased affinity of M1 for ACh (see 
Chapter IV).  Residues Y179 and W400 which lie in the second (o2) and third (o3) 
extracellular loop of the receptor were shown to be required for the potentiation of M1 by 
BQCA as mutations of these residues completely illuminated potentiation.  Interestingly, 
BQCA is systemically active and fully reversed the cognitive impairment induced by 
scopolamine in a contextual fear-conditioning model of episodic-like memory (Ma et al., 
2009).  In addition, BQCA induces changes in electroencephalography oscillations in a 
manner that is consistent with a potential cognition-enhancing effect.  These findings 
provide exciting new data in support of the hypothesis that it will be possible to develop 
highly selective M1 PAMs that have potential for cognition-enhancing effects in animal 
models. 
  In agreement with findings by Ma et al. (2009), our lab has also characterized the 
M1 PAM, BQCA; our results are discussed in detail in Chapter IV of this thesis.  We also 
found BQCA to be highly selective for M1 relative to other mAChRs as well as to a panel 
of other GPCRs (Shirey et al., 2009).  Because studies in M1 knockout mice supported a 
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role for this receptor in supporting cognitive behaviors requiring normal functioning of the 
prefrontal cortex (PFC) (Anagnostaras et al, 2003), we sought to examine the effect of 
selective M1 activation in mPFC pyramidal cells.  Nonselective mAChR activation with 
CCh induced a robust inward current, and BQCA increased the inward current induced by 
a low concentration of CCh.  We also found that CCh dose-dependently increased 
excitatory drive to these cells as seen by an increase in spontaneous EPSCs, and that 
BQCA potentiates this effect as well.  Furthermore, systemic administration of BQCA 
drastically increases the firing rate of mPFC pyramidal cells in vivo in multichannel single 
unit recordings and is able to reverse impairments in PFC-dependent learning in a mouse 
model of AD (Shirey et al., 2009).  Together, studies by our group (Lebois et al., 2009; 
Shirey et al., 2009) and Ma et al. (2009) support a pivotal role for the M1 receptor in 
modulating both hippocamapal- and PFC-dependent learning and suggest that this mAChR 
subtype represents an exciting potential therapeutic target for the treatment of CNS 
disorders characterized by memory and cognitive impairment. 
  Lastly, it is important to note that, at present, the mechanisms underlying the 
selectivities of muscarinic allosteric agonists and PAMs are not fully established. The 
initial rationale driving this approach is that allosteric ligands bind to evolutionarily less-
conserved allosteric sites on the M1 or M4 receptor, as opposed to the highly conserved 
orthosteric (ACh) binding site and might, therefore, bind selectively to allosteric sites on 
individual mAChR subtypes.  This hypothesis has been clearly established for 
metabotropic glutamate receptors where selective binding of allosteric ligands to individual 
subtypes has been established as the basis for the selectivity of some ligands (Conn et al., 
2009a).  However, this does not rule out the possibility that these compounds bind to 
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allosteric sites on multiple mAChR subtypes with similar affinities but that selectivity is 
conferred by selective cooperativity with orthosteric-site agonists (May et al., 2007; Conn 
et al., 2009a), as has been suggested for the functionally selective PAM activity of 
thiochrome on M4 (Lazareno et al., 2004).  If this is the case, it is possible that selectivity 
of these compounds will vary depending on the system in which their effects are measured.  
Thus, it will be crucial to develop a clear understanding of the molecular basis for the 
observed selectivity in future studies.  Optimally, this should be addressed with 
radioligands that act at the allosteric but not the orthosteric sites.  However, studies 
involving detailed analysis of effects of allosteric compounds on binding of orthosteric-site 
ligands in addition to mutagenesis studies will also shed light on this important issue.  
Finally, it will be critical to understand whether selectivity of PAMs holds constant in the 
presence of multiple different classes of orthosteric agonists; examples of probe 
dependence of allosteric modulators are now surfacing (Kenakin, 2008).  Preliminary 
findings by our group and others with the M4 PAM LY2033298 and related analogs 
suggest that selectivity of these compounds across mAChR subtypes exists in the presence 
of ACh but not another orthosteric agonist, oxotremorine.  Considering that co-
administration of low doses of systemically active muscarinic agonists may be required to 
see efficacy of PAMs in different behavioral models, it will be critical to explore selectivity 
profiles of allosteric modulators not only in careful radioligand binding experiments but 
also in multiple functional assays in vitro with different classes of orthosteric agonists. 
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mAChR pharmacology and novel allosteric ligands: conclusions 
  Exciting new data from animal and clinical studies indicate that ligands at mAChR 
subtypes might provide a novel approach to the treatment of multiple CNS disorders. This 
includes compelling evidence that selective increases in the activity of M1 and M4 could 
provide a novel approach to the treatment of AD and schizophrenia and perhaps have 
efficacy in treating psychosis and cognitive impairment in other neurodegenerative 
diseases. Major advances have been made in establishing selective allosteric agonists and 
PAMs of both M1 and M4 as an alternative approach to orthosteric agonists for the 
development of selective receptor activators. These molecules have now been optimized 
for use in animal models, and early studies indicate that they have effects in animal models 
that predict efficacy in the treatment of these disorders. In addition to potential clinical 
utility of selective mAChR activators, abundant clinical and animal studies indicate that 
highly selective antagonists of specific mAChR subtypes might have utility in the treatment 
of other CNS disorders including dystonia, Parkinson's disease, epilepsy and others 
(Bymaster et al., 2002; Bymaster et al., 2003c; Bymaster et al., 2003b; Katzenschlager et 
al., 2003; Wess et al., 2007; Fisher, 2008b; Langmead et al., 2008a; Conn et al., 2009b).  In 
each case, subtype selectivity will be a key to achieving clinical efficacy in the absence of 
adverse effects.  For other GPCRs, it has been possible to discover allosteric modulators 
that serve as allosteric activators or inhibitors (i.e. NAMs) of receptor function (Gasparini 
et al., 1999; Mannaioni et al., 2001; Campbell et al., 2004).  Thus, it might be possible to 
discover selective allosteric antagonists of mAChR subtypes.  Indeed, a recent high-
throughput screening campaign that focused on M1 PAMs was also successful in 
identifying NAMs of mAChR subtypes that are still under development (Marlo et al., 
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2009).  These exciting advances are providing a fundamental advance in our approaches to 
regulating mAChRs as drug targets and may provide a novel approach to treatment of AD 
and schizophrenia in addition to other CNS-related disorders. 
 
Muscarinic receptors as therapeutic targets 
          A prominent characteristic of AD is a degeneration of a group of cholinergic 
projection neurons in the basal forebrain that project from the medial septum and nucleus 
basalis of Meynert to the hippocampus and other forebrain areas involved in cognition, 
learning and memory (Francis et al., 1999).  There is a subsequent decrease in the 
synaptic levels of ACh that seem to correlate with cognitive impairment, and in AD, there 
is can be up to a ninety percent loss of cholinergic neurons in the basal forebrain.  A large 
number of animal and human studies suggest that these cholinergic projections play a 
critical role in memory and attention mechanisms and that the clinical syndrome 
associated with AD results, at least in part, from failed neurotransmission at cholinergic 
synapses (Bartus et al., 1982; Whitehouse et al., 1982; Arendt et al., 1983; Damasio et al., 
1985; Reinikainen et al., 1990; Fibiger, 1991; Voytko et al., 1994; Auld et al., 2002).  
Evidence suggests that cholinergic transmission in the forebrain is mediated primarily by 
mAChRs and these receptors are likely to mediate the cholinergic involvement in 
learning and memory (Coyle et al., 1983; Brown and Zador, 1990; Fibiger et al., 1991).  
Despite a loss in presynaptic cholinergic markers such as the vesicular ACh transporter 
and the choline transporter as well as presynaptic M2 receptor expression, it appears that 
postsynaptic M1 and M3 receptors remain intact whereas presynaptic M4 levels have been 
shown to increase in AD (Flynn et al., 1995b; Flynn et al., 1995a). 
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These studies suggest that agents that enhance cholinergic transmission could be 
clinically useful for ameliorating the loss of cognitive function in patients with AD and 
other memory disorders.  Some of the earliest therapies developed for the treatment of AD 
employed the strategy of inhibiting the enzyme responsible for degrading ACh, 
acetylcholinesterase (AChE).  The cholinergic hypothesis of AD has been partially 
substantiated by clinical trials with AChE inhibitors such as tacrine, rivastigmine, 
donepezil, and galantamine, establishing dose-related improvements in measures of 
cognitive performance and quality of life (Davis et al., 1992; Farlow et al., 1992; Knapp et 
al., 1994; Rogers et al., 1998; Raskind et al., 1999; Wilkinson and Murray, 2001; Munoz-
Torrero, 2008).  Several factors have limited this therapeutic approach, the first being that 
AChE inhibitors increase levels of ACh not only in the CNS but in the periphery.  This 
leads to a host of adverse side effects mediated primarily by peripheral mAChRs.  The 
most prominent adverse effects of AChE inhibitors are mediated by activation of peripheral 
M2 and M3 mAChRs and include bradycardia, GI distress, excessive salivation, and 
sweating (Krejci and Tucek, 2002; Bymaster et al., 2003c; Bymaster et al., 2003a; Unno et 
al., 2005).   
An alternative therapeutic strategy involves the used and development of 
cholinergic agonists that activate mAChRs directly and would replace the deficiency in 
endogenous acetylcholine signaling.  This approach would circumvent one of the 
limitations of AChE inhibitors in that those drugs rely on intact ACh release; as discussed 
above, one of the prominent pathologies underlying AD and the cholinergic hypothesis is 
the degeneration of cholinergic inputs.  Direct acting agonists therefore would not rely on 
presynaptic cholinergic projections to be intact and functional. 
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The M1 receptor subtype has been viewed as the most likely candidate for 
mediating the beneficial effects of cholinergic therapies on cognition, attention 
mechanisms, and sensory processing.  Because of this, considerable effort has been focused 
on developing selective M1 agonists for treatment of AD (Fisher, 1997; Korczyn, 2000; 
Messer et al., 2000; Greenlee et al., 2001; Fisher et al., 2002; Messer, 2002a).  The 
development and use of compounds such as AF102B and AF267B, talsaclidine and 
xanomeline (Pittel et al., 1996; Bodick et al., 1997b; Nitsch et al., 2000; Fisher et al., 2002; 
Messer, 2002a; Shekhar et al., 2008) have provided important proof of concept evidence 
that this is a viable approach.  Treatment with these compounds caused a modest 
improvement in cognitive impairments measured by the AD assessment scale; however, 
these efforts were limited because cholinergic side effects similar to those seen with AChE 
inhibitors were seen.  These findings indicate that despite claims of M1 selectivity in vitro, 
these compounds are not selective for M1 in vivo.  Differences in receptor expression levels 
in recombinant systems and the use of varying functional readouts of receptor activation 
does lead to discrepancies in selectivity profiles of many compounds when characterized 
by different research groups.  Our lab and others have found that AF267B (Fisher et al., 
2002; Caccamo et al., 2009), also activates M3 and M5 receptor subtypes (Jones et al., 
2008; Langmead et al., 2008b).  Furthermore, we and others have found that xanomeline 
not only activates M1 and M4 but M2, M3, and M5 in recombinant cell lines (Langmead et 
al., 2008b).    
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Xanomeline 
  Of the mAChR agonists to date, xanomeline has progressed furthest in clinical 
development.  In an early large multicenter trial, it had a modest effect on cognitive 
function in AD patients that barely reached significance (Bodick et al., 1997b; Bodick et 
al., 1997a).  Although the cognition-enhancing effects of this compound in Phase III trials 
were somewhat disappointing, the most exciting and surprising finding in the xanomeline 
trial was that this agonist had robust therapeutic effects on psychotic symptoms and 
behavioral disturbances such as vocal outbursts, suspiciousness, delusions, agitation, and 
hallucinations that are associated with AD (Bodick et al., 1997a).  These data indicate that 
activation of mAChRs could be a therapeutic strategy for treatment of psychosis and 
behavioral disturbances in patients suffering from a broad range of disorders including 
schizophrenia, AD and other neurodegenerative disorders (Felder et al., 2000; Bymaster et 
al., 2002; Mirza et al., 2003; Langmead et al., 2008a; Conn et al., 2009b).  Indeed, initial 
clinical findings from a small-scale double-blind, placebo-controlled study testing the 
efficacy of xanomeline in treating the various positive, negative, and cognitive symptoms 
in twenty subjects with schizophrenia, significant improvements in positive and negative 
symptoms occurred with treatment compared to placebo.  Subjects in the xanomeline group 
also showed improvements in cognitive measures of verbal learning and short-term 
memory function.  Together, these studies provide strong clinical validation of mAChR 
agonists as novel therapeutic agents used for the treatment of psychosis and behavioral 
disturbances in patients suffering from a broad range of disorders including schizophrenia, 
AD and other neurodegenerative disorders.  Unfortunately, because xanomeline lacks true 
M1/M4 specificity and has significant affinity and efficacy at M2, M3, and M5 (Jakubik et 
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al., 2006; Langmead et al., 2008b; Noetzel et al., 2009) and is also poorly brain penetrable 
so that high plasma concentrations are required to achieve sufficient brain levels for M1 
activation, it suffers from the same peripheral side effects as those of AChE inhibitors.  
This dose-limiting toxicity prevented determination of whether higher doses would have 
induced a more robust effect on cognition (Bodick et al., 1997b; Bodick et al., 1997a; 
Shekhar et al., 2008). 
 
mAChR subtypes involved in the therapeutic efficacy of xanomeline 
  Although the exact mAChR subtype responsible for the effects of xanomeline in 
schizophrenia patients agents is not certain, xanomeline is an M1/M4-preferring agonist and 
multiple animal studies indicate that one or both of these mAChR subtypes is likely to be 
responsible for the clinical efficacy of this compound (Felder et al., 2001; Gerber et al., 
2001; Miyakawa et al., 2001; Bymaster et al., 2002; Marino and Conn, 2002; Anagnostaras 
et al., 2003; Tzavara et al., 2004; Langmead et al., 2008a). Thus, it will be important to 
rigorously evaluate the potential roles of both of these receptor subtypes in animal models 
that predict efficacy in the different symptom clusters associated with schizophrenia (i.e. 
positive, negative and cognitive symptoms). Interestingly, the M1-selective allosteric 
agonist TBPB has activity in multiple animal models used to predict the efficacy in 
treatment of positive symptoms of schizophrenia.  These include the reversal of 
amphetamine-induced hyperlocomotor activity and disruption of prepulse inhibition, in 
addition to changes in c-fos expression that are almost identical to changes induced by 
atypical antipsychotic agents (Jones et al., 2008).  Furthermore, the M1-selective allosteric 
agonist 77-LH-28-1 increases hippocampal pyramidal cell firing and initiates gamma 
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frequency network oscillations in slices and increased pyramidal cell firing in rat 
hippocampus in vivo (Langmead et al., 2008b).  Our studies show that the selective M1 
PAM BQCA increases spontaneous EPSCs and firing rate of mPFC neurons in slices and 
in vivo and acute administration of this compound also reverses impairments in reversal 
learning in an animal model of AD (Shirey et al., 2009).  BQCA also increases c-fos 
expression and ERK phosphorylation in rodent cortex and hippocampus in addition to 
dose-dependently reversing scopolamine-induced memory deficits in contextual fear 
conditioning, a measure of hippocampal-dependent memory (Ma et al., 2009).  Despite 
data from M1 knockout mice showing a lack of major impairments in hippocampal-
dependent learning in behavioral paradigms (Anagnostaras et al., 2003) current data 
employing selective pharmacological activation of M1 strongly support the hypothesis that 
is a promising therapeutic target for psychosis and cognitive impairment. 
 
The dopamine hypothesis of schizophrenia 
  Another neurotransmitter system involved in the etiology of schizophrenia is the 
dopminergic system.  Clinically relevant antipsychotic drugs block dopamine D2 receptors, 
and drugs such as amphetamine and cocaine that cause increases in DA levels are 
psychotomimetics that can mimic positive symptoms of schizophrenia in healthy 
individuals (Bymaster and Felder, 2002; Raedler et al., 2007).  The dopamine hypothesis of 
schizophrenia (Kapur et al., 2005) also suggests that hyperactivity of the mesolimbic 
dopaminergic pathway underlies the positive symptoms and that hypoactivity of the 
mesocortical dopaminergic pathways causes the negative and cognitive symptoms of the 
disease.  Typical and atypical antipsychotics do not possess efficacy in treatment of many 
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of the negative and cognitive symptoms, however, implying that dopaminergic dysfunction 
cannot fully account for the array of symptoms seen in this patient population (Gold, 2004).  
In addition, these therapies also are often poorly tolerated because of numerous side effects 
including sedation, weight gain, sexual dysfunction, diabetes, and Parkinson's disease-like 
symptoms related to DAR blockade. Furthermore, greater than 25% of schizophrenia 
patients do not respond to these dopamine-based therapies (Hirsch and Barnes, 1995). 
Thus, although it is evident that dopamine does play a prominent role in the pathogenesis 
and treatment of schizophrenia, the dopamine hyperfunction hypothesis of schizophrenia 
fails to account for all aspects of this disorder, and it is increasingly evident that other 
neurotransmitter systems are probably involved.  Interestingly, M1 and M4 knockout mice 
both display significantly elevated dopamine neurotransmission in basal ganglia structures, 
increased basal locomotor activity, and increased responsiveness to the stimulatory effects 
of amphetamine (Gerber et al., 2001; Tzavara et al., 2004).  M4 knockout animals also 
showed elevated basal levels and stimulated dopamine efflux and metabolites in the 
nucleus accumbens compared to wild-types; basal levels of ACh in the midbrain were also 
significantly increased (Tzavara et al., 2004).  These data indicate that M4 controls ACh 
release from cholinergic projections to the midbrain and also controls mAChR-regulated 
dopamine release.  It has been speculated that selective activation of M4 may alleviate mid-
brain dopamine hyperactivity that is attributed to the psychosis observed in schizophrenia 
(Langmead et al., 2008a).  Growing data supporting this hypothesis includes the finding 
that the selective M4 PAM LY2033298 potentiates oxotremorine-stimulated dopamine 
release in the PFC but not in nucleus accumbens; when the compound was administered 
subcutaneously, it attenuated conditioned avoidance responding and apomorphine-induced 
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disruption of prepulse inhibition of the acoustic startle reflex when co-administered with a 
subthreshold dose of oxotremorine, two preclinical animal models predictive of 
antipsychotic efficacy (Chan et al., 2008).  Additionally, as described in this thesis, we 
found that the related M4 PAMs VU0152100 and VU0152099 reversed amphetamine-
induced hyperlocomotion without affecting baseline levels of motor performance as 
assessed by the rotorod test (Brady et al., 2008). 
 
Therapeutic promise of mAChR ligands: conclusions 
  In summary, abundant and burgeoning preclinical and clinical data bolster the 
theory that selective activation of either or both M1 and M4 receptors represents an exciting 
and promising approach to the treatment of numerous CNS disorders including AD and 
schizophrenia, bringing together the potential for both cognitive improvements via M1 and 
dopaminergic imbalances via M4.  New tools described in this thesis including BQCA and 
VU0152100 provide an exciting opportunity to activate M1 and M4 receptors in vivo with 
exquisite selectivity.  It remains to be seen if selective activation of either receptor alone 
will be enough to replicate and improve upon the antipsychotic efficacy and cognitive-
improving effects of xanomeline without inducing undesirable, dose-limiting cholinergic 
side effects.      
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CHAPTER II 
 
METHODS 
 
Compounds and Materials 
 Commercially available test compounds from the M4 PAM analog structure 
similarity database mining search were purchased from ChemBridge Research 
Laboratories (San Diego, CA).  Probenecid, dimethyl sulfoxide (DMSO), acetylcholine 
chloride (ACh), adenosine-5´triphosphate (ATP), guanosine 5´-[γ-thio]triphosphate 
(GTPγS), guanosine 5'-diphosphate (GDP) and atropine were purchased from Sigma-
Aldrich (St. Louis, MO), and glutamate was purchased from Tocris Cookson (Ellisville, 
MO).  All tissue culture reagents as well as fluo-4 AM were purchased from Invitrogen 
(Carlsbad, CA).  BioCoat poly-D-lysine 384-well culture plates were obtained from 
Becton Dickinson Biosciences Discovery Labware (Bedford, MA); Greiner optical 
bottom TC-treated 384-well culture plates and Axygen polypropylene 96-well deep well 
plates were obtained from VWR Scientific Products (Sewanee, GA).  l-[N-methyl-
3H]scopolamine was purchased from GE Healthcare (Little Chalfont, Buckinghamshire, 
UK); [35S]GTPγS, Unifilter-96 GF/B plates and MicroScint-20 were obtained from 
PerkinElmer Life and Analytical Sciences (Boston, MA). 
 
Chemical Database Mining for M4 PAM LY2033298 Analogs: Chapter IIIa 
        Substructures searches were performed using ChemFinder (CambridgeSoft Corp., 
Cambridge, MA) to search the commercially available database of ChemBridge Corp. 
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(San Diego, CA).  The thienopyridine-2-carboxamide core of LY2033298 (Chan et al., 
2008) was used to search the library yielding approximately 500 substructure hits.  The 
set of compounds was then limited by properties such as molecular weight, polar surface 
area, rotatable bonds and number of hydrogen bond donor/acceptors to provide a library 
of 232 compounds. 
 
General procedure for the synthesis of compounds VU10001-VU10010:         
Chapter IIIa 
 
2-bromo-N-(4-chlorobenzyl)acetamide:  To a solution of 4-chlorobenzylamine (12.0 g, 
85.1 mmol) in CH2Cl2 (300 mL) at 0 ºC was added Et3N (14.32 g, 141.8 mmol, 1.7 
equiv) and bromoacetyl bromide (21.49 g, 106.4 mmol, 1.25 equiv). The reaction was 
stirred for 2 h. The reaction was quenched with the addition of water (400 mL) and 
mixture was extracted with CH2Cl2 (3 x 300 mL). The combined organic layers were 
dried (MgSO4), filtered, and concentrated under reduced pressure to afford the 
bromoamide. (22.3g, quant.) as a light brown solid. 1H-NMR (400 MHz, CDCl3) δ 7.35 
(d, J = 8.5 Hz, 2H), 7.25 (d, J = 8.5 Hz, 2H), 6.80 (s, 1H), 4.47 (d, J = 6 Hz, 2H), 3.96 (s, 
2H). MS (m/z): calcd for (C9H9BrClNO+H)+, 262; found, 262.   
3-amino-N-(4-chlorobenzyl)-4,6-dimethylthieno[2,3-b]pyridine-2-carboxamide     
(M4 PAM VU10010) synthesis:  To a solution of mercaptopyridine (5.0 g, 30.48 mmol) 
in DMF (100 mL) was added bromo amide (11.95 g, 45.73 mmol, 1.5 equiv) followed by 
KOH (6.82 g, 121.9 mmol, 5 equiv) and water (4 mL). The reaction was stirred at room 
temperature for 15 h and then heated to 50 ºC for 24 h. The reaction mixture was diluted 
with water (500 mL) and extracted with EtOAc (2 x 400 mL). The combined organic 
layers were washed with brine (300 mL), dried (MgSO4), filtered, and concentrated 
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under reduced pressure to afford the free amine title compound (6.75 g, 64%) as a light 
brown solid.  The free amine was suspended in acetonitrile (30 mL) and water (5 mL) 
and TFA was added (2 mL). The mixture was filtered and the filtrate was concentrated to 
give the title compound as the mono TFA salt. 
VU10001: 1H-NMR (400 MHz, DMSO-d6): δ 7.68 (t, J = 6.0 Hz, 1H), 7.01 (s, 1H), 3.01 
(t, J = 6 Hz, 2H), 2.70 (s, 3H), 2.50 (s, 3H), 1.89-1.77 (m, 1H), 0.85 (d, J = 6 Hz, 6H). 
13C-NMR (100 MHz, DMSO-d6): δ 165.6, 158.7, 158.6, 147.8, 145.0, 122.2, 98.2, 46.7, 
28.5, 24.1, 20.6, 20.1. HRMS (m/z): calcd for (C14H19ClN3OS+H)+, 278.1327; found, 
278.1324. 
VU10002: 1H-NMR (400 MHz, DMSO-d6): δ 7.66 (t, J = 6.0 Hz, 1H), 7.00 (s, 1H), 3.19-
3.10 (m, 2H), 2.70 (s, 3H), 2.50 (s, 3H), 1.56-1.41 (m, 2H), 0.85 (t, J = 7 Hz, 3H). 13C-
NMR (100 MHz, DMSO-d6): δ 165.2, 158.5, 158.3, 147.4, 144.4, 123.2, 121.7, 97.7, 
40.6, 23.7, 22.6, 19.7, 11.4. HRMS (m/z): calcd for (C13H17N3OS+H)+, 264.1171; found, 
264.1173. 
VU10003: 1H-NMR (400 MHz, DMSO-d6): δ 7.02 (s, 1H), 2.71 (s, 3H), 2.50 (s, 3H), 
1.37 (s, 9H). 13C-NMR (100 MHz, DMSO-d6): δ 165.8, 158.5, 158.3, 147.6, 145.1, 
123.8, 122.2, 99.1, 51.6, 29.1, 24.0, 20.2. HRMS (m/z): calcd for (C14H19N3OS+H)+, 
278.1327; found, 278.1330. 
VU10004: 1H-NMR (400 MHz, DMSO-d6): δ 7.72-7.66 (m, 1H), 7.99 (s, 1H), 2.80-2.72 
(m, 1H), 2.69 (s, 3H), 2.47 (s, 3H), 0.67-0.52 (m, 4H). 13C-NMR (100 MHz, DMSO-d6): 
δ 167.0, 158.9, 158.7, 148.0, 144.9, 123.5, 122.1, 97.7, 24.1, 23.3, 20.1, 6.2. HRMS 
(m/z): calcd for (C13H15N3OS+H)+, 262.1014; found, 262.1015. 
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VU10005: 1H-NMR (400 MHz, DMSO-d6): δ 8.28 (t, J = 6.0 Hz, 1H), 7.37-7.30 (m, 
2H), 7.17-7.09 (m, 2H), 7.03 (s, 1H), 4.37 (d, J = 6 Hz, 2H), 2.70 (s, 3H), 2.50 (s, 3H). 
13C-NMR (100 MHz, DMSO-d6): δ 165.6, 158.7, 158.5, 148.3, 145.1, 136.6, 129.6, 
123.6, 122.2, 115.4, 115.2, 97.6, 42.0, 24.1, 20.1. HRMS (m/z): calcd for 
(C17H16FN3OS+H)+, 330.1076; found, 330.1078. 
VU10006: 1H-NMR (400 MHz, DMSO-d6): δ 8.01 (d, J = 6.0 Hz, 1H), 7.42-7.16 (m, 
5H), 7.01 (s, 1H), 5.19-5.10 (m, 1H), 2.70 (s, 3H), 2.50 (s, 3H), 1.46 (d, J = 8 Hz, 3H). 
13C-NMR (100 MHz, DMSO-d6): δ 165.0, 158.9, 158.7, 148.3, 145.4, 145.0, 128.5, 
126.9, 126.5, 123.6, 122.2, 97.8, 48.6, 24.1, 22.2, 20.2. HRMS (m/z): calcd for 
(C18H19N3OS+H)+, 326.1327, found, 326.1330. 
VU10007: 1H-NMR (400 MHz, DMSO-d6): δ 8.01 (d, J = 6.0 Hz, 1H), 7.42-7.16 (m, 
5H), 7.01 (s, 1H), 5.19-5.10 (m, 1H), 2.70 (s, 3H), 2.50 (s, 3H), 1.46 (d, J = 8 Hz, 3H). 
13C-NMR (100 MHz, DMSO-d6): δ 165.0, 158.9, 158.7, 148.3, 145.4, 145.0, 128.5, 
126.9, 126.5, 123.6, 122.2, 97.8, 48.6, 24.1, 22.2, 20.2. HRMS (m/z): calcd for 
(C18H19N3OS+H)+, 326.1327; found, 326.1329. 
VU10008: 1H-NMR (400 MHz, DMSO-d6): δ 8.36 (t, J = 6.0 Hz, 1H), 7.68 (d, J = 8 Hz, 
2H), 7.51, (d, J = 8 Hz, 2H), 7.03 (s, 1H), 4.46 (d, J = 6 Hz, 2H), 2.70 (s, 3H), 2.50 (s, 
3H). 13C-NMR (100 MHz, DMSO-d6): δ 165.8, 158.9, 158.8, 148.4, 145.3, 145.2, 128.2, 
125.6, 125.5, 123.6, 122.3, 97.3, 42.4, 24.1, 20.1. HRMS (m/z): calcd for 
(C18H16F3N3OS+H)+, 380.1044; found, 380.1051. 
VU10009: 1H-NMR (400 MHz, DMSO-d6): δ 7.73-7.64 (t, J = 6.0 Hz, 1H), 7.01 (s, 1H), 
3.28-3.16 (m, 2H), 2.70 (s, 3H), 2.50 (s, 3H), 1.08 (t, J = 8 Hz, 3H). 13C-NMR (100 MHz, 
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DMSO-d6): δ 165.4, 158.6, 158.5, 147.8, 145.0, 123.7, 122.2, 98.2, 34.1, 24.1, 20.1, 
15.4. HRMS (m/z): calcd for (C12H15N3OS+H)+, 250.1014; found, 250.1019. 
VU10010: 1H-NMR (300 MHz, DMSO-d6): δ 8.30 (t, J = 6.0 Hz, 1H), 7.39 (d, J = 8.5 
Hz, 2H), 7.33 (d, J = 8.5 Hz, 2H), 7.05 (s, 1H), 4.38 (d, J = 6 Hz, 2H), 2.72 (s, 3H), 2.50 
(s, 3H). 13C-NMR (100 MHz, DMSO-d6): δ 166.1, 159.3, 159.2, 148.8, 145.6, 140.0, 
132.0, 130.0, 129.0, 124.1, 122.7, 98.0, 42.6, 24.5, 20.6. MS (m/z): calcd for 
(C17H16ClN3OS+H)+, 346; found, 346. Analysis (calcd, found for C19H17ClF3N3O3S): C 
(49.62, 49.96), H (3.73, 3.72), N (9.14, 8.94). 
 
General Medicinal Chemistry Methods: Chapter IIIb 
 All NMR spectra were recorded on a 400-MHz Bruker NMR. 1H chemical shifts 
were reported in values in parts per million down-field from tetramethylsilane as the 
internal standard in DMSO. Data are reported as follows: chemical shift, multiplicity (s = 
singlet, d = doublet, t = triplet, q = quartet, br = broad, and m = multiplet), integration, 
and coupling constant (in Hertz). 13C chemical shifts are reported in values in parts per 
million with the DMSO carbon peak set to 39.5 ppm. Low resolution mass spectra were 
obtained on an Agilent 1200 LC/MS with electrospray ionization (Agilent Technologies, 
Santa Clara, CA). High-resolution mass spectra were recorded on a Quadrupole Time of 
Flight (Q-ToF)-API-US plus Acquity system (Waters, Milford, MA). Analytical thin-
layer chromatography was performed on 250-µm Silica Gel 60 F254 plates. Analytical 
HPLC was performed on an Agilent 1200 analytical LC/MS with UV detection at 214 
and 254 nm along with ELSD detection. Preparative purification was performed on a 
custom Agilent 1200 preparative LC/MS with collection triggered by mass detection. 
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Solvents for extraction, washing, and chromatography were of HPLC grade. All reagents 
were purchased from Aldrich Chemical Co. (Milwaukee, WI), Maybridge Chemicals 
(Trevillet, UK), ChemBridge Corporation (San Diego, CA), and SPECS Technologies 
Corporation (Sarasota, FL) and were used without purification. All polymer-supported 
reagents were purchased from Biotage AB (Uppsala, Sweden). 
General Procedure for M4 PAM Library Synthesis of Analogs 7:  Each of the 31 glass 
vials containing 3 ml of CH2Cl2 was loaded with N,N-diisopropylethylamine (0.3 ml, 1.70 
mmol), AM-807/25050004 (50 mg, 0.225 mmol; SPECS Technologies Corporation), 1-
hydroxybenzotriazole hydrate (30.4 mg, 0.225 mmol, 1.0 equivalents), polystyrene-bound 
N-cyclohexylcarbodiimide (317 mg, 0.450 mmol, 1.42 mmol/g, 2.0 equivalents), and one 
of 31 amines (0.225 mmol, 1.0 equivalents). The reactions were stirred for 48 h at room 
temperature. Macroporous triethylammonium methylpolystyrene carbonate (145 mg, 
0.225 mmol, 3.11 mmol/g, 2.0 equivalents) was added, and the reactions were stirred for 
an additional 3 h at room temperature. Then, the reactions were filtered and concentrated 
on a heat-air block to afford 84 to 99% pure products. Those <99% pure were purified by 
mass-directed HPLC.  
M4 PAM VU0152099 Synthesis:  The following components were added to a stirred 
solution of 3-amino-4,6-dimethylthioenol[2,3-b]-pyridine-2-carboxylic acid (3.0 g, 13.51 
mmol; ChemBridge Corporation) in CH2Cl2 (90 ml) at 25°C under room atmosphere: 
N,N-diisopropylethylamine (10 ml, 56.66 mmol); 1-hydroxybenzotriazole hydrate (1.83 
g, 13.51 mmol, 1.0 equivalents); 4-methoxybenzylamine (2.04 g, 14.86 mmol, 1.1 
equivalents); and N-(3-dimethylaminopropyl)-N'-ethyl-carbodiimide hydrochloride (5.18 
g, 27.02 mmol, 2.0 equivalents). After 48 h, macroporous triethylammonium 
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methylpolystyrene carbonate (4.4 g, 13.51 mmol, 3.077 mmol/g, 1.0 equivalents) was 
added to the solution, which was then stirred for 3 h at 25°C under room atmosphere. The 
solution was vacuum-filtered next, and the filtrate was separated with citric acid (1.0 M in 
water) and CH2Cl2. The organics were dried over MgSO4 and concentrated in vacuo to 
produce a dark yellow solid. The solid was purified by column chromatography (silica 
gel, fixed 1:2 EtOAc/hexanes) to afford 2.5 g (7.33 mmol, 54%) of the title compound as 
a bright yellow solid. Analytical LC/MS (J-Sphere80-S4, 3.0 x 50 mm, 4.0-min gradient, 
5%[CH3CN]: 95%[0.1% trifluoroacetic acid/H2O] to 100%[CH3CN]): 2.773 min, >99% 
(214 nm and ELSD), M + 1 peak m/e 342.12; 1H NMR (400 MHz, DMSO-d6) 7.27 (d, J 
= 8.8 Hz, 2H), 6.89 (s, 1H), 6.86 (d, J = 8.8 Hz, 2H), 6.34 (br s, 2H), 5.80 (s, 1H), 4.53 
(d, J = 6.0 Hz, 2H), 3.79 (s, 3H), 2.73 (s, 3H), 2.57 (s, 3H); 13C NMR (100 MHz, DMSO-
d6) 165.9, 159.3, 159.2, 147.7, 143.9, 130.7, 129.3, 123.7, 122.4, 114.4, 98.5, 55.5, 43.3, 
24.5, 20.4; high-resolution mass spectroscopy (Q-ToF): m/z calc for C18H19N3O2S[M + 
H]: 342.1198; found, 342.1276.  
M4 PAM VU0152100 Synthesis:  The following components were added to a stirred 
solution of 3-amino-4,6-dimethylthioenol[2,3-b]-pyridine-2-carboxylic acid (2.50 g, 
11.26 mmol; ChemBridge Corporation) in CH2Cl2 (90 ml) at 25°C under room 
atmosphere: N,N-diisopropylethylamine (10 ml, 56.66 mmol); 1-hydroxybenzotriazole 
hydrate (1.52 g, 11.26 mmol, 1.0 equivalents); piperonylamine (1.87 g, 12.38 mmol, 1.1 
equivalents); and N-(3-dimethylaminopropyl)-N'-ethyl-carbodiimide hydrochloride (4.32 
g, 22.52 mmol, 2 equivalents). After 48 h, macroporous triethylammonium 
methylpolystyrene carbonate (3.66 g, 11.26 mmol, 3.077 mmol/g, 1.0 equivalents) was 
added to the solution, which was then stirred for 3 h at 25°C under room atmosphere. The 
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solution was vacuum-filtered next, and the filtrate was separated with citric acid (1.0 M in 
water) and CH2Cl2. The organics were dried over MgSO4 and concentrated in vacuo to 
produce a dark yellow solid. The solid was purified by column chromatography (silica 
gel, fixed 1:2 EtOAc/hexanes) to afford 2.0 g (5.63 mmol, 50%) of the title compound as 
a yellow solid. Analytical LC/MS (J-Sphere80-S4, 3.0 x 50 mm, 4.0 min gradient, 
5%[CH3CN]: 95%[0.1% trifluoroacetic acid/H2O] to 100%[CH3CN]): 2.740 min, >99% 
(214 nm and ELSD), M + 1 peak m/e 356.10; 1H NMR (400 MHz, DMSO-d6) 8.38 (s, 
1H), 7.18 (s, 1H), 6.88 (s, 1H), 6.84 (d, J = 8.0 Hz, 1H), 6.78 (d, J = 8.0 Hz, 1H), 5.98 (br 
s, 2H), 5.97 (s, 2H), 4.30 (d, J = 5.2 Hz, 2H), 2.77 (s, 3H), 2.57 (s, 3H); 13CNMR (100 
MHz, DMSO-d6) 179.9, 164.8, 161.7, 158.0, 153.4, 147.4, 133.8, 122.4, 121.9, 120.5, 
108.0, 107.9, 100.8, 92.8, 42.1, 22.4, 20.0; high-resolution mass spectroscopy (Q-ToF): 
m/z calc for C18H17N3O3S[M + H]: 356.0991; found, 356.1069. 
 
General Medicinal Chemistry Methods: Chapter IV 
 All NMR spectra were recorded on a 400 MHz Bruker NMR.  1H chemical shifts 
are reported in δ values in ppm downfield from TMS as the internal standard in DMSO.  
Data are reported as follows:  chemical shift, multiplicity (s = singlet, d = doublet, t = 
triplet, q = quartet, br = broad, m = multiplet), integration, coupling constant (Hz).  13C 
chemical shifts are reported in δ values in ppm with the DMSO carbon peak set to 39.5 
ppm.  Low resolution mass spectra were obtained on an Agilent 1200 LCMS with 
electrospray ionization.  High resolution mass spectra were recorded on a Waters QToF-
API-US Plus Acquity system.  Analytical thin layer chromatography was performed on 
250 mM silica gel 60 F254 plates.  Analytical HPLC was performed on an Agilent 1200 
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analytical LCMS with UV detection at 214 nm and 254 nm along with ELSD detection.  
Preparative purification was performed on a custom Agilent 1200 preparative LCMS 
with collection triggered by mass detection.  Solvents for extraction, washing and 
chromatography were HPLC grade.  All reagents were purchased from Aldrich Chemical 
Co., Ryan Scientific, Maybridge, and BioBlocks, and were used without purification.  All 
polymer-supported reagents were purchased from Biotage, Inc. 
General Procedure for M1 PAM Library I Synthesis:  Each of seven glass vials 
containing 2 mL of DMF were loaded with ethyl 8-fluoro-4-oxo-1,4-dihydroquinoline-3-
carboxylate (25 mg, 0.106 mmol, Maybridge BTB02003EA), K2CO3 (30 mg, 0.212 
mmol, 2.0 equivalents), KI (2 mg, 0.011 mmol, 0.1 equivalents), and one of seven benzyl 
bromides (0.319 mmol, 3.0 equivalents).  The reactions were stirred for 24 hours at room 
temperature before receiving polystyrene-bound thiophenol (0.159 mmol, 1.5 
equivalents) each, and then stirred for an additional 3 hours.  The reactions were then 
judged complete by LCMS, filtered, and separated into CH2Cl2 and H2O.  The organics 
were washed with brine, dried over MgSO4, filtered, and concentrated in vacuo yielding 
seven benzyl-substituted ethyl 8-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylates 
confirmed by analytical LCMS.  Next, crude products (0.1 mmol) and LiOH (8 mg, 0.3 
mmol, 3.0 equivalents) were dissolved in 3 mL of THF:H2O (9:1) in glass vials.  The 
reactions were microwave irradiated at 120°C for 10 minutes and then separated into 
EtOAc and H2O, which was acidified to pH 4 drop-wise using 1N HCl.  Organics were 
dried over MgSO4, filtered, and concentrated in vacuo yielding seven benzyl-substituted 
8-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acids confirmed by LCMS.  
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Purification using mass-directed HPLC afforded the seven compounds (25-85% total 
yield) as TFA salts with >98% purity. 
General Procedure for M1 PAM Library II Synthesis:  Each of seven glass vials 
containing 2 mL of DMF were loaded with ethyl 4-oxo-1,4-dihydroquinoline-3-
carboxylate (25 mg, 0.115 mmol, Ryan Scientific 6J-050), K2CO3 (32 mg, 0.230 mmol, 
2.0 equivalents), KI (2 mg, 0.012 mmol, 0.1 equivalents), and one of seven benzyl 
bromides (0.345 mmol, 3.0 equivalents).  The reactions were stirred for 24 hours at room 
temperature before receiving polystyrene-bound thiophenol (0.173 mmol, 1.5 
equivalents) each, and then stirred for an additional 3 hours.  The reactions were then 
judged complete by LCMS, filtered, and separated into CH2Cl2 and H2O.  The organics 
were washed with brine, dried over MgSO4, filtered, and concentrated in vacuo yielding 
seven benzyl-substituted ethyl 4-oxo-1,4-dihydroquinoline-3-carboxylates confirmed by 
analytical LCMS.  Next, crude products (0.1 mmol) and LiOH (8 mg, 0.3 mmol, 3.0 
equivalents) were dissolved in 3 mL of THF:H2O (9:1) in glass vials.  The reactions were 
microwave irradiated at 120°C for 10 minutes and then separated into EtOAc and H2O, 
which was acidified to pH 4 drop-wise using 1N HCl.  Organics were dried over MgSO4, 
filtered, and concentrated in vacuo yielding seven benzyl-substituted 4-oxo-1,4-
dihydroquinoline-3-carboxylic acids confirmed by LCMS.  Purification using mass-
directed HPLC afforded the seven compounds (25-85% total yield) as TFA salts with 
>98% purity. 
General Procedure for M1 PAM Library III Synthesis:  Each of seven glass vials 
containing 2 mL of DMF were loaded with ethyl 5,8-difluoro-4-oxo-1,4-
dihydroquinoline-3-carboxylate (25 mg, 0.099 mmol, Ryan Scientific 6J-020), K2CO3 
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(27 mg, 0.198 mmol, 2.0 equivalents), KI (2 mg, 0.099 mmol, 0.1 equivalents), and one 
of seven benzyl bromides (0.297 mmol, 3.0 equivalents).  The reactions were stirred for 
24 hours at room temperature and atmosphere before receiving polystyrene-bound 
thiophenol (0.149 mmol, 1.5 equivalents) each, and then stirred for an additional 3 hours.  
The reactions were then judged complete by LCMS, filtered, and separated into CH2Cl2 
and H2O.  The organics were washed with brine, dried over MgSO4, and concentrated in 
vacuo yielding seven benzyl-substituted ethyl 5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-
carboxylates confirmed by analytical LCMS.  Next, crude products (0.1 mmol) and LiOH 
(8 mg, 0.3 mmol, 3.0 equivalents) were dissolved in 3 mL of THF:H2O (9:1) in glass 
vials.  The reactions were microwave irradiated at 120°C for 10 minutes and then 
separated into EtOAc and H2O, which was acidified to pH 4 drop-wise using 1N HCl.  
Organics were dried over MgSO4 and concentrated in vacuo yielding seven benzyl-
substituted 5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acids confirmed by 
LCMS.  Purification using mass-directed HPLC afforded the seven compounds (25-85% 
total yield) as TFA salts with >98% purity. 
Sodium 1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate (BQCA) 
synthesis:  To stirred solution of 200 mL DMF in a glass flask was added ethyl 4-oxo-
1,4-dihydroquinoline-3-carboxylate (3.40 g, 15.66 mmol, Ryan Scientific 6J-050), K2CO3 
(4.33 g, 31.32 mmol, 2.0 equivalents), KI (260 mg, 1.57 mmol, 0.1 equivalents), and 4-
methoxybenzyl bromide (4.70 g, 23.49 mmol, 1.5 equivalents).  After 48 hours of stirring 
at room temperature and atmosphere, the reaction was monitored by LCMS and judged 
complete.  The reaction was then partitioned into CH2Cl2 and H2O, and the organics were 
washed with brine, dried over MgSO4, and concentrated in vacuo.  Purification by diethyl 
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ether washing (6 x 50 mL) afforded the intermediate product ethyl 1-(4-methoxybenzyl)-
4-oxo-1,4-dihydroquinoline-3-carboxylate (4.99 g, 14.83 mmol, 95%) as an off-white 
solid at >98% purity by LCMS.  To a glass vial containing ethyl 1-(4-methoxybenzyl)-4-
oxo-1,4-dihydroquinoline-3-carboxylate (4.99 g, 14.83 mmol) in 90 mL THF:H2O (5:1) 
was added LiOH (1.07 g, 44.49 mmol, 3.0 equivalents).  The reaction was microwave 
irradiated at 120°C for 10 minutes and then partitioned into CH2Cl2 and H2O.  The 
solution was re-acidified to pH 5 drop-wise using 2N HCl.  The organics were dried over 
MgSO4, filtered, concentrated in vacuo, and analyzed by LCMS.  The crude product was 
purified by diethyl ether washing (6 x 50 mL) and additional H2O wash (1 x 100 mL) to 
afford the intermediate product 1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-
carboxylic acid (3.20 g, 10.35 mmol, 70%) as an off-white crystalline solid at >98% 
purity by LCMS.  To a stirred solution of 1-(4-methoxybenzyl)-4-oxo-1,4-
dihydroquinoline-3-carboxylic acid (1.89 g, 6.11 mmol) in 25 mL DMF in a glass flask at 
0°C was added NaH (143 mg, 5.99 mmol, 0.98 equivalents).  The reaction was allowed 
to warm to room temperature and stirred for 1 hour before concentration in vacuo.  The 
crude product was washed with diethyl ether (3 x 30 mL) to afford the title compound 
(1.80 g, 5.44 mmol, 89%) as a white solid at >98% purity by LCMS.  1H NMR (400 
MHz, D2O): δ = 9.07 (s, 1H), 8.25 (d, J = 8.0 Hz, 1H), 7.53 (t, J = 8.4 Hz, 1H), 7.45 (d, J 
= 8.4 Hz, 1H), 7.39 (t, J = 8.0 Hz, 1H), 7.11 (d, J = 8.8 Hz, 2H), 6.79 (d, J = 8.8 Hz, 2H), 
5.35 (s, 2H), 3.67 (s, 3H).  13C NMR (100 MHz, D2O, externally referenced to DMSO-
d6): δ = 176.3, 172.2, 158.0, 147.4, 138.5, 132.3, 127.5, 127.2, 126.9, 125.5, 124.5, 117.5, 
116.9, 113.8, 55.8, 54.7.  HRMS calcd for C18H14NO4Na2 [M + 2Na] 354.0718, found 
354.0716. 
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JetMilling 
 M4 PAMS VU0152099 and VU0152100 as well as M1 PAM BQCA were Jet-
milled, to afford uniform nanoparticles, before vehicle formulation and in vivo studies 
employing a Model 00 Jet-O-Mizer with a High-Yield® Collection Module from Fluid 
Energy Processing & Equipment Company. 
 
Stable Recombinant Cell Line Establishment and Cell Culture 
 Chinese hamster ovary (CHO) cells stably expressing rat M1 were purchased from 
the American Type Culture Collection (ATCC) and cultured following their 
recommendations.  CHO cells stably expressing human M2 (hM2), human M3 (hM3), and 
human M5 (hM5) were generously provided by A. Levey (Emory Medical School, 
Atlanta, GA); rat M4 (rM4) cDNA provided by T.I. Bonner (National Institutes of Health, 
Bethesda, MD) was used to stably transfect CHO-K1 cells purchased from the ATCC 
using Lipofectamine 2000 reagent according to manufacturer protocol.  To make stable 
hM2 and rM4 cell lines for use in calcium mobilization assays, these cells were also stably 
co-transfected with a chimeric G protein, Gqi5 (Coward et al., 1999), obtained from Bruce 
Conklin at the University of California using Lipofectamine 2000.  Gqi5 is a Gqα protein 
containing the five c-terminal amino acid residues corresponding to those of Giα 
(EYNLV Æ DCGLF) and was expressed in a pcDNA3.1 vector containing a hygromycin 
resistance cassette.  Large quantities of Gqi5 DNA were made by transforming DH5α E. 
coli cells with the construct, plating bacteria for individual colonies and expanding a 
single colony in liquid growth medium (LB containing hygromycin and tetracycline).  A 
Qiagen MaxiPrep kit was used to isolate DNA from the bacterial culture.  rM1, hM3, and 
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hM5 cells were grown in Ham’s F-12 medium containing 10% heat-inactivated fetal 
bovine serum (FBS), 2 mM GlutaMax I, 20 mM HEPES, and 50 μg ml–1 G418 sulfate.  
hM2-Gqi5 cells were grown in the same medium also containing 500 μg ml–1 Hygromycin 
B.  Stable rM4 cells lacking the Gqi5 construct were grown in Dulbecco’s modified 
Eagle’s medium (DMEM) containing 10% heat-inactivated FBS, 2 mM GlutaMax I, 1 
mM sodium pyruvate, 0.1 mM nonessential amino acids, 20 mM HEPES, and 400 μg ml–
1 G418 sulfate; rM4-Gqi5 cells were grown in the same medium also containing 500 μg 
ml–1 Hygromycin B.  Parental untransfected CHO-K1 cells were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) containing 10% heat-inactivated FBS, 2 mM 
GlutaMax I, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, and 20 mM 
HEPES.  Human embryonic kidney (HEK) 293A cells stably expressing rat mGluR5a 
were grown in DMEM containing 10% heat-inactivated FBS, 2 mM GlutaMax I, 0.1 mM 
nonessential amino acids, 20 mM HEPES, and 500 μg ml–1 G418 sulfate. 
 
Calcium Mobilization Assays 
 For experiments in Chapter III, recombinant muscarinic cell lines were plated at 
a seeding density of 3 to 5 x 105 cells per well in Greiner clear-bottomed, TC-treated 384-
well plates (VWR Scientific, Suwanee, GA) in antibiotic-free growth medium and 
incubated overnight at 37°C in 5% CO2.  Rat mGluR5a HEK cells were plated in an 
identical manner in clear-bottomed, poly-D-lysine-coated 96-well plates in glutamate-
glutamine-free medium for growth overnight.  For experiments in Chapter IV, all 
recombinant Chinese Hamster Ovary (CHO-K1) cell lines stably expressing rM1, hM3, or 
hM5 receptors were plated at a seeding density of 50,000 cells/100µl/well in Greiner 
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clear-bottomed, TC-treated 384-well plates.  CHO-K1 cells stably co-expressing hM2-
Gqi5 and rM4-Gqi5 were plated at a seeding density of 60,000 cells/100µl per well.  Cells 
were incubated in antibiotic-free medium overnight at 37°C/5% CO2 and assayed the 
following day.  The following day, medium was replaced with 2 μM calcium indicator 
dye, fluo-4 AM, for 1 h at 37°C.  Dye was removed and replaced with 20 µl per well 
assay buffer containing 1x Hanks balanced salt solution (Invitrogen, Carlsbad, CA), 20 
mM HEPES, and 2.5 mM probenecid, pH 7.4.   
 For experiments in Chapter IIIa/b, cell plates were then loaded into the 
Functional Drug Screening System 2000 (FDSS 6000, Hamamatsu, Japan), and cells 
were preincubated with either vehicle or test compound for 5 min before a 1 min 
incubation with agonists (i.e., ACh, glutamate, or ATP).  All test compounds were 
dissolved and diluted in 100% DMSO and then serially diluted into assay buffer for a 
2.5x stock in 0.25% DMSO; stock compounds were then added to the assay for a final 
DMSO concentration of 0.1%.  ACh, ATP, and Glu were prepared as 5x stock solutions 
in assay buffer before addition to the assay plate.  Calcium mobilization was measured 
using the FDSS 6000 and data recorded as fold over basal fluorescence; raw data was 
then normalized to the maximal response to agonist in the presence of vehicle for each 
receptor type.   
 For experiments in Chapter IV, all compounds were serially diluted in assay 
buffer for a final 2X stock in 0.6% DMSO. This stock was then added to the assay plate 
for a final DMSO concentration of 0.3%.  ACh (EC20 concentration or full dose-response 
curve) was prepared at a 10X stock solution in assay buffer prior to addition to assay 
plates.  Calcium mobilization was measured at 25°C using a FLEXstation II (Molecular 
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Devices, Sunnyvale, CA).  Cells were preincubated with test compound (or vehicle) for 
1.5 min prior to the addition of the agonist, ACh.  Cells were then stimulated for 50 sec 
with a submaximal concentration (EC20) or a full dose-response curve of ACh.  The 
signal amplitude was first normalized to baseline and then as a percentage of the maximal 
response to ACh. 
 
GIRK-Mediated Thallium Flux Assay 
 Because the M4 receptor couples to Gi/o G proteins, we were able to use a novel 
functional assay recently developed in our lab that takes advantage of the ability of 
endogenous Gi/oβγ subunits of Gi/o-coupled GPCRs to alter the kinetics of G-protein 
regulated inwardly rectifying K+ (GIRK) channels to conduct the ion, thallium 
(Niswender et al., 2008). For these studies, HEK293 cells stably co-expressing 
heteromeric GIRK1/2 channels and the hM4 muscarinic receptor were pre-incubated with 
test compound and then stimulated with agonist (ACh) in the presence of thallium ion.  
Cells were incubated with 80 µl/well of 1.7 µM benzothiazole coumarin-acetoxymethyl 
ester indicator dye [prepared as a stock in DMSO and mixed in a 1:1 ratio with 10% 
Pluronic acid F-127 in assay buffer (1x Hanks' balanced salt solution supplemented with 
20 mM HEPES)] for 1 h at room temperature in the dark.  The dye was then replaced 
with 40 µl of assay buffer.  Test compounds were prepared as described above.  
Acetylcholine (EC20 concentration or full dose-response curve) was prepared as a 5x 
stock solution in thallium buffer (pH 7.3, 12 mM thallium sulfate, 1 mM MgSO4, 1.8 mM 
CaSO4, 5 mM glucose, and 10 mM HEPES) to which 125 mM NaHCO3 was added 
immediately before use.  Thallium flux was measured at 25°C using the FLEXstation II, 
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as described above for calcium mobilization assays. The slope of the fluorescence 
increase was obtained over a 10-s window beginning at 5 s after agonist/thallium 
addition.  The signal amplitude was first normalized to baseline and then as a percentage 
of the maximal response to acetylcholine. 
 
Ancillary Pharmacology Assays 
 Before conducting in vivo experiments, M4 PAMs VU0152099 and VU0152100 
were submitted to MDS Pharma Services (King of Prussia, PA) and evaluated in the 
LeadProfiling Screen, a radioligand binding assay panel employing 68 GPCRs, ion 
channels, transporters, and enzymes, to ensure a clean ancillary pharmacology profile. 
VU0152099 was also submitted to GPCR Profiler Service (Millipore Corporation, 
Billerica, MA) where it was evaluated for agonist, antagonist, and allosteric potentiator 
activity against a panel of 16 GPCRs in a functional screening paradigm.  M1 PAM 
BQCA was also submitted to Millipore’s GPCR Profiler™. 
 
Equilibrium Radioligand Binding Assays 
 To prepare membranes from CHO-K1 cells stably expressing rM1, hM2, hM3, 
rM4, or hM5, cells were washed once with ice-cold phosphate-buffered saline, pH 7.4.  
Cells were then harvested with a cell scraper, resuspended in ice-cold buffer (20 mM 
HEPES, 100 mM NaCl, 10 mM MgCl2, pH 7.4), and homogenized using a glass 
homogenizer (Dounce).  The homogenate was centrifuged at 20,000xg for 20 min at 4°C.  
This final step was repeated twice more with homogenization between centrifugations, 
and the final pellets were resuspended and homogenized in ice-cold buffer in aliquots at a 
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final protein concentration of 1-3 mg ml–1 and stored at -80°C until use.  Protein 
concentrations were measured using the Bio-Rad Protein Assay Kit (Bio-Rad, Hercules, 
CA) with serum albumin (Pierce Chemical, Rockford, IL) as the standard.  For each 
binding experiment, membranes were resuspended and homogenized in ice-cold buffer.  
Non-specific binding, calculated in the presence of 1 µM atropine, was never greater than 
10% of total binding; in both saturation and competition binding experiments, bound 
radioligand did not exceed 10%.   
 For competition binding experiments in Chapter IIIa/b and IV, VU10010, 
BQCA and atropine were dissolved in 100% DMSO, diluted in assay buffer to make a 3x 
stock, and then added to the assay plate for a final maximum DMSO concentration of 
0.3% for VU10010 and 0.01% for atropine.  Vehicle for each condition was DMSO-
matched control made in binding buffer.  For ACh competition experiments, VU10010 
was diluted in binding buffer to make a 5x stock and then added to the assay plate for a 
maximum final DMSO concentration of 0.1%.  Binding reactions were incubated at room 
temperature for 2 h on a Titer Plate Shaker (Lab-Line Instruments, Melrose, IL), and 
equilibrium binding was terminated by rapid filtration through Unifilter-96 GF/B filter 
plates presoaked for at least 2 h with 0.1% polyethylenimine (PEI, Sigma).  Filter plates 
were washed three times with ice-cold harvesting buffer (50 mM Tris-HCl, 150 mM 
NaCl, pH 7.4) using a 96-well Brandel harvester (Brandel Inc., Gaithersburg, MD).  
Plates were then dried overnight and 35 μl MicroScint-20 was added to each well the 
following day.  Radioactivity was counted using a TopCount NXT microplate 
scintillation and luminescence counter (PerkinElmer Life and Analytical Sciences, 
Downers Grove, IL).  All binding reactions were carried out in 1 ml volumes containing 
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12-25 μg membrane protein, and non-specific binding was determined in the presence of 
1 µM atropine.  [3H]NMS saturation binding was performed to calculate the Bmax and 
NMS Kd for each mAChR-expressing cell line using GraphPad Prizm software.  
Competition binding reactions contained membrane protein, appropriate concentrations 
of test compounds or vehicle, and 0.1 nM [3H]NMS in 96-well deep well plates.  Counts 
were normalized to maximal specific binding in the presence of vehicle. 
 
[35S]GTPγS Binding Assays 
 Membranes were prepared from rM4-CHO cells that were not transfected with the 
Gqi5 construct as described above for [3H]NMS binding.  After thawing, membranes were 
diluted and homogenized in ice-cold assay buffer containing 20 mM HEPES, 150 mM 
NaCl, 10 mM MgCl2, and 1 mM EDTA, pH 7.4, and 5 μM GDP.  Assay reactions 
contained 25 μg membrane protein, 10 μM VU10010 or vehicle, ACh, and 0.1 nM 
[35S]GTPγS in a total volume of 100 μl; samples were incubated in a 96-well deep well 
plate for 1 h at room temperature.  Nonspecific binding in each experiment was 
determined in the presence of 10 μM unlabeled GTPγS.  Equilibrium binding was 
terminated and radioactivity counted as described above.  Counts were normalized to 
maximal specific binding in the presence of vehicle and 100 μM ACh. 
 
Animals: Slice Electrophysiology in Chapter IIIa/b and IV, behavior in Chapter III 
 All experiments were conducted in accordance with the National Institutes of 
Health regulations of animal care covered in Principles of Laboratory Animal Care 
(National Institutes of Health publication 85-23, revised 1985) and were approved by the 
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Institutional Animal Care and Use Committee.  Subjects were housed in groups of four to 
five per cage in a large colony room under a 12-h light/dark cycle (lights on at 6:00 a.m.) 
with food and water provided ad libitum.  Animals were housed in an Association for 
Assessment and Accreditation of Laboratory Animal Care (AALAC) approved, and all 
efforts were made to minimize animal suffering and to reduce the number of animals 
used. 
 
Brain Slice Electrophysiology: Chapter IIIa 
 All whole-cell recordings were carried out using hippocampal slices prepared 
from 16- to 23-day old Sprague Dawley rats (Charles River Laboratories, MA, USA) or 
15- to 23-day WT and M4 knockout (KO).  Animals were anesthetized with isoflurane 
and decapitated. The brain was rapidly removed from the skull and submerged in ice-cold 
modified artificial cerebrospinal fluid (ACSF), which was oxygenated with 95% O2 and 
5% CO2 and was composed of (in mM) 230 sucrose, 2.5 KCl, 0.5 CaCl2, 10 MgSO4, 1.25 
NaH2PO4, 26 NaHCO3, and 10 D-glucose. The brain was then blocked in the horizontal 
plane, glued to the stage of a vibratome (Vibratome, St. Louis, MO, USA) that was filled 
with ice-cold modified ACSF, and cut at a thickness of 300 μm for rat hippocampal slices 
and 275-280 μm for mice.  Slices were then incubated in oxygenated normal ACSF (in 
mM, 126 NaCl, 2.5 KCl, 2 CaCl2, 2 MgSO4, 1.25 NaH2PO4, 26 NaHCO3, and 10 D-
glucose) at 31-32°C for 1 h and maintained at room temperature afterward until 
transferred individually to a recording chamber, which was continuously perfused with 
oxygenated ACSF at 31-32°C.  Whole-cell recordings were made from visually identified 
hippocampal CA1 pyramidal neuron soma under an Olympus BX50WI upright 
90 
 
microscope (Olympus, Lake Success, NY, USA).  A low-power objective (4x) was used 
to identify CA1 region of the hippocampus, and a 40x water immersion objective coupled 
with Hoffman optics and infrared video was used to visualize individual pyramidal cells.  
A MultiClamp amplifier (Molecular devices, Union City, CA) was used for current- and 
voltage-clamp recordings. Patch pipettes (2-3 MΩ) were prepared from borosilicate glass 
(World Precision Instrument, Sarasota, FL, USA) using a Narashige vertical patch pipette 
puller (Narashige, Japan). Excitatory or inhibitory postsynaptic currents (EPSCs or 
IPSCs) were evoked in CA1 pyramidal cells by electrical stimulation of Schaffer 
collaterals using a concentric bipolar stimulating electrode (FHC, Bowdoinham, ME, 
USA) in the presence of the GABAA receptor antagonist bicuculine (20 μM) or 
ionotropic glutamate receptor antagonists CNQX (10 μM) and AP-5 (50 μM), 
respectively. For recordings of EPSCs, the recording pipette solution contained (in mM) 
123 K-gluconate, 7 KCl, 1 MgCl2, 0.025 CaCl2, 10 HEPES, and 0.1 EGTA, 2 Mg-ATP, 
and 0.2 Na-GTP. For recordings of IPSCs, the recording pipette solution contained (in 
mM) 65 K-gluconate, 65 CsCl, 3.5 NaCl, 1 MgCl2, 0.025 CaCl2, 10 HEPES, 0.1 EGTA, 
2 Mg-ATP, and 0.2 Na-GTP.   The pH of the pipette solutions were adjusted to 7.3 with 1 
M KOH, and osmolarity was adjusted to ~295 mOsm.  All drugs were bath applied.  
Cells were typically voltage-clamped at -60 mV. IPSCs were inward currents in such 
recording conditions because the calculated Cl- equilibrium potential was approximately -
20 mV.  The access resistance was continuously monitored, and only recordings that had 
access resistance less than 20 MΩ with < 15% change were used for further analysis. 
Data analysis was performed using a PC computer equipped with pClamp data 
acquisition and analysis system (Molecular Devices, Union City, CA). 
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Statistical analysis:  Electrophysiology data was analyzed using the nonparametric 
Wilcoxon matched-pairs signed-ranks test or Mann-Whitney U test, and p-values less 
than 0.05 (P < 0.05) were considered to be statistically significant.  All cell-based, 
binding, and electrophysiological data are presented as mean ± S.E.M. 
 
Brain Slice Electrophysiology: Chapter IV 
 Brain slices were prepared from Sprague-Dawley rats (Charles River, 
Wilmington, MA), wild-type C57Bl/6Hsd (Harlan, Indianapolis, IN) or M1 receptor KO 
mice (Taconic, Cambridge City, IN with permission from J. Wess); all animals were 
postnatal day 16-26.  Animals were anesthetized with isoflorane.  Brains were rapidly 
removed and submerged in ice-cold modified oxygenated artificial cerebrospinal fluid 
(ACSF) composed of 126 mM choline chloride, 2.5 mM KCl, 8 mM MgSO4, 1.3 mM 
MgCl, 1.2 mM NaH2PO4, 26 mM NaHCO3, 10 mM D-glucose, 5 µM glutathione, and 0.5 
mM sodium pyruvate.  Coronal brain slices (295-300 µm) containing the mPFC were 
made using a Leica VT1000S or 3000 vibratome (St. Louis, MO).  Slices were incubated 
in oxygenated ACSF at 32°C for 30-60 min and then maintained at 20-22°C (room 
temperature) for 1-6 hr until they were transferred to a recording chamber.  The recording 
chamber was continuously perfused at 30 ± 0.2°C with oxygenated ACSF containing 126 
mM NaCl, 2.5 mM KCl, 3.0 mM CaCl2, 2.0 mM MgSO4, 1.25 mM NaH2PO4, 26 mM 
NaHCO3, and 10 mM D-glucose.  Spontaneous and miniature EPSCs were recorded from 
layer V pyramidal cells in whole-cell voltage-clamp mode using either an Axon 
Multiclamp 700B amplifier (Molecular Devices, Sunnyvale, CA) or a Warner 501A 
amplifier (Warner Instruments, Hamden, CT) and visualized with an Olympus BX50WI 
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upright microscope (Olympus, Lake Success, NY) coupled with a 40x water immersion 
objective and Hoffman optics.  Borosilicate glass (World Precision Instruments, Sarasota, 
FL) patch pipettes were prepared using a Flaming-Brown micropipette puller (Model P-
97; Sutter Instruments, Novato, CA) and filled with 123 mM potassium gluconate, 7 mM 
KCl, 1 mM MgCl2, 0.025 mM CaCl2, 10 mM HEPES, 0.1 mM EGTA, 2 mM ATP, and 
0.2 mM GTP at a pH of 7.3 and osmolarity of 285-295 mOsM.  Filled patch pipettes had 
resistances of 2 to 4 MΩ. EPSCs were recorded at a holding potential of -70 mV; GABAA 
receptor-mediated inhibitory currents were undetectable under these conditions.  The 
voltage-clamp signal was low-pass-filtered at 5 kHz, digitized at 10 kHz, and acquired 
using a Clampex9.2/DigiData1332 system (Molecular Devices, Sunnyvale, CA). All 
drugs were bath-applied.  Compounds were made in a 100X or 1000X stock in either 
purified water or 100% DMSO and diluted in oxygenated ACSF immediately before use.  
After a stable baseline was recorded for 5 – 10 min, the effect of each compound on 
baseline sEPSC or mEPSC amplitude and frequency was examined.  Miniature EPSCs 
and inward currents were recorded in the presence of 1 µM tetrodotoxin, a concentration 
which completely blocked action potential firing upon depolarizing current injections in 
current clamp mode. 
Statistical analysis:  EPSCs were analyzed using the Mini Analysis Program 
(Synaptosoft, Decatur, GA). The peak amplitude and inter-event interval of sEPSCs and 
mEPSCs from 2-min episodes during control and drug application were used to generate 
cumulative probability plots.  The mean values of EPSC amplitude and inter-event 
interval from the 2-min episode were grouped (mean ± S.E.M.) and compared using a 
paired t-test.  Inward current data analysis was performed using Clampfit software (v9.2, 
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Molecular Devices, Sunnyvale, CA).  All electrophysiology data was quantified and 
graphed using GraphPad Prism (GraphPad Software Inc, San Diego, CA) and Excel 
(Microsoft Corp., Redmond, WA).  Cumulative probability plots were made using Origin 
(v6, Microcal Origin, Northampton, MA).  Statistical analysis was performed using the 
student's paired or unpaired t-test, and statistical significance was set at P < 0.05.  
Averaged data are presented as mean ± standard error of the mean (S.E.M.). 
   
In vivo mPFC Unit Activity Recordings 
 Multichannel single unit recordings were obtained from extracellular electrode 
arrays (NeuroLinc, Corp., New York, NY) chronically implanted in the medial prefrontal 
cortex (mPFC) of 300-400g Sprague-Dawley rats performing an auditory detection task 
for food reward.  For recording sessions, animals were fitted with a HST/16V-G20 
miniature headstage 20x pre-amplifier (Plexon Corp., Dallas, TX) and spike event data 
(1.1 ms data window) was captured by a Cheetah 32-channel acquisition system 
(Neuralynx, Bozeman, MT) for offline processing.  Individual data sessions consisted of 
a 30-minute pre-injection baseline followed by three 30-minute post-injection (vehicle or 
BQCA, 20mg/kg) epochs.  Single neurons were isolated offline using a manual spike 
sorter (Mclust; A.D. Redish).  A sorted file was only considered to emanate from the 
activity of a single neuron if bins within +/-1.1 ms (considered absolute refractory period) 
of the autocorrelogram contained counts <1% of the overall mean of the autocorrelogram.  
In addition, cells with properties characteristic of fast-spiking interneurons (spike width 
<250 ms and firing rate > 6 Hz) were eliminated from analysis.  Following offline 
clustering, the mean firing rate for each neuron within an epoch was calculated by 
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averaging rates across all 10-s pre-tone intervals within an epoch (approximately 50 tone 
presentations / 30 minute epoch).  The average firing rate in an epoch was expressed as a 
percent of the pre-injection baseline rate and data were compared across treatment 
conditions with respect to changes in mean rate across the three 30-minute post-injection 
epochs. 
 
Brain and Plasma Exposure Pharmacokinetic Profiling of M4 PAMs 
 Male Sprague-Dawley rats (Harlan Sprague-Dawley, Inc., Indianapolis, IN) 
weighing 225 to 250 grams were fasted overnight before dosing.  Compounds were 
dissolved at a concentration of 56.6 mg/ml in 10% Tween 80 and double deionized water, 
with the pH adjusted to approximately 7.0 using 1 N NaOH, and sonicated until a uniform 
homogenous solution was obtained.  The dose was administered i.p. at 56.6 mg/kg per 
compound.  Three animals were used for each time point.  The rat blood and brain were 
collected at 0.5, 1, 2, and 4 h.  Animals were euthanized and decapitated, and the brains 
were removed and frozen on dry ice.  Trunk blood was collected in EDTA vacutainer 
tubes, and plasma was separated by centrifugation and stored at -80°C until analysis.  For 
the brain sample preparation, frozen whole-rat brains were weighed (1.5–1.8 g) and 
placed in 3 ml of ice-cold solution of acetonitrile and methanol (1:1, volume) with a 
synthetic internal standard (50 ng/ml) and homogenized using a Sonic Dismembrator 
model 100 (Thermo Fisher Scientific, Waltham, MA) at maximal speed for 2 min.  A 1-
ml aliquot of each homogenate was placed next into 1.5-ml centrifuge tubes and 
centrifuged at 16,000 rpm for 5 min.  Finally, 100 µl of supernatant was injected into LC-
MS-MS.  
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 Plasma samples (100 µl) were combined with 200 µl of ice-cold solution of the 
internal standard (100 ng/ml) in acetonitrile with 0.1% formic acid.  After vortexing for 1 
min, the mixture was centrifuged at 16,000 rpm for 5 min in a bench-top Spectrafuge 
16M Microcentrifuge (Labnet, Woodbridge, NJ).  The supernatant (100 µl) was injected 
again into LC-MS-MS.  
 For the LC-MS-MS analysis, the LC separation was carried out on a Luna ODS 
column (5 µm, 2.1 mm x 5 cm; Phenomenex, Torrance, CA) at a flow rate of 0.3 ml/min.  
The gradient started with 80% solvent A (0.1% formic acid in water) and 20% solvent B 
(0.1% formic acid in CH3CN), held for 1 min, increased to 100% B in 4 min, and held for 
1 min.  Mass spectrometry was carried out using a ThermoFinnigan TSQ Quantum Ultra 
(Thermo Fisher Scientific, Waltham, MA) mass spectrometer in positive ion mode.  The 
software Xcalibur version 2.0 was used to control the instrument and collect data.  The 
electrospray ionization source was fitted with a stainless steel capillary (100 µm i.d.).  
Nitrogen was used as both the sheath gas and the auxiliary gas.  The ion transfer tube 
temperature was 300°C.  The spray voltage, tube lens voltage, and pressure of sheath gas 
and auxiliary gas were optimized to achieve maximal response using the test compounds 
mixing with the mobile phase A (50%) and B (50%) at a flow rate of 0.3 ml/min.  
Collision-induced dissociation was performed on the test compounds and internal 
standards under 1.0 mTorr of argon.  Selected reaction monitoring was carried out using 
the transitions from m/z 356 to 205 at 30 eV for VU0152099, m/z 342 to 205 at 27 eV for 
VU0152100, and m/z 310 to 223 at 25 eV for our internal standard.  The calibration 
curves were constructed by spiking known amounts of test compounds in blank brain 
homogenates and plasma. The samples went through the same extraction steps as 
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described above.  A linear response was achieved from 50 ng/ml to 100 µg/ml in both 
matrices. Compound exposure following administration was determined by calculating 
AUC0-∞ using the trapezoidal method. 
 
Pharmacokinetics and Brain /Plasma Exposure Profiling of M1 PAM, BQCA 
 Male Sprague-Dawley rats (Harlan, Indianapolis, USA) weighing 225-250 g, 
were injected i.p. with the micro-suspension (containing 10% tween 80) of BQCA at the 
dose of 10 mg/kg.  The blood and whole brain tissue samples were collected at 0.5, 1, 2, 
4 and 8 hours post-injection.  Blood samples were collected through cardiac puncture in 
EDTA vacutainer tubes.  The plasma was separated by centrifugation and stored at -80°C 
until analysis.  The animals were decapitated and the whole brain tissue were removed 
and immediately frozen on dry ice.  
 Brain tissue was weighed and homogenized in 5 ml of ice-cold phosphate 
buffered saline using a Sonic Dismembrator Model 100 (Fisher Scientific) at maximal 
speed for 2 min.  Five hundred µL of the homogenate samples were treated with 2.0 mL 
of an ice-cold solution of acetonitrile containing 0.1% formic acid and VU178 (internal 
standard), 100 ng/mL, and vortexed for 1 min.  Plasma samples (100 µl) were combined 
with 500 µl of ice-cold solution of the internal standard (100 ng/ml) in acetonitrile with 
0.1% formic acid and vortexed.  The samples were centrifuged at 14,000 rpm for 5 min 
using a Spectrafuge 16M Microcentrifuge (Labnet, Woodbridge, NJ).  The supernatants 
were evaporated and the residues were reconstituted in 100 µl of 80:20 acetonitrile/water, 
filtered through 0.2 µm nylon filter and injected onto LC-MS-MS.  
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 LC separation was carried out on Waters Acquity UPLC® BEH C18 (1.7 µm 1.0 x 
50 mm) column at a flow rate of 0.6 ml/min flow rate.  The gradient started with 80% 
solvent A (0.1% formic acid in water) and 20% solvent B (0.1% formic acid in 
acetonitrile), and held for 1 min.  The mobile phase composition was increased to 100% 
B by 2 min. and held for 1 min., before it was returned to the initial conditions.  The 
samples were analyzed in a run time of 6 min. Mass spectrometry was carried out using a 
ThermoFinnigan TSQ Quantum Ultra (Thermo Scientific, Waltham, MA) mass 
spectrometer in positive ion mode.  Xcalibur (version 2.0) software was used for 
instrument control and data collection.  The ESI source was fitted with a stainless steel 
capillary (100 μm i.d.).  Nitrogen was used as both the sheath gas and the auxiliary gas. 
The ion- transfer capillary tube temperature was 300ºC.  The spray voltage, tube lens 
voltage, pressure of sheath gas and auxiliary gas were optimized to achieve maximal 
response using the test compounds infused with the mobile phase A (50%) and B (50%) 
at a flow rate of 0.6 ml/min. Collision-induced dissociation (CID) was performed on the 
test compounds and internal standards under 1.0 mTorr of argon.  Selected reaction 
monitoring (SRM) was carried out using the transitions from m/z 310 to 121 @ 17 eV for 
BQCA and m/z 310 to 223 @ 25 eV for the internal standard.  The unknown 
concentrations were determined against calibration curves constructed by spiking known 
amounts of test compounds into the blank brain homogenate and plasma samples. A 
linear response was achieved from 10 ng/ml to 2 µg/ml in plasma and 10 ng/ml to 1 
µg/ml in brain homogenates.  PK parameters were calculated by non-compartmental 
analysis of individual concentration-time data using WinNonLin, version 5.2.1 (Pharsight 
Corporation, Mountain View, CA). 
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Amphetamine-Induced Hyperlocomotion: Chapter IIIb 
 All behavioral studies were conducted using male Sprague-Dawley rats (Harlan 
Sprague-Dawley, Inc., Indianapolis, IN) weighing 270 to 300 g.  Subjects were housed in 
pairs in a large colony room under a 12-h light/12-h dark cycle (lights on at 6:00 AM) 
with food and water provided ad libitum. Test sessions were performed between 6:00 AM 
and 6:00 PM.  Dose groups consisted of 8 to 16 rats per dose group.  All doses of M4 
PAMs VU0152099 and VU0152100 refer to the salt form and were injected in a 1.0 
ml/kg volume.  Each compound was dissolved in 10% Tween 80 and double deionized 
water with the pH adjusted to approximately 7.0 using 1 N NaOH.  
Apparatus:  Amphetamine-induced hyperlocomotor activity studies were conducted 
using a SmartFrame Open Field System (Kinder Scientific., San Diego, CA) equipped 
with 32 horizontal (x- and y-axes) infrared photobeams located 1 cm above the floor of 
the chamber.  Changes in ambulation or locomotor activity were measured as the number 
of total photobeam breaks, expressed in 5-min intervals, and were recorded with a 
Pentium I computer equipped with the Motor Monitor System software (Kinder 
Scientific).  
Procedure:  Rats were placed in the open-field chambers for a 30-min habituation 
interval (data not shown), followed by a pretreatment with vehicle or a 56.6 mg/kg i.p. 
dose of either M4 PAM VU0152099 or M4 PAM VU0152100 for an additional 30 min.  
Next, all rats received an injection of 1 mg/kg s.c. amphetamine, and locomotor activity 
was measured for an additional 60 min.  Data were analyzed by a one-way ANOVA with 
comparison with the vehicle + amphetamine control group using Dunnett's test.  
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Calculations were performed using JMP version 5.1.2 (SAS Institute Inc., Cary, NC) 
statistical software.  
Rotorod Test:  The effects of M4 PAM VU0152100 on motor performance were 
evaluated using a rotorod (Columbus Instruments, Columbus, OH).  All rats were given 
an initial training trial of 120 s, followed by two additional training trials of 85 s, 
approximately 10 min apart, using a rotorod (7.5 cm in diameter) rotating at a constant 
speed of 20 revolutions per min.  After initial training trials, a baseline trial of 85 s was 
conducted, and any rats that did not reach the 85-s criteria were excluded from the study.  
Rats were then pretreated for 30 min i.p. with vehicle or dose of M4 PAM VU0152100, 
specifically 30, 56.6, or 100 mg/kg, and then the time each animal remained on the 
rotorod was recorded; animals not falling off of the rotorod were given a maximal score 
of 85 s.  Data were analyzed by a one-way ANOVA, with comparison to the vehicle 
control group using Dunnett's test.  Calculations were performed using JMP version 5.1.2 
(SAS Institute Inc.) statistical software. 
 
Reversal Learning: Chapter IV 
 Forty Tg2576 mice on the 129S6 background were obtained when they were 10 to 
12 weeks of age from Taconic (Hudson, NY, USA).  Tg2576 APPsw mice over-
expressed a 695 amino acid splice form (Swedish mutation K670N M671L) of the human 
amyloid precursor protein (APP695) that results in an five-fold increase in Aβ 1–40 and a 
14-fold increase in Aβ 1–42 with increasing age (Hsiao et al., 1996).  In this study, 10 
hemizygous males and 12 of their wild type male littermates and  9 hemizygous females 
and 9 of their wild type female litter mates were individually housed, maintained on a 12 
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hour light:dark cycle (lights on at 8:00 a.m), with ad libitum food and water.  At 
approximately 12 months of age evaluation of reversal learning began.  The mice were 
divided into groups and counter-balanced for genotype and treatment type, either BQCA 
or vehicle.  Experiments were performed during the light cycle.  Before the start of 
testing, subjects were placed on a restricted food diet of approximately 1 to 2 grams of 
food per day, contingent on their performance on the food motivated tasks.  A weight 
basis of 85% of their pre-food deprivation weight was used as a guideline to avoid 
excessive weight loss.  Water was available ad libitum during all phases of testing.  All 
experimental procedures were approved by the Wake Forest University School of 
Medicine Animal Care and Use Committee and were conducted in compliance with 
guidelines set forth in the NIH Guide for Care and Use of Laboratory Animals. 
Apparatus:  The reversal-learning test was adapted from a rat set-shifting paradigm.  
Subjects were trained to dig in identical terra cotta pots to retrieve a food reward.  A 
1/20th piece of a Reese’s Peanut Butter Chip (The Hershey Company) was the food 
reward.  Pots were 1 ¾” in diameter and 1 ½” deep.  A square of vinyl window screen 
was glued inside the pot to form a cavity underneath the pot in which to place a food 
reward that was unobtainable by the subject to serve as a control for odor.  Essential Oils 
(New Directions Aromatics, San Ramon, CA) were applied to the rim of the pot to 
produce a long-lasting odor and media placed inside the pots to a depth that produced 
vigorous digging for the subject to reach the food reward.  Each odor had unique pots 
assigned to it and the pots were filled with the corresponding media and placed in a 
plastic sealable container where they were returned after each use.     
101 
 
 Testing was carried out in the subject’s home cage placed inside an ordinary 24” 
(length) x 16” (width) x 16” (depth) cardboard box to shield the subject from seeing 
movement within the room.  A plexiglass holder was fabricated to insert and remove two 
pots at a time from the testing cage. The two pots were separated by a plexiglass 
partition.  A 1000 ml plastic beaker was painted black and placed over the subject at the 
end of the cage closest to the experimenter to create a holding area.  When the holder 
with the two pots was placed at the opposite end of the cage, the subject was then 
released from the black beaker.  Upon completion of the dig, the subject was recovered to 
the holding area with the black beaker.  Between all discriminations, the inter-
discrimination delay was approximately three minutes. 
Habituation and Shaping:  After three days of food deprivation, subjects in their home 
cages were habituated to the test apparatus (holding beaker and pot holder) and then 
shaped to dig a reward after release from the holding beaker. Two pots were filled with 
Alpha-Dri (Shepherd Specialty Papers) and a reward was randomly placed at the very 
bottom of either pot to encourage the subject to dig vigorously to find it.  The subjects 
were released from the holding area and allowed to dig in the pots.  When the reward was 
found, the subject was recovered to the holding area using the black beaker.  A pot was 
re-baited randomly and the trial re-run until a total of ten digs was recorded.  If the 
subject did not reach ten digs, this habituation procedure was repeated the following day.  
No subject required more than two days of habituation. 
Testing Paradigm:  The reversal learning digging task was used previously in Tg2576 
mice (Zhuo et al., 2007; Zhuo et al., 2008).  The reversal learning testing was performed 
with olfactory discriminations as this has proven, in our hands, to be the more difficult of 
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discriminations compared to using media as the stimulus.  One hour before testing, 
BQCA or vehicle was administered s.c. to the subjects at 30 mg/kg.  The first four trials 
of the discriminations (exploratory trials) allowed the subject to explore both pots to find 
the reward.  If the reward was found, a correct response was recorded and the subject 
recovered to the beaker.  If digging first occurred in the non-reward pot, an error was 
recorded and the subject was allowed to search the other pot for the reward.  If the subject 
remained motionless for one minute, a “no dig” was recorded, the trial discontinued and 
the next trial started.  In the subsequent trials after the initial four, a correct dig was 
recorded when the subject retrieved the reward and an incorrect dig “error” was recorded 
if the subject dug vigorously in the incorrect pot.  Vigorous digging was defined as the 
subject having its head and shoulders within the pot and using its paws to vigorously 
move the media.    The subject was limited to 40 trials to reach criteria.  No subjects were 
eliminated due to the 40 trial limit. Analysis was based on the total number of trials the 
subject took to reach the criteria of six correct trials in a row including the first four 
exploratory trials but not counting correct trials within the exploratory trials as part of the 
six correct trials.   
 Media and odor for the compound discriminations were established in pairs to 
reduce the degrees of freedom (see Table 1).  For example, in a simple discrimination 
(SD) using odor as the relevant dimension, aniseed odor would always be on one pot 
while benzoin odor would always be on the other pot.  Alpha-Dri medium was always 
used as the irrelevant dimension in both pots in the simple discriminations.  In the 
compound discrimination (CD), two separate pairs of pots were used and presented to the 
subjects in pairs in a random order.  For example, the first pair of pots would have the 
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exemplar, jamaroosa root, paired with soft sorbent in one pot and myrrh paired with soft 
snow in the other.  The second pair of pots would have the exemplar, jamaroosa root, 
paired with soft snow in one pot and myrrh paired with soft sorbents in the other. 
 Two shaping SD’s were run the first day of testing.  Each subject was allowed one 
discrimination with medium as the relevant dimension and one discrimination with odor 
as the relevant dimension.  Once a pair of dimensions had been used during the shaping 
SD’s, they were not presented to the subjects again in the testing paradigm (for an 
example of experimental design, see Table 2).   
 On the second day of testing, simple odor discrimination was performed first.  
Upon reaching criteria for the SD, a simple discrimination reversal (SDR) was performed 
so that the pot with the odor that was not rewarded now became the rewarded pot.  
Following that, a compound discrimination was performed.  An irrelevant dimension 
(different media) was added at this point that had no predictive power on the location of 
the reward.  Upon reaching criteria on the compound discrimination, a compound 
discrimination reversal (CDR) was performed so that the pot with the odor that was not 
rewarded now became the pot with the odor with the reward.   
Statistical analysis:  Data for each phase of the digging test (e.g., simple discrimination, 
compound discrimination) were analyzed using a chi-square analysis and subsequent 
odds ratio calculation to identify the relative likelihood of choice errors on the 
discrimination tests in the presence of BQCA within the two groups.  Each task phase 
was analyzed independently.  Since most subjects had excellent performance with no 
errors, only those subjects making 1 or more errors were selected for analysis. 
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Table 1.  Media and Odor Pairings for reversal learning with exemplars in bold. 
 
 
Media Pairs Odor Pairs 
M1A = CUT FOAM M1B = CUT MOSS O1A = ANISEED O1B = BENZOIN 
  02A = VANILLA O2B = ORANGE 
M3A= SOFT 
SORBENT 
M3B = SOFT 
SNOW 
O3A = 
JAMAROOSA 
ROOT
O3B = MYRRH 
 
 
 
 
 
Table 2.  Example of Experimental Design for reversal learning with exemplars in bold. 
 
 
Discriminations Dimensions Exemplar Combinations 
 Relevant Irrelevant + - 
Day 1 Shaping     
SD1 Odor  O1A O1B 
SD2 Media  M1A M1B 
Day 2 Testing     
SD3 Odor Medium O2A O2B 
SDR Odor Medium O2B O2A 
CD Odor Medium O3A/M3A O3B/M3B 
CDR Odor Medium O3B/M3B O3A/M3A 
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Amyloid precursor protein (APP) processing 
 PC12 N21 cells (a gift from Dr. Richard Burry, Ohio State University, Columbus, 
OH) were maintained in DMEM containing 10% horse serum, 5% fetal clone, 100 U/ml 
penicillin, and 100 µg/ml streptomycin at 37°C and 5% CO2.  A humanized amyloid 
precursor protein sequence bearing the Swedish mutation (KM670/671/NL) was cloned 
in place of green fluorescent protein (GFP) in the FUGW backbone.  High titer virus (~1 
x 109 infectious particles/ml) was used to transduce PC12 N21 cells.  The amyloid 
precursor protein (APP)-infected cells were subsequently infected with a lentivirus in 
which GFP was replaced by the human M1 muscarinic receptor sequence.  For amyloid 
processing experiments, cells were plated at 50,000 in 12-well trays 3-4 days before the 
experiment.  On the day of the experiment, the culture medium was replaced with 450 μL 
of Dulbecco’s Modified Eagle’s Medium (DMEM) containing the indicated 
concentration of BQCA or DMSO.  Following a 10 min pre-treatment, CCh was added in 
50 μL DMEM to the indicated final concentrations, and the medium was conditioned for 
4 hr at 37°C.  Conditioned medium was collected and centrifuged at 17,000 x g for 5 min 
to remove any cellular debris. Cells were placed on ice, rinsed with cold PBS, and 
harvested in PBS containing protease inhibitor cocktail (Roche Diagnostics).  Primary 
antibodies included 6E10 (APP Aβ domain; Signet) and C8 (APP C terminus; a gift from 
Dr. Dennis Selkoe, Center for Neurologic Diseases, Harvard Medical School, Boston, 
MA).  Amyloid-β40 (Aβ40) levels were measured using the hAmyloid β40 ELISA (HS) kit 
(The Genetics Company) according to the instructions of the manufacturer.  Plates were 
read at 450 nm on a Spectra Max Plus plate reader (Molecular Devices).  For Western 
blots, a total of 50 µg of protein from cell extracts or 15 µl of conditioned medium was 
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prepared in Laemmli's sample buffer, separated by SDS-PAGE, and transferred to 
Immobilon-P membranes (Millipore, Bedford, MA).  Membranes were blocked at room 
temperature for 30 min and incubated with primary antibodies overnight at 4°C.  Blots 
were rinsed and incubated with fluorophore-conjugated secondary antibodies (Invitrogen 
and Rockland) for 1 h at room temperature.  Blots were imaged, and band intensities were 
quantified using an Odyssey Image Station (LI-COR).  Statistical analysis was performed 
using Graphpad Prism 4.0 software. 
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CHAPTER IIIA 
 
AN ALLOSTERIC POTENTIATOR OF M4 mAChR MODULATES 
HIPPOCAMPAL SYNAPTIC TRANSMISSION 
 
Introduction 
One of the most important neuromodulatory systems responsible for regulation of 
multiple aspects of central nervous system (CNS) function is a widespread network of 
neurons that employ ACh as the primary neurotransmitter.  Cholinergic projections from 
the basal forebrain provide major modulatory inputs to the cortex and hippocampus 
(Brown and Zador, 1990) and play a critical role in memory and attention mechanisms 
(Drachman and Leavitt, 1974; Bartus et al., 1982; Fibiger, 1991).  Furthermore, abundant 
evidence suggests that the clinical syndrome associated with Alzheimer’s disease (AD) 
results, at least in part, from failed neurotransmission at cholinergic synapses in the 
hippocampus and neocortex.  There are also a number of other critical cholinergic 
systems in the central nervous system, including cholinergic interneurons in the striatum 
and other midbrain regions, as well as cholinergic projection neurons in various brain 
stem regions (Brown and Zador, 1990; Cooper and Sofroniew, 1996).  Together, these 
cholinergic pathways have been implicated in a wide variety of CNS functions including 
nociception, regulation of sleep/wake cycles, motor control, and arousal.  Agents that 
regulate cholinergic transmission have been proposed to have potential efficacy in a wide 
variety of CNS and neurodegenerative disorders including chronic and neuropathic pain, 
sleep disorders, epilepsy, schizophrenia, Alzheimer’s disease, and Parkinson’s disease 
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(Hartvig et al., 1989; Eglen et al., 1999; Bymaster et al., 2003a; Katzenschlager et al., 
2003).  
Based on this broad influence of cholinergic systems in the CNS, it is surprising 
that there have not been greater advances in development of therapeutic agents that target 
cholinergic signaling.  Efforts to develop agents that enhance cholinergic transmission for 
ameliorating the loss of cognitive function in patients with AD and other memory 
disorders have been partially successful, and clinical trials with tacrine and other acetyl 
cholinesterase (AChE) inhibitors have established dose-related improvements in 
measures of cognitive performance and quality of life (Davis et al., 1992; Rogers et al., 
1998; Raskind et al., 1999; Wilkinson and Murray, 2001).  More recently, cholinergic 
agents have been shown to reduce behavioral disturbances and psychotic symptoms in 
patients suffering from AD as well as a variety of other neurodegenerative disorders 
including Lewy body dementia, Parkinson’s disease dementia, vascular dementia, and 
schizophrenia (Kaufer et al., 1998; Bullock and Cameron, 2002; Feldman, 2002; Rosler, 
2002; Mirza et al., 2003).  However, while this clinical validation of the efficacy of 
cholinergic agents is exciting, all cholinergic agents developed thus far have dose 
limiting adverse effects that prevent widespread use in the clinic.  These adverse effects 
are primarily due to activation of muscarinic acetylcholine receptors (mAChRs) in the 
periphery. To take advantage of the therapeutic potential of manipulating cholinergic 
systems, it will be critical to develop new approaches for selectively regulating 
cholinergic signaling in central circuits involved in CNS disorders while avoiding the 
peripheral adverse effects associated with currently available treatments.   
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Evidence suggests that cholinergic transmission in many of the most critical CNS 
circuits is mediated primarily by mAChRs (Brown and Zador, 1990).  Of the five 
mAChR subtypes that have been identified (termed M1 – M5), M1 and M4 are most 
heavily expressed in the CNS and are the most likely candidates for mediating the effects 
on cognition, attention mechanisms, and sensory processing (Marino et al., 1998; Rouse 
et al., 1999; Rouse et al., 2000b).  In contrast, the most prominent adverse effects of 
cholinergic agents (bradycardia, GI distress, salivation, and sweating) are mediated by 
activation of peripheral M2 and M3 mAChRs (Okamoto et al., 2002; Bymaster et al., 
2003b; Bymaster et al., 2003a).  To attempt to avoid these peripheral side effects, 
considerable effort has been focused on developing subtype-selective agonists for 
treatment of AD and other CNS disorders (Messer, 2002a).  Unfortunately, these efforts 
have been largely unsuccessful because of an inability to develop compounds that are 
highly selective for a single mAChR relative to other mAChR subtypes (Caulfield and 
Birdsall, 1998; Felder et al., 2000).   
The difficulty in developing mAChR subtype-selective compounds is likely due 
to the high level of conservation of the ACh binding site (Wess, 1996).  In recent years, 
we have been very successful in developing highly selective allosteric potentiators of 
metabotropic glutamate receptors (mGluRs) (Marino et al., 2003; O'Brien et al., 2003; 
Kinney et al., 2005; Galici et al., 2006), which are members of the family III/C GPCRs.   
These compounds do not activate the receptor directly but interact with an allosteric site 
to potentiate responses to activation of the receptor by traditional agonists.  These 
compounds provide unprecedented selectivity for the intended receptor and can have 
behavioral effects in vivo that are very similar to those of direct acting agonists.   
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Interestingly, the strychnine analog, brucine, is a weak allosteric potentiator of M1 
(Lazareno et al., 1998), and thiochrome has been reported as an M4 allosteric potentiator 
(Lazareno et al., 2004).  These findings suggest that this approach can also be applied to 
mAChRs.   More recently, a report showed that a novel compound, LY2033298 (Fig. 2), 
is a robust allosteric potentiator highly selective for the human M4 mAChR subtype 
(Chan et al., 2008).  We used this structure to initiate cheminformatics and medicinal 
chemistry studies in which we have now identified a series of highly selective, robust 
allosteric potentiators of rat M4 (rM4).  Using these compounds along with M4 KO mice, 
we now report that M4 is one of the primary mAChR subtypes responsible for regulating 
excitatory but not inhibitory synaptic transmission at a key synapse in the hippocampal 
formation that is thought to be important for cholinergic regulation of certain aspects of 
cognitive function. 
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Figure 2.  Database mining yields a series of compounds from the ChemBridge library 
with allosteric potentiator activity at the rat M4 receptor.  A.  Chemical structures of 
LY2033298 and test compounds 7904200, 7911703, and 7912361.  B.  Effect of a 
representative allosteric potentiator hit on the rat M4 calcium mobilization response to an 
EC20 concentration of ACh (15 nM).  The responses to an EC20 concentration of ACh in 
the presence of vehicle (●) and test compound 7912361 (10 μM, ---) are shown.   Also 
shown is the response to a maximally effective concentration of ACh (10 μM, ).  Traces 
are from one representative experiment.  C.  The activity of the most robust allosteric 
potentiators from the ChemBridge series is shown (black bars); responses were 
normalized as percentage of the maximum response to 10 μM ACh after preincubation 
with vehicle (white bar) and compared to the EC20 response in the presence of vehicle 
(grey bar); bars represent the mean ± S.E.M. from four independent experiments, each 
performed in singlicate.  Database mining performed by A. Rodriguez. 
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Results 
 
Database mining of the ChemBridge chemical library yields a focused library of 232 
compounds with possible M4 PAM activity 
   
 The structure of the novel M4 mAChR allosteric potentiator, LY2033298 (Chan et 
al., 2008), is shown in Fig. 2.  We performed a search of compounds contained within the 
chemical database of ChemBridge Corp. (San Diego, CA) for compounds containing a 
core structure similar to this compound.  This search yielded a set of 232 compounds 
whose chemical ID numbers are listed in Table 3.  These compounds were purchased and 
tested for activity as allosteric potentiators of M4 in Chinese hamster ovary (CHO) cells 
stably expressing rM4 and the chimeric G-protein, Gqi5 (Coward et al., 1999).  Activation 
of rM4 was assessed using a functional fluorescence-based calcium assay.  To identify 
compounds that potentiated agonist activation of rM4, we determined the response to an 
EC20 concentration of acetylcholine (ACh, 15 nM) in the absence and presence of test 
compound.  Representative calcium fluorescence traces illustrating the effects of EC20 
(15 nM, ●) and EC100 (10 μM, ─) concentrations of ACh after pre-incubation with 
vehicle are shown in Fig. 2.  In addition, the effect of a representative test compound that 
potentiated the effect of 15 nM ACh is shown (−−).  Compounds that increased the 
response to 15 nM ACh at least 2 standard deviations above the vehicle control in at least 
three of four independent experiments were defined as putative allosteric potentiators of 
the receptor.  Compounds that met this criterion are highlighted in bold within Table 3.  
Secondary assays were performed to confirm initial hits, and compounds 7904200, 
7911703, and 7912361 were found to be the most robust potentiators in this collection; 
the activity of these compounds is shown in Fig. 3, and the structures of these three lead 
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compounds are shown in Fig. 2.  These compounds had no effect on M4 alone but 
increased the functional response to a sub-maximal concentration of ACh when 
compared to vehicle control. 
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Table 3.  Identification numbers of compounds and hits from the ChemBridge library. 
 
Compounds that potentiated the rM4 response to ACh at least 2 standard deviations above the 
mean EC20 response compared to vehicle in at least three of four independent experiments are 
shown in bold. 
5169108 6387497 7870176 7412870 6659786 7904152 
5212048 7490526 7870578 7414550 6660698 7904200 
5231589 7494270 7854487 7424915 6662916 7904411 
5240462 7498365 7857288 6388075 6663230 7904463 
5240467 7499445 7859283 6389172 7870944 7911696 
5251219 7506534 7863792 6392658 7871282 7911698 
5255524 7512235 7866797 6394090 7872987 7911699 
5271808 7514919 7867196 6394713 7874317 7911700 
5275133 7530053 7870176 6395313 7874468 7911703 
5276901 7535026 7870578 6397197 7875849 7911705 
5277323 7535375 6684242 6399377 7878578 7911706 
5277481 7538140 6686650 6399865 7879850 7912361 
5278619 7542163 6688345 6403645 7880651 7932590 
5280655 7543470 6688888 6406928 7880971 7936360 
5280786 7549000 6691423 6410109 7881499 7938195 
5282186 7562976 6792256 6417144 7903663 7940724 
5282257 7566498 6801885 6418448 7903681 7940923 
5282377 7613501 6816325 6419303 7903683 7950152 
5285006 7659652 6819140 6419575 7903694 7951001 
5377101 7673326 6830908 6420481 7903706 7953070 
5468907 7674625 6837167 6422275 7903729 7954474 
5474303 7674750 6851361 6422766 7903731 7957062 
5716785 7745085 6867990 6426854 7903735 7958103 
5728212 7746407 6933087 6626765 7903737 7959199 
5788658 7753203 6946842 6631832 7903799 7964860 
5835275 7832304 6955524 6632612 7903810 7980513 
5835470 7845204 6975540 6638434 7903841 7981803 
5835633 7845460 6976958 6640339 7903867 7993127 
5919559 7847172 6983578 6640650 7903947 7993539 
6034849 7847589 7084505 6642571 7903960 7993727 
6043941 7850005 7139207 6643255 7903986 7995223 
6045083 7852383 7139699 6645298 7904013 7997155 
6047710 7852850 7149817 6646017 7904046 9000975 
6048642 7854487 7191812 6646204 7904047 9003285 
6157275 7857288 7210223 6646749 7904048 9003877 
6244219 7859283 7354970 6648211 7904049 9004590 
6342131 7863792 7358962 6652559 7904064 5809177 
6350328 7866797 7403247 6653720 7904095  
6362515 7867196 7410242 6656495 7904104  
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Figure 3.  Lead compounds robustly potentiate M4-mediated calcium mobilization and 
are selective for M4 relative to other mAChR subtypes.  A.  CRCs of each compound 
were performed in the presence of an EC20 concentration (15 nM) of ACh.  Data were 
normalized to the maximum M4 response to 10 μM ACh.  Points represent the mean of 
three independent experiments performed in triplicate, and error bars represent S.E.M.  B.  
The CRC of ACh in the presence of 10 μM compound 7904200 (□), 7911703 (Δ), or 
7912361 (○) is shifted leftward when compared to vehicle control, and the leftward shift 
is accompanied by an increase in the maximal M4 response.  Points represent the mean of 
five experiments performed in triplicate, and error bars represent S.E.M.  C.  There was 
no significant change in the ACh EC50 in cells expressing rM1, hM2 and Gqi5, hM3, or 
hM5 after pre-incubation with either vehicle or 10 μM test compound as shown by 
overlapping ACh CRCs.  Data were normalized as percent maximum response to 10 μM 
ACh; points represent mean ± S.E.M (n = 3). 
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Primary screening hits are robust, subtype selective allosteric potentiators of rat M4  
 The potency of each compound was determined by pre-incubating cells with 
vehicle or increasing concentrations of test compound followed by the addition of an 
EC20 concentration (15 nM) of ACh to yield concentration-response curves (CRCs) as 
shown in Fig. 3.  The responses to these compounds did not reach a clear plateau in the 
concentration range used, and solubility limits prevented further increases in 
concentrations.  However, in the concentration ranges tested, compound 7912361 was the 
most potent with an EC50 of 395 ± 28 nM, while compounds 7904200 and 7911703 had 
EC50 values of 6 ± 0.28 μM and 1.3 ± 0.28 μM, respectively.   
We next determined the effects of maximal concentrations of each compound on 
the CRC of ACh.  Cells were pre-incubated with a fixed concentration (10 μM) of test 
compound and subsequently stimulated with increasing concentrations of ACh.  Each 
compound induced a leftward shift of the ACh CRC and increased the maximal response 
to ACh (Fig 3).  The EC50 value for ACh in the presence of vehicle was 87 ± 12 nM, 
whereas the EC50 values were 34, 12, and 4 nM in the presence of compounds 7904200, 
7911703, and 7912361, respectively.   Thus, compound 7912361 proved to be the most 
robust potentiator causing a 21-fold leftward shift in the ACh CRC (Fig. 3).  
Experiments were then performed to assess the functional selectivity of our three 
lead compounds at potentiating M4 responses relative to other mAChRs.  Cells 
expressing rM1, rM2-Gqi5, rM3, or rM5 were incubated first with 10 μM test compound or 
vehicle, then with increasing concentrations of ACh to test whether these potentiators 
would have any effect on functional mAChR responses in these cell lines.  As shown in 
Fig. 3, among the five muscarinic receptor subtypes, these three novel compounds 
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possess perfect functional subtype selectivity for M4 as shown by their lack of effect on 
any other mAChR in the absence or presence of ACh.  Because the experimental protocol 
measures real-time calcium mobilization during a pre-incubation with each test 
compound, any agonist or antagonist as well as allosteric modulator activity is detected.  
The ACh CRCs for rM1, rM2, rM3, and rM5 in the presence of vehicle or 10 μM test 
compound are virtually overlapping with no effect on the functional ACh EC50. 
 
Chemical optimization of primary M4 allosteric potentiator hits 
 The results from the 232 compound screen were analyzed to understand the 
structure activity relationship of the compounds. The top three lead compounds had a 
dimethyl substitution on the pyridine ring, and most compounds that had larger 
substitutions lost all activity. Substitution of the primary amine was mostly tolerated but 
resulted in loss of some activity. We chose to keep the primary amine and substitute the 
amide functionality with side chains related to compounds 7904200 and 7912361.  A 
collection of 10 amines were acylated with bromoacetyl bromide to give the 
corresponding bromo amides (Fig. 4). Subsequent ‘one-pot’ alkylation and cyclization of 
mercaptopyridine with the bromo amides using KOH provided compounds VU10001-
VU10010 (Fig. 4) as yellow solids after conversion to their TFA salts. 
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Figure 4.  Synthesis of compounds in the VU10000 series.  A collection of 10 amines 
were acylated with bromoacetyl bromide to give the corresponding bromo amides.  
Subsequent alkylation and cyclization of mercaptopyridine with the bromo amides using 
KOH provided compounds VU10001-VU10010.  Syntheses performed by D. Orton and 
R. Williams. 
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Characterization of novel compounds in the VU10000 series   
 To test this small library of ten compounds for rM4 allosteric potentiator activity, 
functional experiments identical to the ones described above were performed.  Fig. 5 
shows the response of cells expressing rM4 and Gqi5 to an EC20 concentration of ACh in 
the presence of either vehicle (EC20 grey bar) or test compound (black bars) as compared 
to the maximum response to 10 μM ACh after pre-incubation with vehicle (white bar).  
All compounds except VU10007 showed allosteric potentiator activity; VU10005, 
VU10008, and VU10010 caused the largest potentiation of the EC20 response and these 
compounds were selected for further testing.  CRCs of these potentiators showed that all 
three compounds have submicromolar potencies; compounds VU10005, VU10008, and 
VU10010 have EC50 values of 300 ± 75 nM, 715 ± 160 nM, and 400 ± 100 nM, 
respectively (Fig. 5b).  When comparing the rM4 ACh CRC in the presence of either 
vehicle or 10 μM test compound, we found VU10010 to be the most robust allosteric 
potentiator as is shown by the 47-fold shift in the ACh EC50 (Fig. 5c).  The EC50 value of 
ACh was 33 ± 9 nM in the absence of VU10010 and 0.7 ± 0.2 nM in the presence of this 
compound.  All three lead compounds in the VU10000 series produced greater leftward 
shifts in the functional rM4 response to ACh than the best lead compound from the 
ChemBridge library, compound 7912361, which induced a 21-fold increase in ACh 
potency (Fig. 3 and 5).  Compounds VU10005 and VU10008 produced 30- and 37-fold 
leftward shifts in the curve, respectively.  From these data, we concluded that VU10010 
had the best combination of potency and efficacy of all compounds tested, and we chose 
this allosteric potentiator for use in all subsequent experiments.  The next critical step 
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was to confirm that VU10010 maintained the high degree of subtype selectivity that was 
shown for compounds in the ChemBridge series. 
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Figure 5.  Chemical optimization generates compounds that potentiate M4-mediated calcium 
mobilization with greater efficacy than lead compound 7912361.  A.  Nine of the ten compounds 
synthesized and tested showed allosteric potentiator activity (black bars) compared to the ACh 
EC20 control (grey bar).  Data were normalized to the maximal response to 10 μM ACh (white 
bar).  Bars represent the mean ± S.E.M. of five independent experiments, each performed in 
triplicate.  B.  The three compounds that showed the highest degree of potentiation in panel (A.) 
were further characterized to determine their potencies.  As shown by their CRCs, all three 
compounds have potencies in the submicromolar range.  C.  When compared to compound 
7912361, all three lead compounds in this series induced a more robust leftward shift in the rM4 
ACh CRC as well as a larger increase in the maximal response.  Points represent mean ± S.E.M. 
(n = 3). 
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 Figure 6 shows that the response to ACh in cell lines expressing each of the other 
mAChR subtypes is unaffected in the presence of a maximal (10 μM) concentration of 
VU10010 when compared to vehicle control.  To further investigate the functional 
selectivity of this allosteric potentiator, we performed parallel experiments with cells 
expressing two unrelated receptors.  The family I/A GPCR P2Y1 is a Gαq-coupled 
receptor endogenously expressed in rM4-CHO cells that, when activated by ATP, 
stimulates intracellular calcium mobilization.  The family III/C GPCR mGluR5 also 
activates PLCβ via Gαq to cause calcium release from intracellular stores upon 
stimulation by glutamate.  VU10010 (10 μM) had no agonist, antagonist, or allosteric 
potentiator activity at P2Y1R or mGluR5 (Fig. 7). 
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Figure 6.  VU10010 is selective for the rM4 receptor relative to the other mAChRs.  
VU10010 showed no activity at rM1, hM2, hM3, or hM5 compared to the robust 
potentiation of rM4 where preincubation with 10 μM VU10010 (○) causes a 47-fold 
decrease in the ACh EC50.  Points represent mean ± S.E.M. (n = 3). 
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Figure 7.  VU10010 showed no agonist, antagonist, or potentiator activity at two GPCRs 
unrelated to rM4 mAChR.  Agonist CRCs from cells expressing the ATP receptor, P2Y1  
(A.), or the metabotropic glutamate receptor, mGluR5 (B.), were overlapping in the 
presence of 10 μM VU10010 (○) compared to vehicle control.  Data points represent 
mean ± S.E.M. (n = 3). 
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VU10010 binds allosterically and increases M4 receptor affinity for ACh  
 In order to determine the effects of VU10010 on orthosteric binding and to further 
confirm an allosteric mechanism of binding, we performed equilibrium radioligand 
binding studies.  Membranes prepared from cells expressing rM4 were incubated with a 
non-saturating concentration of the orthosteric site antagonist [3H]NMS (0.1 nM) in the 
absence or presence of increasing concentrations of either atropine or VU10010.  
Consistent with atropine’s high affinity at the orthosteric site, this compound displaced 
[3H]NMS binding with an Ki value of 0.52 ± 0.23 nM.  In contrast, VU10010 did not 
displace [3H]NMS binding at concentrations up to 30 μM, which is 75 times the EC50 
value of this compound at potentiating responses to ACh (Fig. 8).  While this finding 
does not exclude the possibility that VU10010 could alter [3H]NMS binding under some 
conditions, it provides strong support for the functional data and further suggests that 
VU10010 acts at a site on the M4 receptor that is distinct from the 
orthostericantagonist/agonist binding site.  To further confirm that VU10010 is selective 
for M4 relative to other mAChRs, we performed parallel binding experiments using 
membranes from cell lines expressing rM1, rM2, rM3, and rM5.  As shown in Fig. 9, this 
compound does not displace [3H]NMS binding at any mAChR subtype. The [3H]NMS 
Kd, Bmax, and atropine Ki values for each mAChR from saturation and competition 
binding experiments are listed in Table 4. 
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Table 4.  Radioligand binding parameters for mAChR-expressing cell lines.     
 [3H]NMS Kd (nM) Bmax (fmol/mg) Atropine Ki (nM) 
rM1 0.131 ± 0.004 509 ± 12 0.79 ± 0.14 
hM2 0.296 ± 0.018 892 ± 60 1.45 ± 0.18 
hM3 0.109 ± 0.004 2313 ± 57 0.80 ± 0.07 
rM4 0.046 ± 0.004 247 ± 15 0.52 ± 0.23 
hM5 0.264 ± 0.006 968 ± 32 0.86 ± 0.07 
 
[3H]NMS Kd and Bmax for each receptor subtype were determined from saturation binding 
experiments.  Ki values for atropine were determined based on competition with 0.1 nM 
[3H]NMS at each mAChR.  Values are mean ± S.E.M (n = 3). 
 
 
 
127 
 
A.
B.
–12 –11 –10 –9 –8 –7 –6 –5 –4
0
20
40
60
80
100
120
Atropine
VU10010
Log [cold ligand] (M)
Sp
ec
ifi
c
bi
nd
in
g
(%
m
ax
[3 H
]N
M
S
bo
un
d)
-9 –8 –7 –6 –5 –4 –3 –2
0
20
40
60
80
100
120
Vehicle
30 nM
100 nM
300 nM
1 µM
3 µM
10 µM
Log [ACh] (M)
Sp
ec
ifi
c
bi
nd
in
g
0
0
20
40
60
80
100
120
140
160
Vehicle
10 µM VU10010
–9 –8 –7 –6 –5 –4 –3
Log [ACh] (M)
[35
S]
G
TP
γS
 B
in
di
ng
(%
m
ax
AC
h
re
sp
on
se
)
C.
(%
m
ax
[3 H
]N
M
S
bo
un
d)
 
 
Figure 8.  Compound VU10010 binds to an allosteric site on M4 mAChR and causes an 
increase in affinity for ACh and M4-mediated [35S]GTPγS binding.  A.  Binding of 0.1 
nM [3H]NMS was displaced by atropine (■, Ki = 0.52 ± 0.23 nM) but not by VU10010 
(▲).  Data are from three independent experiments performed in triplicate.  Error bars are 
S.E.M.  B.  In a dose-dependent manner, VU10010 shifted the ACh competition curve 
leftward causing a 14-fold decrease in the Ki at maximal concentration of 10 μM (Δ).  
Data are mean ± S.E.M. (n = 3).  C.  VU10010 potentiates the response to ACh in 
membranes from cells expressing rM4.  VU10010 (○, 10 μM) induced a 10-fold decrease 
in the ACh EC50 when compared to vehicle control (■).  The leftward shift in the CRC 
was also accompanied by a 43 ± 12% increase in the maximal response.  Data represent 
mean ± S.E.M. (n = 3). 
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  One possible mechanism by which a compound could enhance receptor activation 
by an agonist is by increasing the receptor’s affinity for that agonist (Christopoulos and 
Kenakin, 2002).  As shown in Fig. 8, compound VU10010 does in fact induce a 
concentration-dependent shift in the potency of ACh at displacing rM4 [3H]NMS binding.  
At 10 μM, a concentration that causes maximal potentiation, VU10010 increased the 
apparent affinity of ACh 14-fold.  Thus, the Ki value for ACh at the orthosteric site 
decreased from 540 ± 72 nM in the absence of VU10010 to 39 ± 7 nM in the presence of 
10 μM VU10010.  These data suggest that this compound binds to an allosteric site on 
M4 mAChR and shifts the receptor into a conformation that has higher affinity for ACh. 
 
VU10010 enhances M4 coupling to downstream effector proteins 
The finding that VU10010 increases affinity of ACh for the orthosteric site 
suggests that this contributes to the ability of this compound to potentiate responses to 
ACh.  However, the magnitude of this shift (14-fold) is not sufficient to account for the 
magnitude of the shift in the ACh potency at increasing calcium mobilization (47-fold).  
Also, the shift in agonist potency was also accompanied by an increase in agonist 
maximal response which cannot be explained by an increase in affinity alone.  Thus, we 
examined the effect of VU10010 on the ability of M4 to increase activation of G proteins 
by measuring effects of this compound on ACh-induced increases in guanosine 5′-O-(3-
[35S]thiotriphosphate ([35S]GTPγS) binding.  To assess this, the effect of increasing 
concentrations of ACh on [35S]GTPγS binding to membranes from rM4-CHO cells was 
measured in the absence and presence 10 μM compound VU10010.  Compound 
VU10010 shifted the CRC of ACh at increasing [35S]GTPγS binding to the left and also 
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increased maximal [35S]GTPγS binding by roughly 50% (Fig. 8).  Thus, the EC50 value 
for ACh was 514 ± 82 nM in the absence of VU10010 and 51 ± 11 nM in the presence of 
this compound.  These data are consistent with the hypothesis that the allosteric 
potentiator not only increases affinity of the receptor for agonist but also increases 
coupling efficiency and efficacy. 
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Figure 9.  VU10010 does not compete for binding at rat M1, M2, M3, or M5.  Binding of 
0.1 nM [3H]NMS was displaced by atropine (■) but not by VU10010 (▲).  Data are from 
three independent experiments performed in triplicate, and error bars are S.E.M. 
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VU10010 enhances muscarinic depression of excitatory post synaptic currents in 
hippocampal CA1 pyramidal cells 
 
 Discovery of novel highly selective and potent allosteric potentiators of M4 
provides an unprecedented opportunity to begin functional studies aimed at determining 
the physiological roles of this receptor subtype in native preparations.  One of the most 
prominent effects of mAChR activation that is seen in a variety of forebrain and cortical 
regions is depression of transmission at excitatory glutamatergic synapses; in addition, 
muscarinic agonists can reduce transmission at inhibitory GABAergic synapses in these 
same circuits (Valentino and Dingledine, 1981; Bilkey and Goddard, 1985; Sheridan and 
Sutor, 1990; Pitler and Alger, 1994; Qian and Saggau, 1997; Fernandez de Sevilla and 
Buno, 2003).  However, the lack of subtype-selective ligands for specific mAChR 
subtypes has made it impossible to definitively determine which mAChR subtypes 
mediate each of these effects. Thus, we determined the effect of VU10010 on the ability 
of the non-selective mAChR agonist, carbachol (CCh), to reduce excitatory and 
inhibitory transmission at the Schaffer collateral-CA1 synapse in the rat hippocampus.  
Consistent with previous findings, CCh reversibly inhibited evoked EPSCs at Shaffer-
collateral-CA1 synapses in a concentration-dependent manner (Fig. 10).  CCh at 100 μM 
caused a marked reduction of EPSCs (16.1 ± 4.0 % of control value, n = 5, Fig. 10), 
whereas at a sub-maximal concentration of 1 μM, CCh induced a relatively small 
reduction of EPSCs (60.5 ± 4.1% of control value, n = 15; Fig. 10). In contrast, VU10010 
(5 μM) had no effect on excitatory transmission at this synapse when added alone (EPSC 
amplitude 107.9 ± 5.2% of the control, P = 0.16, n = 7; Fig. 10).  However, when 
VU10010 (5 μM) was co-applied with a sub-maximal concentration of CCh (1 μM), this 
compound increased the CCh-induced reduction of EPSCs (36.9 ± 5.7% of control, n = 7, 
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Fig. 10) when compared to the effect of 1 μM CCh alone (60.5 ± 4.1% of control value, n 
= 15; P = 0.0038, Fig. 10).  Thus, VU10010 potentiates CCh-induced inhibition of 
excitatory synaptic transmission at this critical synapse in the hippocampus.  As a 
negative control, we used VU10007, a closely related analog of VU10010 that is 
completely inactive as an allosteric potentiator of M4 in cell-based assays (see Fig. 5).  
VU10007 (5 μM) had no effect on the CCh-induced reduction of EPSCs (61.6 ± 5.0% of 
control value, n = 7, Fig. 10; compared to 60.5 ± 4.1% of control value by CCh alone, n = 
15; P = 1).  These results suggest that M4 is one of the mAChRs involved in the 
regulation of excitatory synaptic transmission at Schaffer collateral-CA1 synapses. 
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Figure 10.  VU10010 potentiates CCh-induced reduction of EPSCs but not IPSCs at rat 
hippocampal Shaffer collateral-CA1 synapses.  A.  Averaged EPSCs obtained from 
experiments in which the effects of the following reagents on EPSC amplitude were 
examined: 100 μM CCh (A1), 1 μM CCh (A2), 1 μM CCh with 5 μM VU10010 (A3), 1 
μM CCh with 5 μM VU10007 (an inactive analog of VU10010, A4).  B.  Bar graph 
summarizing the potentiation effect of VU10010 on CCh-induced reduction of EPSCs.  
Data represent mean ± S.E.M.  C.  Averaged IPSCs obtained from experiments in which 
the effects of the following reagents on IPSC amplitude were examined: 100 μM CCh 
(C1), 0.5 μM CCh (C2) and 0.5 μM CCh with 5 μM VU10010 (C3).  D.  Bar graph 
summarizing the effect of VU10010 on CCh-induced reduction of IPSCs in CA1 
pyramidal cells. Data are shown as mean ± S.E.M.  Experiments performed by Z. Xiang. 
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Muscarinic depression of inhibitory post synaptic currents is not affected by M4 
potentiation 
 
 Muscarinic receptors also play a role in regulating inhibitory synaptic 
transmission in hippocampal CA1 pyramidal cells (Valentino and Dingledine, 1981; 
Pitler and Alger, 1994).  Consistent with previous studies, we found that application of 
100 μM CCh greatly reduced monosynaptic IPSC amplitude to 10.9 ± 0.9% of control 
value (n = 3, Fig. 10), and a sub-maximal concentration of CCh (0.5 μM) caused a 
smaller reduction of IPSC amplitude (62.2 ± 3.5% of control, n = 6, Fig. 10). Application 
of the M4 potentiator VU10010 (5 μM) alone had no effect on IPSC amplitude (98.5 ± 
1.7 of control, n = 4, P = 0.875).  Furthermore, VU10010 (5 μM) had no effect on the 
depression of IPSCs induced by 0.5 μM CCh (61.7 ± 3.9% with CCh and VU10010, n = 
6, versus 62.2 ± 3.5% with CCh alone, n = 6, P = 0.82; Fig. 10). These results indicate 
that M4 mAChRs are probably not involved in muscarinic modulation of inhibitory 
synaptic transmission in CA1 pyramidal cells. To further test this hypothesis, we 
compared the effect of sub-maximal concentration of CCh on IPSCs in hippocampal CA1 
pyramidal cells in M4 knockout and WT mice.  At 2 μM, CCh caused a reduction of 
IPSCs with a comparable magnitude in both WT and M4 KO mice (56.0 ± 4.6% and 60.2 
± 2.7% of control values, n = 6 and n = 6, respectively; P = 0.48, Fig. 11).  While these 
data do not completely rule out a role for M4 in regulating IPSCs in WT animals, the data 
are consistent the hypothesis that M4 mAChRs are not involved in modulation of 
inhibitory synaptic transmission in CA1 pyramidal cells. 
 
 
135 
 
10 ms
100 pA
10 ms
200 pA
10 ms
100 pA
10 ms
50 pA
10 ms
50 pA
10 ms
100 pA
Control
2 μM CCh
Washout
5 μM VU10010
2 μM CCh +
5 μM VU10010
100 μM CCh
A. Wild-type
2
3
1
Control
2 μM CCh
Washout
5 μM VU10010
2 μM CCh +
5 μM VU10010
100 μM CCh
B.  M   Knockout
 N
or
m
al
iz
ed
 E
P
S
C
 a
m
pl
itu
de
(%
of
co
nt
ro
l)
2 μ
M
CC
h
2 μ
M
CC
h +
5 μ
M
VU
10
01
0
10
0 μ
M
CC
h
0
20
40
60
80
100
WT
M   KO
C.
2
3
1
4
4
 
 
 
Figure 11.  VU10010 potentiates CCh-induced reduction of EPSCs in wild-type (WT) 
but not in M4 KO mice.  A.  Averaged EPSCs obtained from experiments in which the 
effects of the following reagents on EPSC amplitude in WT mice were examined: 100 
μM CCh (A1), 2 μM CCh (A2), and 2 μM CCh with 5 μM VU10010 (A3).  B.  Averaged 
EPSCs obtained from experiments in which the effects of the same reagents on EPSC 
amplitude in M4 KO mice were examined: 100 μM CCh (B1), 2 μM CCh (B2), and 2 μM 
CCh with 5 μM VU10010 (B3).  (C) Bar graph summarizing the effect of VU10010 on 
CCh-induced reduction of EPSCs in WT mice (white bars) and M4 KO mice (black bars). 
Data represent mean ± S.E.M.  Experiments performed by Z. Xiang and J.E. Ayala. 
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VU10010 potentiates CCh-induced reduction of EPSCs in wild-type (WT) but not in 
M4 knockout (KO) mice 
 
 To confirm that the potentiation effect of VU10010 on CCh-induced reduction of 
EPSCs was due to its action on M4 receptors, we examined the effect of VU10010 in M4 
KO mice (Gomeza et al., 1999).  As a control, we first assessed the effect of VU10010 in 
WT mice of the same mixed genetic background as the M4 KO mice. Similar to the result 
obtained from rats, CCh at 100 μM caused a sizable reduction of EPSCs at Schaffer 
collateral-CA1 synapses in WT mice (18.0 ± 0.9 % of control value, n = 6, Fig. 11), 
whereas at a sub-maximal concentration of 2 μM, CCh induced a smaller inhibition of 
EPSCs (53.7 ± 1.4% of control, n = 6; Fig. 11). Compound VU10010 (5 μM) had no 
effect on excitatory transmission at this synapse when added alone (EPSC amplitude 
102.5 ± 3.8% of the control, P = 0.31, n = 5; Fig. 11).  However, when co-applied with 2 
μM CCh, VU10010 (5 μM) significantly enhanced the CCh-induced reduction of EPSCs 
(39.8 ± 2.7% of the control, n = 5, Fig. 11) when compared to the effect of 2 μM CCh 
alone (54.7 ± 1.1% of control, n = 5; P = 0.0079, Fig. 11). 
In M4 KO mice, application of 100 μM CCh decreased the EPSC amplitude to 
21.1 ± 3.8 % of control value (n = 6, Fig. 11), whereas at the sub-maximal concentration 
of 2 μM, CCh induced a relatively small suppression of EPSCs (70.8 ± 3.6% of control 
value, n = 9; Fig. 11), which was significantly different than the reduction of EPSCs 
caused by 2 μM CCh in WT mice (53.7 ± 1.4% of control, n = 6; P = 0.0076, Fig. 11). 
Furthermore, when compound VU10010 was co-applied with 2 μM CCh, it failed to 
potentiate the CCh-induced reduction of EPSCs in M4 KO mice (77.5 ± 4.6% of control 
value, n = 7, Fig. 11) when compared to the effect of 2 μM CCh alone (70.8 ± 3.6% of 
control value, n = 9; P = 0.14, Fig. 11). These data support the conclusion that the 
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potentiation of CCh-induced reduction of EPSCs by VU10010 is solely due to its action 
on M4 receptors and that M4 participates in the muscarinic modulation of these synaptic 
responses. 
 
Discussion 
Over the past two decades, major attention has been focused on developing highly 
selective agonists of specific mAChR subtypes to use as research tools in order to achieve 
a better understanding of the roles of each subtype in specific organ systems and also to 
develop therapeutic agents that lack the adverse effects of AChE inhibitors and 
nonselective muscarinic agents.  However, the muscarinic receptor agonists developed to 
date lack true specificity for individual muscarinic receptor subtypes.   This thesis chapter 
reports the discovery of a novel series of compounds that act as robust positive allosteric 
modulators (allosteric potentiators) of the M4 mAChR subtype.  These compounds are 
highly selective for M4 and have no detectable activity at any other mAChR subtype.  As 
with previously discovered allosteric potentiators of metabotropic glutamate receptors 
(mGluRs), the novel positive allosteric modulators of M4 reported here have no 
detectable affinity for the orthosteric site on M4.  The action of these compounds at a site 
that is distinct from the highly conserved orthosteric ACh binding site is likely to be 
critical for achieving this high degree of subtype selectivity. 
Interestingly, the M4 allosteric potentiator reported here increases affinity of ACh 
for the orthosteric site.  This is similar to previous reports of allosteric modulators of 
GPCRs acting by altering affinity of ligands at the orthosteric site; the magnitude of 
binding cooperativity or the shift in orthosteric agonist affinity is referred to as the alpha 
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factor (Christopoulos and Kenakin, 2002).  However, while VU10010 apparently acts in 
part by increasing ACh affinity, the magnitude of this effect was only a 14-fold increase 
in ACh affinity whereas VU10010 induced an almost 50-fold shift in the ACh 
concentration response curve for activating calcium mobilization.  Thus, effects on 
agonist binding cannot fully account for the allosteric potentiator activity measured in the 
functional assay; potentiation by this compound must also increase efficacy and coupling 
to downstream effectors.  The present data suggest that VU10010 acts by both increasing 
ACh affinity and also through a positively cooperative interaction with ACh for 
activation of G proteins and downstream signaling pathways.  Studies of the effects of 
VU10010 on [35S]GTPγS binding revealed a 10-fold shift in ACh potency; this value is 
close to the calculated shift in ACh affinity at the orthosteric site, suggesting that the 
increase in ACh affinity could account for the shift in ACh potency at increasing G 
protein activation.  However, VU10010 also increased the maximal ACh-induced 
[35S]GTPγS binding response, suggesting that this potentiator increases the efficiency of 
M4 coupling to G proteins.  These two factors together likely contribute to the robust shift 
in ACh potency for inducing calcium mobilization relative to more modest shift observed 
in ACh affinity. 
Discovery of a highly selective allosteric modulator of M4 provides an 
unprecedented opportunity to selectively increase activity of this receptor and develop a 
more detailed understanding of the functional roles of M4 in brain circuits that are heavily 
modulated by cholinergic innervation.  One of the most important roles of cholinergic 
systems in the CNS is modulation of transmission through the hippocampal formation, a 
limbic cortical structure that plays a critical role in learning and memory and is thought to 
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be important for cholinergic regulation of cognitive function.  Activation of mAChRs in 
the hippocampus induces a marked reduction of transmission at both excitatory 
glutamatergic and inhibitory GABAergic synapses by presynaptic reduction of 
neurotransmitter release (Valentino and Dingledine, 1981; Bilkey and Goddard, 1985; 
Fernandez de Sevilla and Buno, 2003).   Multiple mAChR subtypes are expressed in the 
hippocampus, and evidence suggests that both M2 and M4 are localized in presynaptic 
terminals where they could regulate excitatory and inhibitory synaptic transmission 
(Levey et al., 1995; Rouse et al., 1999; Rouse et al., 2000a).  In addition, evidence 
suggests that activation of postsynaptic mAChRs on hippocampal pyramidal cells where 
M1 and M4 are expressed could reduce synaptic transmission in the hippocampus by 
inducing release of endocannabinoids that activate presynaptic CB1 cannabinoid 
receptors (Ohno-Shosaku et al., 2003).  Thus, the specific mAChR subtypes involved in 
regulating transmission at these important synapses has not been clear.  The present 
finding that VU10010 potentiates effects of mAChR agonists on excitatory but not 
inhibitory synaptic transmission provides strong evidence that M4 is one of the mAChR 
subtypes responsible for regulating transmission at glutamatergic synapses in the 
hippocampus but is not likely to be involved in regulation of transmission at inhibitory 
synapses in this brain region.  This selective regulation of excitatory synaptic 
transmission is a first critical step in developing a detailed understanding of the roles of 
M4 in modulating hippocampal function.   In future studies, it will be important to take 
advantage of this novel class of allosteric potentiators to further investigate the roles of 
M4 in hippocampus as well as other cortical and basal ganglia structures where this 
receptor has been postulated to play a critical neuromodulatory role.  Also, it will be 
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important to further optimize these compounds for use as tools that will provide a path 
for developing an understanding of the impact of selectively increasing M4 activation in 
vivo. 
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CHAPTER IIIB 
 
CENTRALLY ACTIVE ALLOSTERIC POTENTIATORS OF THE M4 
MUSCARINIC ACETYLCHOLINE RECEPTOR REVERSE AMPHETAMINE-
INDUCED HYPERLOCOMOTOR ACTIVITY IN RATS 
 
 
Introduction 
To date, five muscarinic acetylcholine receptor (mAChR) subtypes have been 
identified (M1-M5) and play important roles in mediating the actions of ACh in the 
peripheral and central nervous systems (Wess, 1996).  Of these, M1 and M4 are the most 
heavily expressed in the CNS and represent attractive therapeutic targets for cognition, 
Alzheimer’s disease (AD) and schizophrenia (Bymaster et al., 2002; Messer, 2002; 
Raedler et al., 2007).  In contrast, the adverse effects of cholinergic agents are thought to 
be primarily due to activation of peripheral M2 and M3 mAChRs (Bymaster et al., 2003b; 
Bymaster et al., 2003a).  Due to the high sequence homology and conservation of the 
orthosteric ACh binding site among the mAChR subtypes, development of chemical 
agents that are selective for a single subtype has been largely unsuccessful, and in the 
absence of highly selective activators of M4, it has been impossible to test the role of 
selective M4 activation.  Clinical trials with xanomeline (Fig. 12), an M1/M4 preferring 
orthosteric agonist, demonstrated efficacy as both a cognition enhancing agent, and as an 
antipsychotic agent (Bodick et al., 1997b; Shekhar et al., 2001; Shekhar et al., 2008).  In 
follow-up studies in rats, xanomeline displayed an antipsychotic-like profile comparable 
to clozapine (Stanhope et al., 2001).  However, a long standing question concerned 
whether or not the antipsychotic efficacy or antipsychotic-like activity in animal models 
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is mediated by activation of M1, M4, or a combination of both receptors.  Data from 
mAChR knock-out mice led to the suggestion that a selective M1 agonist would be 
beneficial for cognition, whereas an M4 agonist would provide antipsychotic activity for 
the treatment of schizophrenia (Felder et al., 2001; Bymaster et al., 2003b; Bymaster et 
al., 2003a).  This proposal is further supported by recent studies demonstrating that M4 
receptors modulate the dynamics of cholinergic and dopaminergic neurotransmission and 
that loss of M4 function results in a state of dopamine hyperfunction (Tzavara et al., 
2004).  These data, coupled with findings that schizophrenic patients have altered 
hippocampal M4, but not M1, receptor expression (Scarr et al., 2007) suggest that 
selective activators of M4 may provide a novel treatment strategy for schizophrenia 
patients.  However, multiple studies suggest that M1 may also play an important role in 
the antipsychotic effects of mAChR agonists and the relative contributions of M1 and M4 
to the antipsychotic efficacy of xanomeline or antipsychotic-like effects of this compound 
in animal models are not known.  Unfortunately, the lack of highly selective, systemically 
active activators of M1 and M4 has made it difficult to fully evaluate the effects of 
activation of these mAChR subtypes in animal models. 
 Recently, we reported discovery of a number of positive allosteric modulators for 
class C GPCRs that bind to allosteric sites, provide high levels of subtype selectivity and 
display behavioral effects in vivo comparable to direct acting agonists (O'Brien et al., 
2003; Lindsley et al., 2004; O'Brien et al., 2004; Kinney et al., 2005; Galici et al., 2006; 
Hemstapat et al., 2006; Marino and Conn, 2006; Zhao et al., 2007).  In addition, we 
identified a highly selective positive allosteric modulator of M4 termed VU10010 (Fig. 
12) (Shirey et al., 2008).  This compound induces a 47-fold potentiation of the M4 ACh 
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concentration response curve (CRC), possesses an EC50 in the 400 nM range and causes 
no activation of the other mAChR subtypes.  Additional in vitro pharmacological 
characterization studies suggested that VU10010 binds to an allosteric site on the M4 
receptor to increase affinity for ACh and coupling to G proteins (Shirey et al., 2008).  
Subsequent studies with VU10010 revealed that selective potentiation of M4 increased 
carbachol (CCh)-induced depression at excitatory, but not inhibitory, synapses and that 
the effect on excitatory currents was not mimicked by an inactive analog of VU10010 or 
in M4 knock-out mice (Shirey et al., 2008). 
   
 
 
Figure 12.  Chemical structures of Xanomeline [3-[3-hexyloxy-1,2,5-thiadiazo-4-yl]-
1,2,5,6-tetrahydro-1-methylpyridine] and VU10010 [3-amino-N-(4-chlorobenzyl)-4,6-
dimethylthieno[2,3-b]pyridine-2-carboxamide]. 
 
  
 Despite this notable advance, VU10010 suffered from poor physiochemical 
properties (logP~4.5) and in vivo studies proved infeasible because we were unable to 
formulate VU10010 into a homogeneous solution in any acceptable vehicle, regardless of 
salt form or particle size.  Several suspensions were prepared and dosed i.p., but 
VU10010 was not found to be centrally active.  In order to evaluate the role of selective 
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M4 activation in vivo, VU10010 would require further chemical optimization.  Here we 
report the development and characterization of two novel analogs of VU10010 that are 
CNS penetrant following systemic administration. 
 
Results 
 
Chemical Lead Optimization 
 For the chemical optimization of VU10010, undertook a diversity-oriented 
synthesis (DOS) approach to explode Structure-Activity-Relationships (SAR) with a 
variety of hypothesis-driven, structural changes to the lead compound.  The rationale for 
this approach for the optimization of VU10010 is that SAR for allosteric ligands is often 
‘flat’ or ‘shallow’, with subtle structural modifications leading to a complete loss of 
activity, and often only one portion of an allosteric ligand is amenable to change.  
Therefore, a multi-dimensional, DOS library approach provides the best opportunity to 
quickly identify productive SAR as opposed to a lead optimization strategy based on 
classical, single compound synthesis (Lindsley et al., 2004; Zhao et al., 2007). One 
explanation for the lack of central activity observed with VU10010 could be the result of 
the poor physiochemical properties alone, or in combination with P-glycoprotein (P-gp) 
efflux.  P-gp is an efflux transporter with broad substrate specificity present on the 
luminal membrane of epithelial cells comprising the blood-brain barrier, which is known 
to impair the brain penetrability of a number of drugs.  The β-aminoamide motif 3 present 
in VU10010 represents a potential P-gp liability, which could be removed by cyclization 
to analogs such as 2 (Fig. 13A).  Alternatively, P-gp susceptibility could also be 
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diminished by electronically attenuating the basicity of the amine moieties by the 
incorporation of distal fluorine atoms.  Utilizing solution phase parallel synthesis (Fig. 
13B), we synthesized small, 12- to 24-member focused libraries around each of the 10 
scaffolds 4, 5-13 (Fig. 13C) which were then purified by mass-directed preparative 
HPLC to analytical purity (>98%).  This collection of VU10010 analogs incorporated 
CF3 moieties (scaffolds 7 and 8) to electronically attenuate potential P-gp susceptibility, 
deletion of the β-amino moiety (scaffold 12), or replacement of the β-amino moiety with 
an isosteric methyl group (scaffold 11).  Other scaffolds explored the deletion of 
substituents on the pyridine nucleus (9), incorporation of an additional nitrogen atom  to 
afford a pyrimidine nucleus (10) or removal of the pyridine nitrogen atom in VU10010 
(13).  Finally, library 5 focused on maintaining the core structure of VU10010, but 
explored alternative amides, selected to improve physiochemical properties and lower the 
logP value. 
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Figure 13.  Chemical optimization of VU10010 using a diversity-oriented approach to 
achieve soluble, centrally penetrant M4 positive allosteric modulators.  A.  β-aminoamide 
as a potential P-gp liability in series 1 and cyclization strategy to diminish this liability in 
series 2.  B.  Solution phase parallel synthesis of libraries of VU10010 analogs.  
Commercial heterocyclic carboxylic acids 3 (X, Y = C or N) were coupled to 12 different 
amines (HNR1R2, 4) to afford focused VU10010 analog libraries 5-13 in yields ranging 
from 15% to 99%.  C.  Generic structures of analogs of VU10010 evaluated in the 
chemical lead optimization program in an effort to develop soluble, centrally penetrant 
M4 positive allosteric modulators.  Syntheses performed by T.M. Bridges and J.P. 
Kennedy. 
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Screening Paradigm for Analog Libraries  
 As observed with positive allosteric modulators of Class C GPCRs, SAR around 
VU10010 was relatively flat, possibly due to a shallow binding pocket (Lindsley et al., 
2004; Zhao et al., 2007).  An EC20 triage screen, employing a functional, fluorescence-
based Ca2+ assay in CHO-K1 cells stably co-expressing the rat M4 mACh receptor and 
the chimeric G protein, Gqi5, (Fig. 14) quickly eliminated all VU10010 analogs except 
those in library 5.  Within library 5, all aliphatic and non-benzyl amides were inactive, 
and only benzyl and heteroaryl methyl congeners of VU10010, 5a-5p, retained M4 PAM 
activity (Table 5).  Analogs were synthesized as described in the methods section 
(Chapter II).  To identify compounds that potentiated agonist activation of M4, we 
determined the response to an EC20 concentration of ACh in the absence and presence of 
test compound.  The potency of each compound was determined by pre-incubating cells 
with vehicle or increasing concentrations of test compound followed by the addition of an 
EC20 concentration of ACh to yield concentration-response curves (CRCs).  Subtle 
substitution changes on the arene ring lost activity 5-10-fold in terms of M4 EC50 and/or 
fold-shift of the ACh CRC (Table 5).  For instance, 5d, in which the 4-Cl moiety of 
VU100010 is moved to the 3-position results in a loss in potency of over 9-fold (EC50 = 
3.7 µM).  Similarly, the unsubstituted phenyl congener 5a retains M4 PAM activity (EC50 
= 630 nM), but the fold-shift diminishes to 8.6-fold, versus the 47-fold shift observed for 
VU10010 (Shirey et al., 2008).  In general, functionalized benzyl amides and pyridyl 
methyl congeners (5f and 5g) were well tolerated, providing selective M4 PAMs with 
EC50 values ranging from 380 nM to 3.7 µM and with fold-shifts of the ACh dose-
response curve from 8.6- to 70-fold (Table 5).   
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Figure 14.  Screening paradigm for analog libraries 5-13 allowing for the rapid triage of 
inactive analogs.  A representative library of 61 analogs from library 5 (Fig. 13C) were 
tested at a single concentration (10 µM) for their ability to potentiate an EC20 
concentration of ACh in CHO-K1 cells stably co-expressing the rM4 mAChR and the 
chimeric G protein, Gqi5.  Calcium mobilization was measured using a Flexstation II, as 
described in Methods (Chapter II).  Of those tested, 16 compounds (denoted by an 
asterisk) were selected for further evaluation.  The response to an EC20 concentration of 
ACh alone is shown in the bar on the far left and this level of activity is indicated by the 
solid line spanning the panel.  Thus, test compounds increasing the % max ACh response 
above this level were considered potentiators of the rM4 mAChR.  VU10010 was 
included as a positive control.  Bars represent the mean ± S.E.M. of 3 or more 
determinations, each performed in duplicate.  Experiments performed by A.E. Brady. 
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Table 5.  Structures, activities, and ACh CRC fold-shifts of M4 PAM library 5 analogs. 
N S
NH2
O
HN
R
Library 5
5a 0.63
5b 0.83
5c 1.83
5d 3.70
5e 2.63
5e 2.04
5f 2.88
5g 1.44
5h 1.80
5i 2.96
5j 3.04
5k 0.88
5l 1.12
5m 0.72
5n 0.40
5o 0.38
F
F
F
OMe
O
O
CF3
Br
Cl
N
N
F
Cl
OCF3
F
F
F
8.6
11.8
ND
ND
ND
ND
ND
ND
ND
ND
70.1
29.7
13.7
ND
ND
ND
Compound           R             rat M4 EC50      rat M4 ACh
                                                   (µM)                fold-shift
EC50s and fold-shifts are an average of at least 3
determinations; ND, not determined.  
Subtle substitution changes on the arene ring lost 5-10-fold in terms of M4 EC50 and/or 
fold-shift of the ACh CRC.  For instance, 5d, in which the 4-Cl moiety of VU100010 is 
moved to the 3-position results in a loss in potency of over 9-fold (EC50 = 3.7 µM).  
Similarly, the unsubstituted phenyl congener 5a retains M4 PAM activity (EC50 = 630 
nM), but the fold-shift diminishes to 8.6-fold, versus the 47-fold shift observed for 
VU10010 (Shirey et al., 2008).  Compounds 5o (VU0152099) and 5p (VU0152100) 
retained M4 PAM activity comparable to VU10010 (EC50 values of 403 ± 117 nM and 
380 ± 93 nM, respectively). 
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VU0152099 and VU0152100 are Potent Positive Allosteric Modulators of M4 in two 
independent in vitro assays 
 
 Two compounds were selected for further evaluation of their ability to potentiate 
the M4-mediated calcium response.  VU0152099 (5o, Fig. 15A) and VU0152100 (5p, 
Fig. 15D) retained M4 PAM activity (EC50 values of  403 ± 117 nM and 380 ± 93 nM, 
respectively) comparable to VU10010, and in the absence of an ACh EC20, neither 
VU0152099 nor VU0152100 elicited a response (Fig. 15B, E).  We next determined the 
effects of maximal concentrations of each compound on the CRC of ACh.  Cells were 
pre-incubated with a fixed concentration (0.1 - 30 µM) of test compound and 
subsequently stimulated with increasing concentrations of ACh.  Both VU0152099 and 
VU0152100 induced a dose-dependent leftward shift of the ACh CRC with maximal 
shifts of 30-fold observed with 30 µM VU0152099 (Fig. 15C) and 70-fold observed with 
10 µM VU0152100 (Fig. 15F). 
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Figure 15.  VU0152099 and VU0152100 are potent positive allosteric modulators of rM4 
in vitro.  Chemical structures of VU0152099 (A.) and VU0152100 (D.).  B.,E.  Potency 
of VU0152099 (403 ± 117 nM, B.) and  VU0152100 (380 ± 93 nM, E.) was evaluated at 
the rM4 receptor by measuring calcium mobilization in Chinese hamster ovary (CHO) 
cells stably expressing rM4 and the chimeric G-protein, Gqi5.  A range of concentrations 
of test compound was added to cells, followed 1.5 minutes later by addition of an EC20 
concentration of ACh.  In the absence of an EC20 concentration of ACh, neither test 
compound elicited a response. Data were normalized as a percent of the maximal 
response to 10 µM ACh and represent the mean ± S.E.M. of three independent 
experiments.  C.,F.  VU0152099 (C.) and VU0152100 (F.) potentiate the response of 
rM4 to ACh, as manifest by a dose-dependent leftward shift in the ACh CRC.  At the 
highest concentrations tested, VU0152099 (30 µM) induced a 30-fold shift and 
VU0152100 (10 µM) induced a 70-fold shift in the ACh CRC.  Data were normalized as 
a percent of the maximal response to 10 µM ACh and represent the mean ± S.E.M. of 3-5 
independent experiments.  Experiments performed by A.E. Brady. 
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 Using calcium mobilization to assess the functional activity of VU0152099 and 
VU0152100 at the M4 receptor requires co-expression of the chimeric G protein, Gqi5, in 
order to link the Gi/o-coupled M4 receptor to the PLCβ/Ca2+ pathway.  As an alternative 
approach to measure M4 PAM activity, we chose to take advantage of a novel functional 
assay recently developed in our lab that takes advantage of the ability of endogenous Gβγ 
subunits of Gi/o-coupled GPCRs to alter the kinetics of G-protein regulated inwardly 
rectifying K+ (GIRK) channels to conduct the ion, thallium (Niswender et al., 2008).  For 
these studies, HEK293 cells stably co-expressing heteromeric GIRK1/2 channels and the 
human M4 muscarinic receptor were pre-incubated with test compound and then 
stimulated with agonist (ACh) in the presence of thallium ion.  Both VU0152099 and 
VU0152100 dose-dependently potentiated the response to an EC20 concentration of ACh 
with EC50 values of 1.2 ± 0.3 µM and 1.9 ± 0.2 µM, respectively, and increased the 
maximal response to ACh to approximately 130 % (Fig 16A).  As observed in the 
calcium mobilization assays described above, both VU0152099 and VU0152100 (10 µM) 
also enhanced the potency of ACh to induce GIRK-mediated thallium flux, as manifest 
by a robust (~30-fold) leftward shift in the ACh CRC from 77 ± 1.2 nM to 2.09 ± 0.3 nM 
and 2.35 ± 0.5 nM, respectively (Fig 16B).  Taken together, these in vitro studies suggest 
that VU0152099 and VU0152100 are potent positive allosteric modulators that enhance 
the response of the M4 receptor to the endogenous agonist, ACh. 
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Figure 16.  VU0152099 and VU0152100 potentiate GIRK-mediated thallium flux in 
response to ACh in HEK cells expressing the human M4 receptor.  A.  Both VU0152099 
(■) and VU0152100 (▲) potentiate hM4 -induced GIRK-mediated thallium flux in 
response to an EC20 concentration of ACh with potencies of 1.2 ± 0.3 μM and 1.9 ± 0.2 
μM, respectively.  B.  In the presence of 10 μM VU0152099 (▲) and VU0152100 (▼), 
the ACh CRC for induction of GIRK-mediated thallium flux was leftward shifted (≈30-
fold) from 77 ± 1.2 nM (■ Veh) to 2.09 ± 0.3 nM (▲, VU0152099) and 2.35 ± 0.5 nM 
(▲, VU0152099).  Data were normalized as a percent of the maximal response to 10 μM 
ACh and represent the mean ± S.E.M. of 3-4 independent experiments performed in 
quadruplicate.  Experiments performed by A.E. Brady. 
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VU0152099 and VU0152100 are selective for M4 relative to other mAChR subtypes 
 We next evaluated VU0152099 and VU0152100 in calcium mobilization assays 
for effects at all mAChR subtypes to determine whether these compounds are selective 
for M4.  Both VU0152099 and VU0152100 were selective for M4 relative to M1, M2, M3 
and M5.  Thus, neither VU0152099 (Fig. 17A) nor VU152100 (Fig. 17B) had any effect 
on the ACh dose-response curves at these other mAChR subtypes at concentrations up to 
30 µM.  To further assess selectivity of these compounds for M4 relative to other 
potential targets, the activity of VU0152099 and VU0152100 also were evaluated in 
radioligand binding assays against a large panel of 68 discrete GPCRs, ion channels, 
transporters and enzymes (Table 6).   These compounds were largely inactive at each of 
the targets in this panel screen.  At concentrations of 10 µM, both compounds were 
completely inactive at most targets and induced less than 50% displacement of binding 
for all targets tested, with the single exception of  GABAA receptors (assessed by 
flunitrazepam binding), where VU0152099 displayed 51% displacement.  This suggests 
that VU0152099 may interact with the flunitrazepam site with an IC50 value of 
approximately 10 µM, which still provides high selectivity for M4 relative to GABAA 
receptors. 
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Figure 17.  VU0152099 (A.) and VU0152100 (B.) are functionally selective for the M4 mAChR 
subtype relative to other mAChRs.  No shift in the ACh CRC was observed in the presence of 30 
μM test compound at CHO-K1 cells stably expressing rM1, hM2-Gqi5, hM3, or hM5.  Calcium 
mobilization was measured in response to increasing concentrations of ACh following 
preincubation with either vehicle or test compound (30 μM), as described in Methods.   Assays of 
rM1, hM3, and hM5, took advantage of endogenous coupling to Gq proteins, and for hM2, cells co-
expressing the chimeric G protein, Gqi5, to allow coupling of this receptor to calcium 
mobilization.  Points represent the mean ± S.E.M. of three independent experiments.  
Experiments performed by A.E. Brady. 
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Table 6. Selectivity of VU0152099 and VU0152100 determination in radioligand 
binding assays in the LeadProfilingScreen® by MDS Pharma. 
 
Target Species VU0152099 VU0152100 Target Species VU0152099 VU0152100
Adenosine A1 human 28 -1 Histamine H3 human 10 9
Adenosine A2 human 46 43 Imidazoline I2, Central rat 7 8
Adenosine A3 human 28 40 Interleukin IL-1 mouse -19 -4
Adrenergic α1A rat 10 9 Leukotriene, Cysteinyl CysLT1 human -4 -6
Adrenergic α1B rat -7 -7 Melatonin MT1 human 15 20
Adrenergic α1D human 1 1 Muscarinic M1 human -3 0
Adrenergic α2A human 7 17 Muscarinic M2 human -1 -4
Adrenergic β1 human 17 17 Muscarinic M3 human -1 -2
Adrenergic β2 human 30 35 Neuropeptide Y Y1 human 2 9
Androgen (testosterone)AR rat 6 6 Neuropeptide Y Y2 human -2 2
Bradykinin B1 human 13 1 Nicotinic Acetylcholine human 6 -6
Bradykinin B2 human -5 -9 Nicotinic Acetylcholine α1, Bungarotoxin human -10 -4
Calcium channel L-type, benzothiazepine rat 13 7 Opiate δ (OP1, DOP) human 2 -13
Calcium channel L-type, dihydropyridine rat 21 17 Opiate κ (OP2, KOP) human 5 2
Calcium channel N-type rat -8 -4 Opiate μ (OP3, MOP) human 2 -2
Dopamine D1 human 6 7 Phorbol Ester mouse 2 4
Dopamine D2S human 2 0 Platelet Activating Factor (PAF) human 13 22
Dopamine D3 human -1 5 Potassium Channel [KATP] hamster 3 6
Dopamine D4.2 human -13 -11 Potassium Channel hERG human 5 5
Endothelin ETA human -8 -8 Prostanoid EP4 human 15 7
Endothelin ETB human 2 -4 Purinergic P2X rabbit 6 -4
Epidermal Growth Factor (EGF) human 9 -5 Purinergic P2Y rat 15 14
Estrogen ERα human -1 -1 Rolipram rat 36 29
G protein-coupled receptor GPR103 human -3 -4 Serotonin (5-Hydroxytryptamine) 5-HT1A human 2 2
GABAA Flunitrazepam, central rat 51 43 Serotonin (5-Hydroxytryptamine) 5-HT3 human -2 14
GABAA Muscimol, central rat 6 9 Sigma σ1 human 2 6
GABAB1A human -7 12 Sigma σ2 rat -8 -3
Glucocorticoid human -3 8 Sodium Channel, Site 2 rat 11 20
Glutamate, Kainate rat 3 -15 Tachykinin NK1 human -15 -18
Glutamate, NMDA, Agonism rat 17 22 Thyroid Hormone rat -1 0
Glutamate, NMDA, Glycine rat 3 2 Transporter, Dopamine (DAT) human 27 46
Glutamate, NMDA, Phencyclidine rat 2 3 Transporter, GABA rat 26 13
Histamine H1 human 14 7 Transporter, Norepinephrine (NET) human 34 22
Histamine H2 human 7 10 Transporter, Serotonin (5-Hydroxytryptamine) (SERT) human 0 4
% Inhibition% Inhibition
 
 
 
 
VU0152099 and VU0152100 were tested at 10 µM for orthosteric radioligand 
displacement against a large panel of 68 GPCRs, ion channels, transporters and enzymes 
to ensure a clean ancillary pharmacology profile. 
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 Since VU0152099 and VU0152100 are allosteric modulators of M4, it is possible 
that they have activity at similar allosteric sites on other GPCRs.  If so, this would not be 
apparent in the radioligand binding assays discussed above.  The finding that these 
compounds are completely inactive at other mAChR subtypes makes this less likely since 
M4 is more closely related to the other mAChR subtypes than to other GPCRs.  However, 
to further evaluate the selectivity of VU0152099 for M4 relative to other family A 
GPCRs, we contracted with Millipore Corp. (St. Charles, MO) to determine the effects of 
these compounds on functional responses of a panel of 15 other GPCRs to activation by 
their respective agonists.  For these studies, we chose family A GPCR subtypes that are 
among the closest relatives of mAChRs.  We first determined the effects of VU0152099 
alone on each receptor and found that these compounds had no agonist activity at any 
receptor studied.  We then determined the effects of VU0152099 on full concentration 
response curves of agonists of each of these receptors.  This allows unambiguous 
evaluation of whether the compounds possess antagonist activity (either allosteric or 
orthosteric) or allosteric potentiator activity at these other GPCRs.  Consistent with our 
internal studies, VU0152099 induced a robust potentiation of ACh-induced activation of 
M4, but had no potentiator activity at M1 (Figure 18).  In addition, VU0152099 had no 
allosteric potentiator activity at any of the other GPCR subtypes tested (Figure 18).  The 
only significant activity detected for VU0152099 in this functional panel screen was 
weak antagonist activity at the serotonin 5HT2B receptor (Figure 18).  Together, these 
data suggest that VU0152099 and VU0152100 possess clean ancillary pharmacology 
profiles, which would allow us to pursue the behavioral effects of selective M4 activation 
in vivo. 
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Fig 18.  Millipore GPCR Profiler™ Functional Screen.  Because of the potential liability 
for off-target activity at other class A GPCRs, VU0152099 was evaluated in Millipore’s 
GPCR Profiler™ screen for activity at 16 GPCR targets using a Fluorimetric Imaging 
Plate Reader (FLIPRTetra, Molecular Device Corp).  This cell-based assay relies on 
endogenous expression of the promiscuous G protein, Gα15/16, to couple recombinant 
receptors to calcium mobilization, and uses a two addition protocol to assess agonist, 
antagonist, and allosteric modulator activity.  VU0152099 exhibited no agonist activity at 
any of the targets tested and was found to possess antagonist activity only at the 5HT2B 
receptor (as indicated by an ≈16 fold rightward shift in the agonist CRC in the presence 
of VU0152099).  Potentiator activity was assessed by performing agonist CRCs in the 
absence (vehicle, ▲) or presence (VU0152099, ■) of 10 μM VU0152099. A.  At the 
human M4 mAChR, 10 μM VU0152099 elicits a robust ≈80-fold leftward shift in the 
carbachol CRC (EC50 values: CCh alone ≈800nM, CCh + 10 μM VU0152099 ≈ 10 nM). 
B-P.  Similar CRC curves were generated for additional GPCRs: Muscarinic M1 (B.), 
Adenosine A2B (C.), α1A-, 2A-, 2B-Adrenergic (D-F.), Dopamine D1 ,D2L, D5 (G-I.), 
Histamine H1, H2, H3 (J-L), and Serotonin 5HT1A, 2A, 2B, 2C (M-P.), with no substantial 
shift observed at any other target tested.  All data represent the mean of duplicate 
determinations.  Experiments performed at Millipore. 
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VU0152099 and VU0152100 bind allosterically and increase ACh affinity  
 To further confirm an allosteric mechanism of action by the novel M4 PAMs, we 
evaluated the effect of VU0152099 and VU0152100 on equilibrium radioligand binding 
studies using membranes prepared from cells expressing the rM4 receptor.  We first 
assessed the ability of increasing concentrations of the two M4 PAMs to displace the 
orthosteric radioligand, [3H]NMS (0.1 nM).  Unlike the orthosteric antagonist, atropine, 
which potently inhibited [3H]NMS binding (Ki = 0.54 ± 0.1 nM), neither M4 PAM 
displaced [3H]NMS at concentrations up to 30 µM (Fig. 19A), strongly suggesting that 
VU0152099 and VU0152100 act at a site on the M4 receptor that is distinct from the 
orthosteric binding site.   
 In addition, we evaluated the effect of VU0152099 and VU0152100 on the 
affinity of ACh for the M4 receptor by assessing the ability of an increasing concentration 
of ACh to displace [3H]NMS (0.1 nM) binding in the absence or presence of the M4 
potentiators.  VU0152099 and VU0152100 were found to induce a 20-25 fold leftward 
shift in the potency of ACh to displace [3H]-NMS binding to M4 as manifest by a 
reduction in the ACh Ki from 252 ± 17.9 nM (veh) to 10.4 ± 0.91 nM (VU0152099) and 
12.2 ± 0.49 nM (VU0152100) (Fig. 19B). These data present a possible mechanism 
whereby these compounds could enhance receptor activation by increasing the affinity of 
M4 for acetylcholine, and are in agreement with data previously determined for 
VU10010, where a 14-fold decrease in the ACh Ki was reported (Shirey et al., 2008). 
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Figure 19.  VU0152099 and VU0152100 bind allosterically and increase ACh affinity at 
rM4.  A.  In competition binding studies, neither VU0152099 (■) nor VU0152100 (▲) 
displaced the orthosteric radioligand, [3H]NMS (0.1 nM), at concentrations up to 30 μM.  
However, the orthosteric antagonist, atropine (▲), potently inhibited [3H]NMS binding 
with a Ki of 0.54 ± 0.1 nM.  B.  In the presence of vehicle alone, an increasing 
concentration of ACh displaces [3H]NMS (0.1 nM) binding with a Ki of 252 ± 17.9 nM 
(■).  In the presence of a fixed concentration (10 μM) of VU0152099 or VU0152100, the 
potency of ACh to displace [3H]NMS binding is shifted leftward, yielding Ki values of 
10.4 ± 0.91 nM (▼, VU0152099) and 12.2 ± 0.49 nM (▲,VU0152100), which represent 
a 25-fold and 21-fold shift in ACh potency, respectively.  Data represent the mean ± 
S.E.M. of 3 independent experiments, performed in duplicate.  Experiments performed by 
A.E. Brady. 
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VU0152099 and VU0152100 Exhibit Improved Physiochemical and 
Pharmacokinetic Properties 
 
 Prior to conducting in vivo studies with VU0152099 and VU0152100, 
pharmacokinetic studies were undertaken to assess brain/plasma ratios following 
systemic dosing of these compounds.  In contrast, to the high logP of VU10010 (4.5), 
both VU0152099 and VU0152100 possessed logPs of 3.65 and 3.6, respectively, a full 
order of magnitude less lipophilic than VU10010 (Shirey et al., 2008).  As a 
consequence, both VU0152099 and VU0152100 displayed improved physiochemical 
properties and afforded homogeneous dosing solutions in multiple vehicles acceptable for 
in vivo studies.  Further, we conducted in vivo exposure (brain and plasma) studies in rats 
at the dose of 56.6 mg/kg, i.p.  Both compounds exhibited substantial systemic absorption 
and brain penetration (Fig. 20).  After 56.6 mg/kg ip administration, peak brain 
concentrations for both the compounds were in the range of 3-5 µg/ml.  VU0152100 
(Fig. 20B) was far superior to VU0152099 (Fig. 20A) in terms of brain penetration, as 
evident from AUC (0-∞) values (Table 7).  The AUC brain/AUC plasma ratio, which is 
an estimate of CNS bioavailability, for VU0152099 was calculated to be 0.39 ± 0.01, 
while the ratio for VU0152100 was determined to be 0.86 ± 0.08 (Table 7).  The half-life 
of the compounds in the brain was 1.25 ± 0.02 h (VU0152099) and 1.12 ± 0.01 h 
(VU0152100) (Table 7). Therefore, our earlier concern of P-glycoprotein (P-gp) 
transport susceptibility within this series was likely unwarranted, and the lack of central 
activity for VU10010 was most likely due solely to physiochemical properties.   
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Figure 20.  Pharmacokinetic profiling of VU0152099 and VU0152100 in rats.  
Concentration-time profile of VU152099 (A.) and VU152100 (B.) in brain (■) and 
plasma (▲) of male Sprague Dawley rats following a 56.6 mg/kg ip administration of 
each compound.  Blood and brain tissue were collected at 0.5, 1, 2 and 4h after injection.  
Samples were extracted as described in Methods and analyzed by LC-MS-MS.  Each 
time point represents the mean determination ± S.E.M. of three rats.  Experiments 
performed by S.B. Jadhav and H. Yin. 
 
 
 
Table 7.  Pharmacokinetic analysis of VU0152099 and VU0152100. 
 
PK Parameter  VU0152099  VU0152100  
Mean AUC (0-∞) brain (ng.h/g)  4751.80 ± 666.17  5726.35 ± 694.68  
Mean AUC(0-∞) plasma (ng.h/ml)  11928.00 ± 1472.36  6570.35 ± 235.87  
AUC brain / AUC plasma  0.39 ± 0.01  0.86 ± 0.08  
t1/2 plasma (h)  1.66 ± 0.39  1.62 ± 0.69  
t1/2 brain (h)  1.25 ± 0.023  1.12 ± 0.01  
 
 
AUC(0-∞) and t1/2 values of  VU0152099 and VU0152100 in exposure studies in male 
rats after 56.6 mg/kg intraperitoneal administration are shown.  Values represent mean ± 
SEM (n = 3 rats). 
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VU0152099 and VU0152100 exhibit in vivo activity in rat 
 Previous studies using the M1/M4-preferring muscarinic agonist xanomeline 
produced robust effects in several preclinical models predictive of antipsychotic-like 
activity, including reversal of amphetamine-induced hyperlocomotion in rats (Stanhope et 
al., 2001).  Based on our initial pharmacokinetic studies suggesting that systemic 
administration of VU0152099 and VU0152100 provides robust brain levels of these 
compounds, the effects of VU0152099 and VU0152100 were evaluated in reversing 
amphetamine-induced hyperlocomotion using a dose of 56.6 mg/kg i.p. for each 
compound with a 30 min pretreatment interval.  As shown in Fig. 21A, both VU0152099 
and VU0152100 produced robust decreases in amphetamine-induced hyperlocomotion 
over the time course tested.  In addition, to provide further confirmation that the M4 
PAMs have no effect on baseline levels of motor performance which could complicate 
the interpretation of the amphetamine-induced hyperlocomotion data, we evaluated the 
effects of one of the M4 PAMs, specifically VU0152100, after administration alone on 
performance in the rotorod test (Fig. 21B). As shown, VU0152100 had no effect on 
performance in the rotorod test, even when tested at a dose of 100mg/kg, which was 
higher than that required to observe reversal of amphetamine-induced hyperlocomotion. 
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Figure 21.  VU0152099 and VU0152100 inhibit amphetamine-induced hyperlocomotor activity 
in rats without causing sedation.  (A.) Rats were pretreated for 30 min with vehicle or a 56.6 
mg/kg dose of either VU0152099 or VU0152100 i.p.  Next, all rats received an injection of 1 
mg/kg s.c. of amphetamine and locomotor activity was measured for an additional 60 min.  Each 
point represents the mean of eight-sixteen rats.  The error bars represent ± S.E.M. and are absent 
when less than the size of the point.  Abscissa, time in minutes; ordinate, ambulations or total 
beam breaks per 5 min intervals; *, P < 0.05 versus veh+amphetamine control group, Dunnett's 
test. (B.) Lack of effect of VU0152100 on motor performance on the rotorod. After initial training 
trials, rats were pretreated for 30 minutes i.p. with vehicle or a dose of VU0152100, specifically 
30, 56.6 or 100 mg/kg, and then the time each animal remained on the rotorod was recorded; 
animals not falling off the rotorod were given a maximum score of 85 s. Abscissa, dose of 
VU0152100 in milligrams per kilogram; ordinate, time spent on the rotorod in sec. Each bar 
graph represents the mean of eight-ten rats.  The error bars represent ± S.E.M.  Experiments 
performed by C.K. Jones, A.D. Thompson, and J.U. Heiman. 
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Discussion 
 In recent years, the mAChRs have emerged as potential novel targets for the 
treatment of schizophrenia.  This is based on clinical studies demonstrating efficacy of 
mAChR agonists in treatment of positive symptoms in schizophrenia patients, as well as 
multiple animal studies suggesting that mAChR agonists could be useful in treatment of 
cognitive dysfunction in schizophrenia patients (Bymaster et al., 2002).  Furthermore, a 
growing body of evidence from clinical and animal studies involving pharmacological 
manipulations, post mortem tissue analysis, and brain imaging is consistent with this 
hypothesis (Raedler et al., 2007).  While recent advances suggesting potential utility of 
mAChR activators in treatment of schizophrenia have been exciting, there have been few 
selective pharmacological tools available to fully explore this emerging muscarinic 
hypothesis of schizophrenia.  Unfortunately, previous attempts to develop traditional 
orthosteric agonists that are highly selective for individual mAChR subtypes have been 
unsuccessful.   
 The current discovery and optimization of VU0152099 and VU0152100 as highly 
selective positive allosteric modulators of M4 provides a major advance in establishing a 
new approach for developing highly selective activators of these receptors.  The data 
presented provide further support for the ability to achieve high subtype selectivity by 
targeting allosteric sites and provide exciting new data demonstrating that highly 
selective M4 PAMs have robust activity in at least one animal model that is similar to 
effects previously described for the non-selective orthosteric mAChR agonist, 
xanomeline (Stanhope et al., 2001).  The finding that VU0152099 and VU0152100 
mimic effects of xanomeline in an animal model that has been used to predict 
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antipsychotic activity of new compounds is especially exciting in light of clinical studies 
demonstrating the clinical efficacy of xanomeline in schizophrenia patients.  This raises 
the exciting possibility that selective activation of M4 may provide a novel approach for 
the treatment of some symptoms associated with schizophrenia. Furthermore, the 
discovery of systemically active M4 PAMs suggests that this will be a viable approach for 
developing selective activators of M1 and other mAChR subtypes.  
 While the in vitro data for VU0152099 and VU0152100 indicate high 
pharmacologic selectivity for M4 relative to any other mAChR subtypes or closely related 
GPCRs, the possibility exists that the observed behavioral effects may be due to an off-
target activity not yet identified. In future studies, it will be critical to further validate that 
the effects of VU0152099 and VU0152100 observed in vivo are mediated by activation 
of M4 using other tools, including structurally distinct M4 PAMs or selective M4 
antagonists, as they become available, and/or M4 knockout mice. Unfortunately, studies 
in M4 knockout mice will be complex since these mice display fundamentally different 
responses to psychomotor stimulants and compounds will need to be optimized for 
appropriate pharmacokinetic properties in mice.  Also, several behavioral parameters are 
substantially altered in the M4 knockout mice, including increases in baseline locomotor 
activity, altered responses to amphetamine, and altered dopamine release in the 
mesolimbic dopamine circuitry (Gomeza et al., 1999; Gomeza et al., 2001; Tzavara et al., 
2004).  These factors will complicate interpretation of studies with M4 knockout mice.  
However, while it is not possible to definitively establish an exclusive role for M4 in 
mediating the behavioral effects observed here, previous studies have established similar 
effects of structurally distinct mAChR agonists (Stanhope et al., 2001).  This, coupled 
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with the high selectivities of VU0152099 and VU0152100 for M4 relative to any other 
mAChR subtype, suggests that M4 is a likely candidate for mediating these effects.  Also, 
extensive profiling of VU0152099 and VU0152100 showed no functional effects on 
responses to other closely related family A GPCRs and no significant off-target activity 
at any of 68 other GPCRs, ion channels, or enzymes.  Thus, while it is impossible to 
entirely rule out unknown off-target activity, these compounds appear to be much more 
highly selective for the targeted receptor than is typical for most orthosteric GPCR 
ligands.  As new tools become available for targeting M4 and other mAChR subtypes, 
they will provide the means to develop a more complete understanding of the roles of 
each of the individual mAChR subtypes in regulating CNS function.   
  In addition to suggesting the potential roles of M4 in vivo, these data have 
important implications related to the molecular pharmacology of allosteric modulators of 
GPCRs.  One of the most promising properties of allosteric modulators of GPCRs has 
been that it is often possible to achieve high selectivity for a targeted GPCR subtype 
relative to closely related family members (Marino et al., 2003; O'Brien et al., 2003; 
Kinney et al., 2005; Galici et al., 2006).  However, discovery of these compounds also 
raises the question of whether allosteric modulators may have broad activity across other 
GPCRs by interacting at potentially promiscuous allosteric sites.  The present finding that 
VU0152099 and VU0152100 had no major activities across multiple targets in a large 
panel radioligand binding screen was encouraging in suggesting the high selectivity of 
these compounds, but does not address this critical question.  However, the finding that 
these compounds had no allosteric modulator activity across a panel of 15 other family A 
GPCR subtypes is exciting and suggests that they are not likely to have activity at a site 
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that is shared across multiple GPCRs.  While it is impossible to rule out activity at other 
unidentified targets that were not tested, these data suggest that it may be possible to 
achieve higher subtype selectivity across a range of receptors than has been possible with 
many orthosteric ligands. 
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CHAPTER IV 
 
A SELECTIVE ALLOSTERIC POTENTIATOR OF THE M1 MUSCARINIC 
ACETYLCHOLINE RECEPTOR INCREASES ACTIVITY OF MEDIAL 
PREFRONTAL CORTICAL NEURONS AND RESTORES IMPAIRMENTS IN 
REVERSAL LEARNING 
 
 
Introduction 
 The muscarinic acetylcholine (ACh) receptors (mAChRs) play important roles in 
regulating higher cognitive function.  Non-selective mAChR antagonists induce profound 
attention and memory deficits (Aigner et al., 1991; Fibiger, 1991; Miller and Desimone, 
1993)  and degeneration of forebrain cholinergic neurons is one of the earliest 
pathological changes observed in AD (Bartus et al., 1982; Bartus, 2000).  Furthermore, 
acetylcholinesterase inhibitors (AChEIs) have established efficacy in the treatment of AD 
symptoms (Birks, 2006; Munoz-Torrero, 2008). 
 Of the five mAChR subtypes, the M1 receptor is viewed as the most important 
subtype for memory and attention mechanisms (Levey et al., 1991; Felder et al., 2000).  
Based on this, selective activators of M1 have been proposed as having potential utility in 
treatment of AD (Bodick et al., 1997b; Bodick et al., 1997a; Gu et al., 2003; Caccamo et 
al., 2006; Jones et al., 2008; Caccamo et al., 2009).  However, recent studies revealed that 
genetic deletion of M1 does not alter mAChR excitatory effects on hippocampal 
pyramidal cells (Rouse et al., 2000a), impair hippocampal-dependent learning, or alter 
cognition-impairing effects of mAChR antagonists (Miyakawa et al., 2001; Anagnostaras 
et al., 2003).  Interestingly, while hippocampal-dependent learning was intact, M1 
receptor knockout mice had specific deficits in forms of learning and memory that 
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require activation of the prefrontal cortex (PFC) (Anagnostaras et al., 2003).  Thus, M1 
may play a role in regulating PFC function, and M1 receptor-selective activators could 
improve deficits in PFC-dependent learning in patients suffering from AD. 
 Unfortunately, lack of highly selective activators and antagonists of the M1 
receptor has prevented detailed studies of the functional consequences of selective M1 
receptor activation.  The difficulty in developing highly selective M1 agonists is due to 
the high sequence homology among the orthosteric binding sites of mAChR subtypes.  
However, an alternative strategy for achieving high subtype selectivity is targeting 
allosteric binding sites that are distinct from the ACh binding site (Conn et al., 2009a; 
Conn et al., 2009b).  We recently reported discovery of multiple positive allosteric 
modulators (PAMs) of M1 (Marlo et al., 2009).  Furthermore, Ma and colleagues (Ma et 
al., 2009) report evidence that BQCA is a potent and highly selective PAM at the human 
M1 receptor.  Based on these preliminary findings, we synthesized a series of molecules 
related to BQCA and report that BQCA and related compounds are highly selective rat 
M1 PAMs.  These compounds do not interact with the ACh site, but dramatically increase 
the affinity of the M1 receptor for ACh and potentiate the response to orthosteric agonist.  
In addition, activation of the M1 receptor induces an inward current and increases 
excitatory synaptic currents in mPFC layer V pyramidal cells.  Consistent with this, 
BQCA increases firing of mPFC neurons in vivo.  Finally, BQCA reverses deficits in a 
PFC-dependent form of learning and memory in a transgenic mouse model of AD and 
promotes non-amyloidogenic APP processing in vitro.  Together, these data suggest that 
the M1 receptor plays an important role in regulating excitatory drive to the PFC and that 
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selective potentiation of activity at this receptor can reverse deficits in PFC-dependent 
cognitive function. 
 
Results 
 
A panel of 21 compounds related to BQCA has a range of activities as allosteric 
potentiators at the rat M1 mAChR 
   
 Ma et al., (2008) recently reported BQCA as a selective positive allosteric 
modulator (PAM) of the human M1 muscarinic receptor (hM1).  However, GPCR PAMs 
can display species specificity, and the effects of BQCA were not extensively evaluated 
on the rat M1 receptor (rM1).  Thus, in order to determine whether BQCA and related 
compounds have properties needed for use in rodent studies, we synthesized BQCA and a 
panel of 20 structurally related analogs to identify compounds that can act as selective 
PAMs for the rM1 receptor.  Effects of BQCA and related compounds were evaluated by 
measuring effects on calcium mobilization elicited by a submaximal concentration (EC20) 
of ACh (Fig. 22).  Libraries I, II, and III each consisted of seven compounds possessing 
the same N-benzyl substitutions based on either an 8-fluorinated quinolone carboxylic 
acid (Ia-Ig), a quinolone carboxylic acid (IIa-IIg, including BQCA), or a 5,8-
difluorinated quinolone carboxylic acid (IIIa-IIIg) template, respectively (Fig. 22A). The 
activity of test compounds was initially assessed by incubating CHO-K1 cells stably 
expressing the rM1 receptor with fixed concentrations of each compound at 10, 1, or 0.3 
µM (Fig. 22B-D) for 1.5 min prior to the addition of an EC20 concentration of ACh.  
From the panel, four compounds that exhibited robust potentiator activity at 0.3 µM were 
selected for further evaluation based on their structural diversity.  As can be seen in the 
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representative trace, 1 µM BQCA has no effect when added alone, but greatly enhances 
the response to an EC20 concentration of ACh when compared to vehicle.  A maximal 
response to ACh is also shown for comparison (Fig. 22E).  To determine the potency of 
each of these compounds, full concentration response curves (CRCs) were generated by 
pre-incubating rM1 CHO-K1 cells with increasing concentrations of test compound, 
followed 1.5 min later by the addition of an EC20 concentration of ACh (Fig. 23A).  All 
four compounds had similar potencies at rM1 with EC50 values in the 200-400 nM range.  
As a second measure of their ability to potentiate the rM1 receptor-mediated calcium 
response to ACh, rM1 receptor expressing CHO-K1 cells were pre-incubated with a fixed 
concentration (3 µM) of the test compound (or vehicle) and then stimulated with 
increasing concentrations of ACh to generate a series of ACh CRCs.  Each of the four 
test compounds elicited a robust potentiation of the ACh response, as manifest by a 
leftward shift in the ACh CRC (9.5- to 18.6-fold shift, Fig. 23B). 
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Figure 22.  Twenty-one putative M1 receptor PAMs were synthesized and evaluated at 
the rM1 mAChR for their ability to potentiate an EC20 concentration of ACh.  A.  
Synthesis: a. K2CO3, KI, R-Br, DMF, 24 hr. at  r.t., b. LiOH, 9:1 THF:H2O 10 min 120°C 
μwave.  Calcium mobilization was measured using a Flexstation II, as described in 
Methods.  Test compounds were evaluated at fixed concentrations of 10 μM (B.), 1 μM 
(C.), or 0.3 μM (D.) in the presence of an EC20 concentration of ACh.  Four compounds, 
denoted by an asterisk (*) in panel D, were selected for further evaluation based on their 
structural diversity and ability to potentiate an EC20 concentration of ACh at 0.3 μM.  
Data were normalized as a percent of the maximal response to 10 μM ACh and represent 
the mean ± S.E.M. of 3 independent experiments.  D.   A representative calcium trace 
from one experiment shows the effect of 1 µM BQCA on the rM1 receptor response to an 
EC20 concentration of ACh; the response to an EC20 and ECmax concentration of ACh in 
the presence of vehicle are also shown for comparison.  Experiments performed by A.E. 
Brady. 
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Figure 23.  Four of the compounds initially identified as robust M1 potentiators of the 
calcium response were further characterized in vitro at the rM1 mAChR.  A.  Potency of 
each test compound was determined based on its ability to potentiate an EC20 
concentration of ACh, yielding EC50 values of 404 ± 59 nM, VU0238393 (■), 187 ± 39 
nM, VU0238389 (▲), 316 ± 102 nM, VU0238386 (BQCA,▼) and 284 ± 32nM 
VU0238387 (♦).  B.  Test compounds were then evaluated at a fixed concentration of 3 
µM for their ability to shift the potency of an ACh concentration response curve.  ACh 
alone stimulated calcium mobilization with an EC50 value of 2.09 ± 0.43 nM (●).  In the 
presence of each of the four test compounds, a robust leftward shift in the ACh CRC was 
induced resulting in the following EC50 values and fold shift in the ACh curve (in 
parentheses): 0.280 ± 0.164 nM (9.5X), VU0238393 (■), 0.039 ± 0.017 nM (23.2X), 
VU0238389 (▲), 0.142 ± 0.007 nM (16.4X), VU0238386 (BQCA,▼) and 0.107 ± 0.003 
nM (18.6X), VU0238387 (♦).  Data were normalized as a percent of the maximal 
response to 10 µM ACh and represent the mean ± S.E.M. of 3 independent experiments.  
Experiments performed by Ashley Brady. 
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BQCA is a potent and selective positive allosteric modulator of the rat M1 receptor 
in vitro 
   
 Of the molecules tested in this panel screen, BQCA was among the most potent 
and efficacious at potentiating rM1 receptor-mediated responses.  This is consistent with 
its activity at the human receptor (Ma et al., 2009).  Based on this and its favorable 
physiochemical properties, we chose to pursue studies focusing exclusively on BQCA.  
First, we evaluated the potency of BQCA as a positive allosteric modulator of the rM1 
receptor by measuring calcium mobilization in CHO-K1 cells stably expressing this 
receptor.  Cells were incubated with increasing concentrations of BQCA for 1.5 min prior 
to the addition of an EC20 concentration of ACh, yielding a concentration response curve 
for BQCA with an EC50 value of 267 ± 31 nM (Fig. 24A.).  We next determined the 
effect of increasing fixed concentrations of BQCA on the ACh CRC.  Rat M1 CHO-K1 
cells were pre-incubated with a fixed concentration (0.3, 1, and 3 µM) of BQCA and 
subsequently stimulated with increasing concentrations of ACh.  BQCA induced a dose-
dependent leftward shift in the ACh CRC with a maximal shift of 21-fold observed with 
3 µM BQCA (Fig. 24B). 
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Figure 24.  BQCA is a potent positive allosteric modulator of the rM1 receptor in vitro.  
A.  The potency of BQCA was evaluated at the rM1 receptor by measuring calcium 
mobilization in Chinese Hamster Ovary (CHO-K1) cells stably expressing the rM1 
receptor.  Increasing concentrations of test compound was added to cells, followed 1.5 
minutes later by addition of an EC20 concentration of ACh.  BQCA robustly potentiated 
the response to ACh with an EC50 value of 267 ± 31 nM.  B.  The ability of BQCA to 
potentiate the response of the rM1 receptor to ACh is also manifest by a dose-dependent 
leftward shift in the ACh CRC.  ACh alone stimulated calcium mobilization with an EC50 
value of 2.42 ± 0.337 nM (■).  In the presence of increasing fixed concentrations of 
BQCA (0.3 - 3 μM), a robust leftward shift in the ACh CRC was induced, resulting in the 
following EC50 values (fold shift in the ACh curve is shown in parentheses); 0.3 μM (♦) 
= 0.762 ± 0.56 nM (3.3-fold), 1.0 μM (▼) = 0.221 ± 0.079 nM (12-fold), 3 μM (▲) = 
0.123 ± 0.026 nM (21-fold).  Data were normalized as a percent of the maximal response 
to 10 μM ACh and represent the mean ± S.E.M. of 3-4 independent experiments.  
Experiments performed by A.E. Brady. 
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BQCA is functionally selective for the M1 mAChR subtype   
 One of the primary difficulties in developing novel selective ligands for 
muscarinic receptors has been the failure to identify compounds that can distinguish 
between the highly conserved orthosteric binding site shared by the five members of this 
GPCR subfamily.  Development of ligands that bind to allosteric sites, both potentiators 
and direct acting agonists, has proven to be a practical way to circumvent this issue 
(Conn et al., 2009a; Conn et al., 2009b).  Thus, it was important to determine whether 
BQCA is selective for the M1 mAChR relative to other mAChR subtypes.  We evaluated 
the effect of BQCA on the ACh CRC in calcium mobilization assays at each of the other 
mAChR subtypes.  As shown in Fig. 24B, pre-incubation of rM1 receptor-expressing 
CHO-K1 cells with 3 µM BQCA results in a robust leftward shift in the CRC for ACh.  
However, at this same concentration, BQCA had no effect on the ACh concentration 
response curves generated in CHO-K1 cells stably expressing the hM2, hM3, rM4, or hM5 
receptors (Fig. 25A-D).  To further assess selectivity of BQCA for the M1 receptor 
relative to other class A GPCR targets that may also harbor similar allosteric sites, we 
took advantage of the GPCR Profiler™ service offered by Millipore Corp. (St. Charles, 
MO) to determine the effect of this compound on the functional response of 15 other 
closely related GPCRs (Fig. 26).  A two-addition protocol afforded the ability to detect 
potential agonist, potentiator, and antagonist activity of BQCA at these other GPCR 
subtypes.  Consistent with our internal studies, BQCA induced robust potentiation at the 
hM1 receptor, but had no activity in this assay at the hM4 receptor.  Moreover, BQCA had 
no effect at any of the other GPCRs tested (Fig. 26A-P).  This included a lack of PAM 
activity or antagonist activity (either allosteric or orthosteric) at any of these other 
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GPCRs, which would have resulted in a rightward shift in the concentration response 
curve.  Together, these data suggest that BQCA is highly selective for the M1 mAChR 
subtype and has no detectable activity at closely related family A GPCRs that were 
tested. 
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Figure 25.  The presence of BQCA has no effect on the ACh concentration-response 
curve at any other mAChR subtype.  No shift in the ACh CRC was observed in the 
presence of 3 μM BQCA in CHO-K1 cells stably expressing M2-Gqi5 (A.), M3 (B.), M4-
Gqi5 (C.), or M5 receptors (D.).  Calcium mobilization was measured in response to 
increasing concentrations of ACh following preincubation of cells with either vehicle (■) 
or 3 μM BQCA (▲), as described in Methods. Data represent the mean ± S.E.M. of three 
independent experiments.  Experiments performed by A.E. Brady. 
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Figure 26.  Millipore GPCR Profiler BQCA selectivity data.  To confirm that BQCA retains 
selectivity at M1 when assayed at non-mAChR GPCRs, it was evaluated in Millipore’s GPCR 
Profiler™ screen for activity at 15 additional Class A GPCR targets.  A Fluorimetric Imaging 
Plate Reader (FLIPRTetra), (Molecular Device Corp), was used to measure calcium mobilization in 
response to agonist stimulation in a proprietary cell line that relies on endogenous expression of 
the promiscuous G protein, Gα15/16, to couple recombinant receptors to the PLCβ/Ca2+ pathway.  
This assay takes advantage of a two addition protocol such that it was possible to detect any 
agonist, antagonist, or allosteric potentiator activity.  BQCA exhibited no agonist or antagonist 
activity at any of the targets tested.  Allosteric potentiator activity was assessed by performing 
agonist concentration response curves in the absence (vehicle, ▲) or presence of 10 µM test 
compound (BQCA, ■).  A.  At the human M1 mAChR, 10 µM BQCA elicits a robust leftward 
shift in the carbachol concentration-response curve.  B-P.  Similar CRC curves were generated 
for additional GPCRs: Muscarinic M4 (B.), Adenosine A2B (C.), α1A-, 2A-, 2B-Adrenergic (D-F.), 
Dopamine D1 ,D2L, D5 (G-I), Histamine H1, H2, H3 (J-L), and Serotonin 5HT1A, 2A, 2B, 2C (M-P), 
with no detectable leftward shift in the agonist concentration-response-curve observed at any 
other target tested.  All data represent the mean of duplicate determinations. 
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BQCA does not compete for orthosteric antagonist binding and it induces a robust 
leftward shift in ACh affinity at the rM1 receptor 
 
 We previously reported that novel selective PAMs of the rM4 receptor, 
exemplified by VU10010 and VU152100, have no detectable affinity at the orthosteric 
ACh binding site of the rM4 receptor but allosterically increase affinity of ACh for the 
rM4 receptor (Brady et al., 2008; Shirey et al., 2008).  To determine whether BQCA 
shares this property with the rM4 PAMs, we assessed the ability of this compound to 
compete for binding with the orthosteric radioligand, [3H]-NMS (0.1 nM) to the 
orthosteric site using membranes prepared from cells expressing the rM1 receptor.  BQCA 
had little effect on [3H]-NMS binding, with no displacement of radioligand observed at 
concentrations up to 10 µM (Fig. 27A).  In contrast, the orthosteric antagonist, atropine, 
potently inhibited [3H]-NMS binding with a Ki value of 1.35 ± 0.022 nM (Fig. 27A).  
The effect of BQCA on the affinity of ACh for the rM1 receptor was also evaluated by 
assessing the ability of increasing concentrations of ACh to displace [3H]-NMS (0.1 nM) 
binding in the absence or presence of fixed concentrations of the M1 receptor potentiator 
(0.3, 1.0, and 3.0 µM).  BQCA induced a robust concentration-dependent leftward shift in 
the concentration response curve of ACh-induced displacement of [3H]-NMS binding to 
the rM1 receptor, with a 30-fold shift observed at the highest concentration tested (3.0 
µM). This shift reveals that BQCA induces a reduction in the ACh Ki from 1700 ± 96.4 
nM (vehicle) to 348 ± 43.4 nM (0.3 µM), 163 ± 22.9 nM (1.0 µM), and 56.1 ± 4.99 nM 
(3.0 µM), respectively (Fig. 27B). Taken together, these data strongly suggest that BQCA 
acts at a site on the rM1 receptor that is distinct from the orthosteric binding site and that 
it may enhance M1 receptor activation by increasing the affinity for ACh.  
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Fig 27.  BQCA does not compete for orthosteric antagonist binding and it induces a 
robust leftward shift in ACh affinity at the rM1 receptor.  A.  At concentrations up to 10 
μM, BQCA (■) did not displace the orthosteric radioligand, [3H]-NMS (0.1 nM) in 
competition binding studies.  However, the orthosteric antagonist, atropine (▲), potently 
inhibited [3H]-NMS binding with a Ki of 1.35 ± 0.022 nM.  B.  In the presence of vehicle 
alone, an increasing concentration of ACh displaces [3H]-NMS (0.1 nM) binding with a 
Ki of 1700 ± 96.4 nM (■).  In the presence of increasing fixed concentrations (0.3 - 3.0 
μM) of BQCA, the potency of ACh to displace [3H]-NMS binding is shifted leftward, 
yielding Ki values of 348 ± 43.4 nM (0.3 μM, ▲), 163 ± 22.9 nM (1.0 μM, ▼), and 56.1 
± 4.99 nM (3.0 μM, ●), which represent 5-fold, 10.6-fold and 30.6-fold shifts in ACh 
potency, respectively.  Data represent the mean ± S.E.M. of 3 independent experiments 
performed in duplicate.  Experiments performed by A.E. Brady. 
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Activation of the M1 receptor induces an inward current in rat mPFC layer V 
pyramidal cells and this effect is potentiated by BQCA 
 
 Prefrontal cortical function is required for higher executive function, memory 
storage and retrieval, and cognition (Miller and Cohen, 2001).  Recent studies suggest 
that M1 receptor signaling may play an important role in activation of the prefrontal 
cortex by lower brain regions (Anagnostaras et al., 2003).  Based on this, it was 
postulated that activation of the M1 receptor could increase excitability of mPFC 
pyramidal cells or increase excitatory synaptic drive to these neurons.  In order to 
examine the effects of M1 receptor activation on mPFC pyramidal cells, layer V 
pyramidal neurons were visually identified and membrane currents measured using patch 
clamp recordings in acute coronal slices.  Cell type was confirmed by examining firing 
properties upon depolarizing current injection.  Typical resting membrane potentials of 
these pyramidal neurons were -55 to -65 mV under the conditions used.  Holding current 
was measured in cells voltage clamped at -70 mV during baseline recording, drug 
application, and wash.  Bath application of CCh induced a robust, concentration-
dependent inward current as shown in Fig. 28 (10 µM CCh, 16.55 ± 1.93 pA, n = 4; 100 
µM CCh, 53.14 ± 5.92 pA, n = 4).  Although this CCh–induced inward current is in 
agreement with previously reported studies, it is not known whether this response is 
mediated by the M1 receptor or another mAChR subtype (Krnjevic, 2004; Carr and 
Surmeier, 2007).  However, previous studies suggest that the M1 receptor may not be 
responsible for induction of inward currents in hippocampal CA1 pyramidal cells (Rouse 
et al., 2000a).  Before evaluating the effect of BQCA on this current, we determined the 
effect of VU0255035, the first highly selective M1 receptor antagonist that was recently 
reported (Sheffler et al., 2009), on the CCh-induced inward current.  The M1 receptor 
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antagonist, VU0255035 (10 µM), had no effect on holding current alone but significantly 
blocked the current induced by 100 µM CCh (P = 0.0202, unpaired t-test).  These results 
suggest that the CCh-induced inward current in rat mPFC layer V pyramidal cells is 
largely mediated by activation of the M1 receptor.  If this is the case, we would predict 
that the M1 receptor PAM BQCA should potentiate the CCh-induced inward current.  
Interestingly, BQCA induced a small change in holding current when applied alone 
(21.54 ± 2.42 pA, n = 5, Fig. 28).  In addition, BQCA significantly increased the inward 
current induced by 10 µM CCh (55.07 ± 6.28 pA upon co-application, n = 5, compared to 
10 µM CCh alone, P = 0.0210).  These data are consistent with the hypothesis that 
activation of the M1 receptor induces an inward current in mPFC layer V pyramidal cells 
and that M1 receptor PAMs can induce a marked potentiation of this response. 
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Figure 28.  CCh-induced inward current in mPFC layer V pyramidal cells is reduced by 
M1 receptor antagonist VU0255035 and potentiated by BQCA.  A.  Sample traces from 
single experiments showing the change in holding currents upon drug treatments.  B.  
Activation of mAChRs by CCh causes a dose-dependent inward current as measured in 
voltage clamp mode as a change in holding current (16.55 ± 1.93 pA in the presence of 
10 µM CCh, n = 4; 53.14 ± 5.92 pA with 100 µM CCh, n = 4).  M1 receptor PAM BQCA 
also caused an inward current when applied alone, and significantly increased the effect 
of 10 µM CCh (21.54 ± 2.42 pA change with 10 µM BQCA, n = 5; 55.07 ± 6.28 pA 
when BQCA was co-applied with 10 µM CCh, n = 5, as compared to 10 µM CCh alone, 
P = 0.0210).  The effect of 100 µM CCh was also significantly inhibited by 10 µM M1 
receptor antagonist VU0255035 (11.78 ± 1.90 pA in the presence of antagonist, n = 3, 
compared to 100 µM CCh alone, P = 0.0202).  Sample traces represent experiments from 
single cells, and bars show duration of drug exposure.  All changes in holding current 
were compared to baseline control and are represented as mean ± S.E.M.  Asterisks 
indicate significant differences from control (*, P < 0.05; unpaired t-test). 
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BQCA does not potentiate CCh-mediated inward currents in M1 knockout mice  
 Application of CCh caused a dose-dependent inward current in mPFC layer V 
pyramidcal cells in slices from wild-type (3 µM CCh, 24.0 ± 3.9 pA; 30 µM CCh, 34.4 ± 
5.8 pA; Fig. 29A) and M1 knockout mice (3 µM CCh, 2.1 ± 1.2 pA; 30 µM CCh, 6.1 ± 
2.0 pA; 100 µM CCh, 42.0 ± 10.5 pA Fig. 29B) but had much lower potency in slices 
from knockout animals.  While BQCA alone (10 µM) induced a slight inward current in 
wildtype cells (17.9 ± 6.0 pA), it induced a much smaller change in holding current in M1 
knockout cells (9.1 ± 1.9 pA);  co-application of BQCA with 3 µM CCh increased the 
inward current induced by this low concentration of CCh (35.2 ± 9.9 pA).  In contrast, 
BQCA did not potentiate the response to 30 µM CCh in M1 knockout slices (3.5 ± 1.2 
pA).  Because of the limited availability of knockout animals during this time, 
experiments testing the ability of atropine or the M1 antagonist, VU0255035, to block the 
inward current caused by 100 µM CCh were not performed.  While this critical control is 
necessary for conclusive interpretation of these data, trends in the dose response to CCh 
between wildtype and M1 knockout animals imply that the M1 subtype mediates, at least 
in part, the CCh-induced inward current.  While the slight response to BQCA (Fig. 29B) 
in knockout animals is somewhat worrisome, holding current stability throughout the 
duration of these experiments is highly variable and futher controls to test the 
significance of this response will be required. 
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Figure 29.  BQCA does not potentiate CCh-mediated inward currents in M1 knockout 
mice.  Application of CCh caused a dose-dependent inward current in mPFC layer V 
pyramidcal cells in slices from wild-type (3 µM CCh, 24.0 ± 3.9 pA; 30 µM CCh, 34.4 ± 
5.8 pA) and M1 knockout mice (3 µM CCh, 2.1 ± 1.2 pA; 30 µM CCh, 6.1 ± 2.0 pA; 100 
µM CCh, 42.0 ± 10.5 pA) but had much lower potency in slices from knockout animals.  
While BQCA alone (10 µM) induced a slight inward current in wildtype cells (17.9 ± 6.0 
pA), it induced a much smaller change in holding current in M1 knockout cells (9.1 ± 1.9 
pA);  co-application of BQCA with 3 µM CCh increased the inward current induced by 
this low concentration of CCh (35.2 ± 9.9 pA).  In contrast, BQCA did not potentiate the 
response to 30 µM CCh in M1 knockout slices (3.5 ± 1.2 pA). 
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mAChR activation increases mPFC spontaneous EPSC amplitude and frequency   
 It is also possible that activation of the M1 receptor could increase activity of 
excitatory synaptic inputs to the mPFC and that this could contribute to the postulated 
role of this receptor in increasing PFC activity from in vivo studies in M1 receptor 
knockout mice (Anagnostaras et al., 2003).  Thus, we determined the effect of mAChR 
activation on spontaneous excitatory postsynaptic currents (sEPSCs) in mPFC pyramidal 
cells.  Application of CCh caused a dramatic, concentration-dependent increase in the 
frequency of spontaneous EPSCs; the effect of a maximal concentration of 100 µM CCh 
on one representative cell is shown in Fig. 30A.  Cumulative probability plots of 
amplitude and inter-event interval from the same cell demonstrate significant shifts in the 
presence of 100 µM CCh that are reversible upon wash (Fig. 30B).  The concentration-
response relationships for CCh effects on sEPSC amplitude and frequency are shown in 
Fig. 30C.  A concentration of 10 µM CCh was without effect (97.5 ± 4.4% control for 
amplitude, 90.1 ± 12.4% control for frequency, n = 6); however, 30 and 100 µM CCh 
increased both amplitude and frequency (30 µM amplitude, 108.3 ± 3.9%, frequency, 
455.0 ± 101.9% control, n = 7; 100 µM amplitude, 154.3 ± 46.2%, 887.6 ± 268.5% 
control for frequency, n = 5).  The effects of 30 µM CCh on both amplitude and 
frequency were completely blocked by the non-selective muscarinic antagonist, atropine 
(5 µM, 102.9 ± 7.8% and 104.4 ± 19.6% control, respectively, n = 3) indicating that the 
effect of CCh was due to activation of mAChRs. 
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Figure 30.  Muscarinic receptor activation increases mPFC spontaneous EPSC amplitude and 
frequency.  A.  Representative traces from one cell showing the effect of a maximal concentration 
of 100 µM CCh.  B.  Change in cumulative probability plots of sEPSC amplitude (top panel) and 
inter-event interval (bottom panel) upon addition and wash of 100 µM CCh from one 
representative cell.  C.  Averaged amplitude and frequency show that CCh treatment induces a 
dose-dependent increase in both sEPSC amplitude and frequency which is reversible upon 
washout and is inhibited by 5 µM atropine  (amplitudes, 10 µM CCh, 97.5 ± 4.4%, n = 6, P = 
0.2727; 30 µM CCh, 108.3 ± 3.9%, n = 7, P = 0.0498; 100 µM CCh, 154.3 ± 46.2%, n = 5, P = 
0.2393; 5 µM atropine/30 µM CCh, 102.9 ± 7.8% of control, n = 3, P = 0.5365.  30 µM CCh vs. 
5 µM atropine/30 µM CCh, P = 0.4478; frequencies, 10 µM CCh, 90.1 ± 12.4%, P = 0.9364; 30 
µM CCh, 455.0 ± 101.9%, P = 0.0139; 100 µM CCh, 887.6 ± 268.5%, P = 0.0314; 5 µM 
atropine/30 µM CCh, 104.4 ± 19.6% of control, P = 0.6260.  30 µM CCh vs. 5 µM atropine/30 
µM CCh, P = 0.0458).  All changes in amplitude and frequency were compared to baseline 
control and are represented as mean ± S.E.M.  Asterisks indicate significant differences from 
control or between conditions (*,P < 0.05; paired or unpaired t-test). 
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The effect of CCh on sEPSC amplitude and frequency is inhibited by VU0255035   
 To further evaluate the role of the M1 receptor in the effect of CCh on sEPSCs, 
slices were treated with the selective M1 receptor antagonist VU0255035 (5 µM) for 2 
min. prior to addition of 30 µM CCh (Fig. 31A, B).  VU0255035 alone decreased sEPSC 
amplitude (92.9 ± 3.4% control, n = 11), and amplitude was further decreased by co-
application with 30 µM CCh (87.1 ± 3.5% control, Fig. 31C).  Antagonist alone had no 
effect of sEPSC frequency (114.1 ± 25.8% control) but caused a significant decrease in 
frequency in the presence of CCh (62.5 ± 10.1% control, Fig. 31C).  These data suggest 
that the CCh-induced increase in sEPSC amplitude and frequency is mediated by 
activation of the M1 receptor.  The reversal of the CCh effect on sEPSC frequency in the 
presence of the M1 receptor antagonist suggests that blocking the M1 receptor unmasks an 
inhibitory action of CCh that may be mediated by another mAChR subtype, possibly M2 
or M4 receptors. 
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Figure 31.  The effect of CCh on sEPSC amplitude and frequency is inhibited by VU0255035.  
A.  Sample traces from one cell showing lack of effect of 30 µM CCh in the presence of the M1 
receptor antagonist VU0255035.  B.  Cumulative probability plots of sEPSC amplitude and 
frequency from the same cell.  C.  Averaged (n = 11) amplitude and frequency.  The increase in 
sEPSC amplitude and frequency induced by 30 µM CCh was reversed by 5 µM VU0255035 
(amplitudes, 5 µM VU0255035, 92.9 ± 3.4%, P = 0.0338; 5 µM VU0255035 + 30 µM CCh, 87.1 
± 3.5%, P = 0.0026; antagonist alone vs. with CCh, P = 0.0350; frequencies, 5 µM VU0255035, 
114.1 ± 25.8%, P = 0.4543; 5 µM VU0255035 + 30 µM CCh 62.5 ± 10.1% of control, P = 
0.0357; antagonist alone vs. with 30 µM CCh, P = 0.0161).  All changes in amplitude and 
frequency were compared to baseline control and are represented as mean ± S.E.M.  Asterisks 
indicate significant differences from control or between drug conditions (*, P < 0.05; **, P < 
0.01; ***, P < 0.0001; paired or unpaired t-test). 
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BQCA increases sEPSCs and potentiates the effect of a sub-threshold concentration 
of CCh on sEPSC frequency 
   
 Our results thus far suggest that the M1 receptor is responsible for the CCh-
induced increase in sEPSC frequency; therefore, this response should be potentiated by 
BQCA.  To test this hypothesis, slices were treated with BQCA alone for 2 min. (10 µM) 
prior to addition of 10 µM CCh.  Sample traces and cumulative probability plots are 
shown in Fig. 32A and 32B.  Treatment with BQCA alone did not significantly affect 
sEPSC amplitude, but increased the frequency of events (108.3 ± 6.6% control, 277.0 ± 
97.7% control, respectively, n = 11, Fig. 32C).  Co-application of BQCA and 10 µM 
CCh induced a further increase in sEPSC frequency (994.5 ± 301.5% control), which 
differed significantly from the effect of 10 µM CCh (P = 0.0045, unpaired t-test) (see 
Fig. 30C) or BQCA alone (P = 0.0116, paired t-test).  
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Figure 32.  BQCA increases sEPSCs and potentiates a sub-threshold concentration of CCh to 
increase sEPSC frequency.  A.  Representative traces from one cell showing the effect of 10 µM 
BQCA alone and in the presence of 10 µM CCh.  This concentration of CCh had no significant 
effect on sEPSC amplitude or frequency when applied alone.  B.  Change in cumulative 
probability plots from one representative cell of sEPSC amplitude (top panel) and inter-event 
interval (bottom panel) upon addition of 10 µM BQCA with and without 10 µM CCh.  C.  
Averaged (n = 11) amplitude and frequency.  Neither drug condition elicited a significant effect 
on sEPSC amplitude (10 µM BQCA, 108.3 ± 6.6%, P = 0.5013; 10 µM BQCA/10 µM CCh, 
136.0 ± 15.3% control, P = 0.0524) but significantly increased frequency (10 µM BQCA, 277.0 ± 
97.7%, P = 0.0229; 10 µM BQCA/10 µM CCh, 994.5 ± 301.5% control, P = 0.0045; the effect of 
combined drug treatment vs. 10 µM BQCA alone was significantly different, P = 0.0116).  The 
effect of 10 µM CCh on frequency in the absence and presence of BQCA was also significantly 
different (P = 0.0177).  All changes in amplitude and frequency were compared to baseline 
control and are represented as mean ± S.E.M.  Asterisks indicate significant differences from 
control or between drug conditions (*, P < 0.05; **, P < 0.01; paired or unpaired t-test). 
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CCh and BQCA have no effect on miniature EPSC amplitude and frequency in rat 
mPFC layer V pyramidal cells 
  
 To determine whether the actions of CCh and BQCA require action potential-
dependent EPSCs, we determined the effects of these compounds on miniature EPSCs 
(mEPSCs).  mEPSCs were recorded in voltage clamp mode at a holding potential of -70 
mV and in the presence of 1 µM tetrodotoxin (TTX) to block voltage-gated sodium 
channels.  At this concentration, TTX completely eliminates action potential firing and 
action potential-mediated synaptic activity (Morisset and Urban, 2001).  Under these 
conditions, neither CCh nor BQCA elicited any effect on mEPSC amplitude or 
frequency.  Sample traces from one cell in a slice to which 100 µM CCh was applied in 
the presence of TTX show a clear lack of effect (Fig. 33A).  Cumulative probability plots 
of amplitude and frequency during control, CCh treatment, and wash from the same cell 
overlap (Fig. 33B).  Pooled amplitude and frequency for all drug treatments are 
quantified in Fig. 33C (10 µM CCh, n = 5; 100 µM CCh, n = 4; 10 µM BQCA with and 
without 10 µM CCh, n = 4).  The only significant effect was that of 10 µM CCh, which 
slightly decreased mEPSC amplitude (88.6 ± 3.8% control).  The effects of M1 receptor 
activation on spontaneous EPSCs thus require action potential firing. 
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Figure 33.  CCh and BQCA have no effect on miniature EPSC amplitude and frequency in rat 
mPFC layer V pyramidal cells.  A.  Sample traces from one cell showing the lack of 100 µM CCh 
on mEPSCs in the presence of 1 µM TTX.  B.  Cumulative probability plots for amplitude and 
frequency of miniature excitatory events from the representative cell shown in A.  C.  Averaged 
amplitude and frequency (10 µM CCh, n = 5; 100 µM CCh, n = 4; 10 µM BQCA alone and with 
10 µM CCh, n = 4) of mEPSCs recorded in rat slices.  No increase in either amplitude or 
frequency of events occurred in the presence of low or high CCh, BQCA, or BQCA co-applied 
with CCh (amplitudes, 10 µM CCh, 88.6 ± 3.8%, P = 0.0475; 100 µM CCh, 90.8 ± 9.4%, P = 
0.2592; 10 µM BQCA, 99.1 ± 2.8%, P = 0.9562; 10 µM BQCA/10 µM CCh, 97.6 ± 5.8%, P = 
0.7334; frequencies: 10 µM CCh, 104.6 ± 14.9%, P = 0.8883; 100 µM CCh, 120.4 ± 27.1%, P = 
0.8174; 10 µM BQCA, 95.3 ± 4.3%, P = 0.2105; 10 µM BQCA/10 µM CCh, 111.5 ± 21.6%, P = 
0.6445).  All changes in amplitude and frequency were compared to baseline control and are 
represented as mean ± S.E.M.  Asterisks indicate significant differences from control or between 
drug conditions (*, P  < 0.05; **, P < 0.01; ***, P < 0.0001; paired t-test). 
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BQCA has no effect on sEPSCs in slices from M1 receptor KO mice  
 In order to confirm that the actions of BQCA were mediated by M1 receptor 
activation, recordings of sEPSCs in mPFC layer V neurons were made using slices from 
mice lacking the M1 receptor and compared to wild-type (WT) controls.  Consistent with 
our studies in rat slices, CCh caused a concentration-dependent increase in sEPSC 
amplitude and frequency in WT mice (Fig. 34A left panel, 34D black bars).  While 3 
µM CCh had no effect on amplitude or frequency, 30 µM CCh significantly increased 
both parameters (amplitudes, 3 µM CCh, 102.6 ± 11.7% of control, n = 3; 30 µM CCh, 
143.1 ± 22.0%, n = 5; frequencies: 3 µM CCh, 83.2 ± 47.1%, 30 µM CCh, 398.3 ± 
56.2%).  In contrast to effects in rat slices, BQCA had no effect alone in WT slices (10 
µM BQCA, 97.3 ± 11.3% control amplitude, 99.8 ± 11.3% control frequency, n = 5), but 
induced robust increases in both amplitude and frequency when co-applied with 3 µM 
CCh (137.2 ± 16.7% control amplitude, 500.5 ± 212.3% control frequency).  In slices 
from M1 receptor KO mice, the response to CCh was markedly reduced.  In M1 KO mice, 
CCh decreased sEPSC amplitude at both concentrations tested and induced a more 
modest increase in sEPSC frequency that did not achieve statistical significance 
(amplitudes, 3 µM CCh, 79.4 ± 14.9%, n = 4; 30 µM CCh, 80.7 ± 5.2%, n = 4; 
frequencies, 3 µM CCh, 186.3 ± 187.4%, 30 µM CCh, 271.7 ± 310.4%).  Importantly, the 
response to BQCA was completely absent in slices from M1 receptor KO mice.  Thus, 
BQCA had no effect when applied alone or when co-applied with 3 µM CCh 
(amplitudes, 10 µM BQCA, 96.9 ± 10.6%; BQCA/CCh, 84.5 ± 25.3%, n = 5; 
frequencies, 10 µM BQCA, 101.3 ± 26.1%; BQCA/CCh, 86.6 ± 17.3%).  Responses to 
co-application of BQCA and CCh differed significantly between WT and M1 receptor 
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KO for both sEPSC amplitude and frequency (P = 0.0046 for amplitude; P = 0.0025 for 
frequency, unpaired t-test).  These results confirmed that the actions of BQCA in WT 
mice and rats are due to its action at M1 receptors. 
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Figure 34.  BQCA has no effect and does not potentiate the CCh effect on sEPSCs in M1 
receptor KO mice.  A.  Sample traces from individual cells in slices made from wild-type 
(left panels) and M1 receptor KO mice (right panels)  showing the robust effects of 30 
µM CCh on both sEPSC amplitude in frequency compared to the milder effect in the M1 
receptor KO slice (top panels).  B.  Bottom panels illustrate the lack of effect of 10 µM 
BQCA in both the WT and M1 receptor KO and contrast the increase in amplitude and 
frequency with the addition of BQCA and 10 µM CCh to the lack of effect in the M1 
receptor KO.  C.  Cumulative probability plots of the inter-event intervals from the two 
cells shown in bottom panels above.  D.  Averaged amplitude and frequency of sEPSCs 
measured in wild-type (black bars: 3 µM CCh, n = 3; 30 µM CCh, n = 5; 10 µM BQCA 
and 10 µM BQCA + 3 µM CCh, n = 5) and M1 receptor KO slices (white bars: 3 µM 
CCh, n = 4; 30 µM CCh, n = 4; 10 µM BQCA and 10 µM BQCA + 3 µM CCh, n = 5).  
In wild-type slices, 3 µM CCh had no significant effect on amplitude or frequency (102.6 
± 11.7%, P = 0.6381 and 83.2 ± 47.1% of control, P = 0.4423, respectively) whereas 30 
µM CCh increased both (143.1 ± 22.0%, P = 0.0306 for amplitude, 398.3 ± 56.2%, P = 
0.0342 for frequency).  BQCA had no effect on amplitude or frequency but potentiated 
the response to 3 µM CCh (amplitudes, 10 µM BQCA, 97.3 ± 11.3%, P = 0.7642 
compared to control; 10 µM BQCA/3 µM CCh, 137.2 ± 16.7%, P = 0.0052 compared to 
control; frequencies, 10 µM BQCA, 99.8 ± 11.3%, P = 0.7261 compared to control; 10 
µM BQCA/3 µM CCh, 500.5 ± 212.3%, P = 0.0209 compared to control).  In M1 
receptor KO slices, 3 µM CCh decreased amplitude but had no significant effect on 
frequency (79.4 ± 14.9%, P = 0.0490 and 186.3 ± 187.4% of control, P = 0.7656, 
respectively).  30 µM CCh also significantly decreased amplitude and increased 
frequency although the effect on frequency was less dramatic than that seen in WT 
controls (80.7 ± 5.2%, P = 0.0092 for amplitude, 271.7 ± 310.4%, P = 0.6010 for 
frequency).  While the difference between the 30 µM CCh effect on amplitude was 
significant between genotypes (P = 0.0229), the effect on frequency was not (P = 
0.4756).  BQCA had no effect alone in KO slices (amplitude, 96.9 ± 10.6%, P = 0.4925; 
frequency, 101.3 ± 26.1%, P = 0.7286) and there was no difference in this lack of effect 
between genotypes (amplitude, P = 0.9596; frequency, P = 0.9133).  When applied with 
3 µM CCh, BQCA had no significant effect on amplitude or frequency (amplitude, 84.5 ± 
25.3%, P = 0.3383; frequency, 86.6 ± 17.3 %, P = 0.1388 compared to KO control), and 
both effects were significantly different those in WT slices (P = 0.0046 for amplitude, P 
= 0.0025 for frequency).   All changes in amplitude and frequency were compared to 
baseline control and are represented as mean ± S.E.M.  Asterisks indicate significant 
differences from control or between drug conditions (*, P < 0.05; **, P < 0.01; ***, P < 
0.0001; paired or unpaired t-test). 
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BQCA achieves brain penetration after systemic admistration  
 The studies outlined above suggest that BQCA could be an excellent tool for 
probing M1 receptor function.  Furthermore, based on these and previous studies, it is 
possible that BQCA could enhance mPFC activity and enhance PFC-dependent cognitive 
function.  However, before using BQCA for in vivo studies, it was critical to determine 
whether this compound had a pharmacokinetic (PK) profile suitable from systemic 
dosing and whether it crossed the blood brain barrier.  Thus, we performed a PK analysis 
of BQCA after systemic dosing.  BQCA was measured at multiple time points in both 
plasma and brain after i.p. injection in rats (Fig. 35 and Table 8).  BQCA is slowly but 
very significantly absorbed into systemic circulation with maximum concentration (~10 
µg/ml) being achieved 2 h after i.p. administration.  The compound is rapidly taken up 
into the brain and achieves a maximal brain concentration between 30 min and 1 hr after 
dosing.  Furthermore the brain concentration is maintained at a stable level for 
approximately 4 hr.  While the brain concentrations are significantly lower when 
compared to plasma concentrations (Fig. 35 and Table 8), BQCA possesss an acceptable 
PK profile and brain penetration to allow use for in vivo studies of effects this compound 
on CNS function. 
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Figure 35.  Pharmacokinetic profiling of BQCA in rats.  Concentration-time profile of 
BQCA in brain and plasma of male Sprague Dawley rats following 10 mg/kg ip 
administration.  Blood and brain tissue were collected at 0.5, 1, 2, 4 and 8 h after dosing.  
Samples were extracted as described in Methods and analyzed by LC-MS-MS (Chapter 
II).  BQCA is characterized by significant absorption into and slow elimination from 
systemic circulation after intraperitoneal administration.  Although the compound is 
rapidly and significantly taken up into the brain, the brain concentrations are rapidly 
eliminated when compared to plasma concentrations.  Each time point represents the 
mean determination ± S.D. of three rats.  Experiments performed by S.B. Jadhav and U. 
Menon. 
 
 
Table 8.  Pharmacokinetic Analysis of BQCA 
 
PK Parameter Plasma Brain 
        
Cmax (ng/mL) 10017.31 ± 1562.77 1181.65 ± 224.43 
Tmax (h)  2   1  
Elimination T1/2 (h)  3.33   2.04  
AUC (0-8) (ng.h/mL) 52344.03± 2382.63  4797.28 ± 388.81  
V/F (L/kg)  0.72   n.d.  
Vss/F (L/Kg)   0.83   n.d.  
Cl/F (L/h/kg)  0.149   n.d.  
 
 
The pharmacokinetic parameters of BQCA in exposure studies in male rats after 10.0 
mg/kg intraperitoneal administration are shown.  AUC (0-8) Brain/AUC (0-8) Plasma = 
0.091.  Values represent mean ± S.E.M.  (n = 3 rats).  (n.d., not determined). 
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BQCA increases the firing rate of mPFC neurons in vivo in rats   
 Having established the PK profile and CNS penetration of BQCA, we performed 
in vivo electrophysiology studies to test the hypothesis that the electrophysiological 
effects observed on mPFC neurons in vitro can lead to increases in activity of mPFC 
neurons in behaving animals.  To accomplish this, multiple single-unit recordings were 
obtained from the mPFC of rats trained to perform an auditory detection task for food 
reward.  A total of 57 cells (vehicle, n = 20; BQCA, n = 37) with waveform and firing 
rate characteristics consistent with those of putative pyramidal cells were obtained from 6 
rats in the presence of either vehicle or drug (20 mg/kg).  Figure 36 shows the average 
percentage change, relative to a thirty-minute pre-injection epoch, in the spontaneous 
firing rate of mPFC cells following drug or vehicle administration.  Consistent with the 
acute cortical slice data, BQCA caused an elevation in spontaneous firing rate 
significantly different from vehicle (2-way anova: drug vs. vehicle, P < 0.005). 
Significant elevations in firing rate were observed within the first thirty-minute epoch 
following injection and were maintained across the entire hour and a half recording 
period.    
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Figure 36.  BQCA increases the firing rate of mPFC neurons in vivo in rats.  Multiple 
single-unit recordings were obtained from the medial prefrontal cortex of conscious, 
freely moving rats.  A total of 57 cells (vehicle, n = 20, BQCA, n = 37) with waveform 
and firing rate characteristics consistent with those of putative pyramidal cells were 
obtained from 6 rats in the presence of either vehicle or drug (20 mg/kg).  The mean 
firing rate for each neuron within an epoch was calculated as a percent of the pre-
injection baseline rate.  Treatment with BQCA (■) resulted in an elevation in spontaneous 
firing rate that was significantly different from vehicle (▲) (2-way anova; BQCA vs. 
vehicle; P < 0.005) within the first 30 min epoch and was maintained across the entire 
trial period.  Experiments performed by E.P. Christian, J.J. Doherty, M.C. Quirk, and 
D.H. Snyder at AstraZeneca Pharmaceuticals. 
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Acute administration of BQCA restores impairment in reversal learning in Tg2576 
mice 
    
 Recent studies have revealed that mice over-expressing a familial AD mutant 
form of the amyloid precursor protein (Tg2576 mice) are impaired on compound 
discrimination reversal learning compared to littermate controls (Zhuo et al., 2007; Zhuo 
et al., 2008).  Interestingly, reversal learning is a PFC-dependent form of learning, 
suggesting that this mouse model of AD leads to disruption of at least one form of PFC-
dependent cognition.  Based on the finding that M1 receptor KO mice have deficits in 
PFC function (Anagnostaras et al., 2003) and that BQCA increases PFC activity, it is 
possible that this M1 receptor-selective PAM could reverse deficits in compound 
discrimination reversal learning observed in Tg2576 mice.  In agreement with previously 
published reports, we found that Tg2576 mice exhibit impaired performance in a 
compound discrimination reversal learning task (Fig. 37).  Acute administration of 
BQCA improved the performance of the Tg2576 mice on the compound discrimination 
and the compound discrimination reversal task by reducing  the odds that errors would be 
committed, x2 = 23.19 and x2 = 13.03, 1, respectively (P < 0.001, Table 9, Fig. 37C-
D). On the compound discrimination, the odds that vehicle-treated Tg2576 mice made 
errors were 6.89 times greater than the BQCA-treated Tg2576 mice.  Similarly, on the 
compound discrimination reversal, the odds of the vehicle-treated Tg2576 mice to make 
errors were 3.22 times greater than the BQCA-treated Tg2576 mice. There prevalence of 
errors on the simple discrimination or the simple discrimination reversal tasks did not 
significantly differ across groups or treatments.  Overall, the results indicate that BQCA 
improves compound reversal learning which is consistent with hypothesis that M1 
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activation may enhance PFC-dependent cognitive function.  Additionally, BQCA may 
also have more widespread effects on cognition, indicated by the reduction of errors on 
the compound discrimination in BQCA-treated Tg2576 mice, and may be of even 
broader utility in enhancing other domains of cognitive function. 
 
Table 9.  BQCA reverses impairments in discrimination learning in Tg2576 mice 
 
Group 
Simple 
Discrimination
 
Simple 
Discrimination 
Reversal 
Compound 
Discrimination* 
Compound 
Discrimination 
Reversal** 
Wild-type + 
Vehicle 2/9 (22%) 5/9 (55%) 4/9 (44%) 3/9 (33%) 
Wild-type + 
BQCA 3/12 (25%) 6/12 (50%) 5/12 (42%) 4/12 (33%) 
Tg2576 + 
Vehicle 1/8 (12%) 4/8 (50%) 5/8 (62%) 7/8 (87%) 
Tg2576 + 
BQCA 2/11 (18%) 5/11 (45%) 1/11 (9%) 3/11 (27%) 
 
 
    
*χ2 = 23.19, P<0.0001 
** χ2 = 13.03, P<0.001 
 
The frequency of errors on discrimination learning between wild-type and Tg2576 mice 
in the presence of vehicle or BQCA (number of subjects with errors ≥1/total number of 
subjects in group expressed as a percentage). 
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Figure 37.  Effects of acute administration of BQCA on discrimination learning in 
Tg2576 mice.  Errors to reach criterion on a discrimination task were assessed in wild-
type and Tg2576 mice at 12 months of age.  Mice were injected s.c. one hour before 
testing with either saline vehicle or 30 mg/kg BQCA.  Shown are the frequency of errors 
on discrimination learning between wild-type and Tg2576 mice in the presence or 
absence of BQCA. Data are expressed as the number of subjects with errors > 0/total 
number of subjects in the group and expressed as a percentage.  BQCA significantly 
reduced the odds of Tg2576 mice making errors on the compound discrimination and the 
compound discrimination reversal. Chi-square, P < .001 for both compound 
discrimination and compound discrimination reversal.  Experiments performed by 
Michelle Nicolle and Mona Watson, Wake Forest University. 
 
 
 
 
 
207 
 
 
BQCA regulates non-amyloidogenic APP processing   
 The data presented above suggest that BQCA has efficacy in improving at least 
one form of cognitive function in an animal model of AD.  In addition to providing 
symptomatic relief, it has been postulated that increasing M1 receptor activity could also 
have disease modifying effects in AD patients (Fisher, 2008; Caccamo et al., 2009).  The 
amyloid precursor protein (APP) undergoes proteolytic cleavage in two competing 
pathways (Thinakaran and Koo, 2008).  In the amyloidogenic pathway, sequential 
cleavage by β-secretase and γ-secretase releases the Aβ peptide which forms the core of 
amyloid plaques found in AD and is implicated in numerous models of neurotoxicity.  
Alternatively, in the non-amyloidogenic pathway, APP is cleaved by α-secretase within 
the Aβ sequence, preventing Aβ generation.  Interestingly, previous studies suggest that 
activation of M1 promotes APP processing through the non-amyloidogenic pathway 
(Caccamo et al., 2006; Jones et al., 2008).  If BQCA can promote non-amyloidogenic 
processing of APP, this could provide a mechanism for slowing accumulation of Aβ and 
potentially slow progression of AD.   
 In order to determine whether BQCA can potentiate the APP processing effect of 
a low concentration of the mAChR agonist CCh, we treated PC12 cells overexpressing 
human APP and the M1 receptor with an approximate EC20 concentration (50 nM) of 
CCh in the presence of increasing concentrations of BQCA and measured the levels of 
APP metabolites in the conditioned media and cell extracts.  BQCA caused a dose-
dependent increase in the shedding of APPsα, the amino-terminal ectodomain of APP 
released by α-secretase cleavage (Fig. 38A-B).  The highest concentration of BQCA 
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tested (30 μM) increased APPsα levels to 244% of vehicle-treated cells (P < 0.05).  
BQCA treatment also resulted in the accumulation of CTFα (C83), the corresponding 
carboxy-terminal fragment generated by α-secretase (Fig. 38A, C; increased to 245% of 
vehicle, P < 0.05).  Finally, consistent with the observed increases in non-amyloidogenic 
APP fragments, 30 μM BQCA treatment resulted in a 30% decrease (P < 0.01) in the 
secretion of the β-secretase derived Aβ40 peptide (Fig. 38D).  Taken together, these 
results indicate that BQCA can effectively regulate non-amyloidogenic APP processing, 
suggesting that M1 receptor PAMs have the potential to provide both symptomatic and 
disease modifying effects in AD patients. 
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Figure 38.  BQCA regulates non-amyloidogenic APP processing.  A.  Western blot 
analysis of APP metabolites from conditioned media and cell lysates demonstrates 
increased generation of APPsα and CTFα with increasing concentrations of BQCA as 
compared to the submaximal concentration of 50 nM CCh.  10 μM CCh is shown as a 
maximum concentration.  β-actin is shown as a loading control.  B.  Quantitation of 
APPsα band intensity from conditioned media demonstrates a dose-dependent effect of 
BQCA on the shedding of APPsα (repeated measures ANOVA, P = 0.0271), and 
pairwise comparisons revealed significant differences at all concentrations of BQCA 
compared to 50 nM CCh alone (P-values for paired t-tests are shown).  C.  Quantitation 
of CTFα band intensity from cell lysates shows a dose-dependent effect of BQCA on the 
production of CTFα (repeated measures ANOVA, P = 0.0017) and a significant 
difference (paired t-test) between 30 μM BQCA plus 50 nM CCh as compared to 50 nM 
CCh alone.  D.  ELISA measurements from conditioned media demonstrate that BQCA 
decreases the secretion of Aβ40 peptide in a dose-dependent manner (repeated measures 
ANOVA, P = 0.0019), with significant differences between 50 nM CCh alone and the 
two highest concentrations of BQCA (paired t-tests).  Mean values are shown from three 
or four independent experiments performed in duplicate.  All values are normalized to 
vehicle-treated cells.  Experiments performed by Albert Davis, Emory University. 
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Discussion 
 The M1 receptor has long been viewed as an exciting potential target for 
increasing cognitive function in patients suffering from AD and other CNS disorders 
(Wess et al., 2007; Fisher, 2008; Langmead et al., 2008a; Caccamo et al., 2009).  Despite 
major efforts to develop highly selective M1 agonists over the past two decades, this 
receptor has proven intractable using traditional approaches, thus preventing M1 agonists 
from advancing to clinical use for treatment of AD and other disorders.  Also, lack of 
agents that selectively activate this receptor has made it impossible to develop a full 
understanding of the functional effects of selectively increasing M1 receptor activity in 
the CNS.  Discovery and characterization of BQCA and its structural analogs provide a 
major advance in establishing the utility of M1 receptor PAMs as an alternative approach 
to increasing activity of this receptor in a highly subtype-selective manner. 
 Studies with BQCA, along with the new M1 receptor- selective antagonist 
VU0255035, provide important support for the hypothesis that the M1 receptor may 
increase activation of the PFC and may enhance PFC-dependent cognitive function 
(Anagnostaras et al., 2003).  Non-selective mAChR agonists, such as CCh, induce an 
inward current in PFC pyramidal cells, and the present data provide strong evidence that 
this response is mediated by activation of the M1 receptor.  In addition, activation of the 
M1 receptor increases the frequency of spontaneous excitatory synaptic events in mPFC 
layer V pyramidal cells.  While the source of glutamatergic afferents giving rise to these 
sEPSCs has not been established, this is consistent with the hypothesis that the M1 
receptor plays an important role in increasing excitability and excitatory drive to mPFC 
pyramidal cells.    
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 One of the most important implications of these studies is that they raise the 
possibility that highly selective M1 receptor PAMs may provide a novel approach for 
treatment of AD and other CNS disorders that may involve impaired cholinergic 
signaling.  Clinical studies using both direct and indirect-acting muscarinic agonists have 
reported improvements in both cognitive function and behavioral disturbances (i.e. 
hallucinations, delusions, outbursts, and paranoia) observed in AD patients (Bodick et al., 
1997b; Cummings et al., 2001).  If M1 receptor activation is responsible for, or plays an 
important role in, these effects of nonselective cholinergic agents, M1 receptor PAMs 
could provide a viable approach to symptomatic treatment of AD.   Furthermore, in 
addition to potential efficacy in reducing symptoms in AD patients, recent studies suggest 
that mAChR activation could reduce accumulation of toxic Aβ protein, thereby also 
providing disease modifying effects.  For instance, the muscarinic agonist AF102B was 
shown to decrease production of the amyloidogenic peptide Aβ42 in the cerebral spinal 
fluid of AD patients (Nitsch et al., 2000).  Furthermore, preclinical studies with a related 
mAChR agonist, AF267B suggest that mAChR activation increases non-amyloidogenic 
processing and prevents Aβ formation (Caccamo et al., 2006).  While these earlier 
mAChR agonists are not selective for the M1 receptor relative to other mAChR subtypes, 
more recent studies revealed that the M1 receptor-selective agonist, TBPB, has similar 
effects in PC12 cells (Jones et al., 2008).   
 Lastly, it is important to note that recent clinical and animal studies raise the 
possibility that mAChR agonists may also provide a novel approach for treatment of 
schizophrenia (Felder et al., 2001; Langmead et al., 2008a; Conn et al., 2009b).  For 
instance, Shekhar and colleagues (Shekhar et al., 2008) recently reported that the M1/M4 
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receptor–preferring agonist xanomeline induced a robust improvement in positive and 
negative symptoms, as well as some measures of cognitive function, in schizophrenic 
patients.  Based on animal studies, it is likely that both M1 and M4 receptors may be 
important for clinical efficacy in this patient population (Felder et al., 2001; Brady et al., 
2008; Chan et al., 2008; Jones et al., 2008; Langmead et al., 2008b; Langmead et al., 
2008a; Conn et al., 2009b).  Availability of BQCA, along with the new systemically 
active M4 receptor- selective PAM, VU0152100 (Brady et al., 2008) should make it 
possible to evaluate the effects of selective activation of each of these mAChR subtypes 
as well as co-administration of both BQCA and VU0152100 in a range of animal models 
that may be relevant to the antipsychotic effects of xanomeline. 
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CHAPTER V 
 
DISCUSSION AND FUTURE DIRECTIONS 
 
Over the past two decades, major attention has been focused on developing highly 
selective agonists of specific mAChR subtypes to use as research tools in order to achieve 
a better understanding of the roles of each subtype in specific organ systems and also to 
develop therapeutic agents that lack the adverse effects of AChE inhibitors and 
nonselective muscarinic agents.  We now report the discovery of a novel series of 
compounds that act as robust positive allosteric modulators (allosteric potentiators) of the 
M4 and M1 mAChR subtypes.  Unlike traditional agonists, these small molecules do not 
bind to the orthosteric ACh binding site, but instead act at a distinct site to potentiate 
activation of the receptor by its natural ligand, ACh.  This is directly analogous to the use 
of benzodiazepines as selective GABA receptor PAMs, which provide an effective and 
safe approach to the treatment of anxiety and sleep disorders without inducing the 
potentially lethal effects of direct-acting GABAA receptor agonists (Mohler et al., 2002).  
While allosteric modulators of ion channels are well established as research tools and 
therapeutic agents, they have not been a traditional focus of drug discovery efforts for 
GPCRs.  The discovery of VU10010 and related M4 PAMS as well as M1 PAM BQCA 
adds to recent major advances in developing highly selective allosteric modulators of 
mAChRs (Chan et al., 2008; Ma et al., 2009; Marlo et al., 2009) and other GPCRs (May 
et al., 2007; Conn et al., 2009a).  These compounds are highly selective for each targeted 
receptor subtype with no detectable functional activity at other mAChRs.  As with 
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previously discovered allosteric potentiators of metabotropic glutamate receptors 
(mGluRs), the novel PAMs of M1 and M4 receptors reported here have no detectable 
affinity for the orthosteric site when examined in competition radioligand studies at 
equilibrium (Brady et al., 2008; Shirey et al., 2008; Shirey et al., 2009).  The action of 
these compounds at a site that is distinct from the highly conserved orthosteric ACh 
binding site is likely to be critical for achieving this high degree of subtype selectivity. 
In addition to providing advantages in terms of achieving high selectivity for an 
individual mAChR subtype, it is possible that the mechanism of action of these 
compounds could provide other properties that are ultimately advantageous for 
developing therapeutic agents.  Positive allosteric modulators of M1 and M4 mAChRs 
described here do not activate the receptor directly but induce a dramatic potentiation of 
the response to activation by ACh.  This could provide an advantage to traditional 
agonists by amplifying endogenous cholinergic signaling for a specific mAChR subtype 
and thereby maintaining a level of activity dependence of receptor activation.  
Interestingly, the majority of clinically useful drugs that activate other neuromodulatory 
systems exert more subtle actions rather than serving as direct-acting receptor agonists.  
For instance, serotonin reuptake inhibitors have been highly successful in treatment of 
depression, whereas highly effective serotonin receptor agonists have not been 
successfully developed.  For anxiety disorders, it is likely that direct acting GABAA 
receptor agonists would have a narrow therapeutic window and would be lethal.  In 
contrast, benzodiazepines are selective allosteric potentiators of GABAA receptor 
chloride channels and are safe and highly effective in the clinic.  Dopamine receptor 
agonists are used but exert more profound acute adverse effects than indirect acting 
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agents such as L-DOPA, amphetamine, and methylphenidate (Ritalin).  Interestingly, 
highly selective allosteric potentiators of different mGluR subtypes have robust effects in 
animal models used to predict efficacy in treatment of multiple CNS disorders, including 
schizophrenia, anxiety disorders and Parkinson’s disease (Marino et al., 2003; Kinney et 
al., 2005; Galici et al., 2006).  Furthermore, a highly selective allosteric potentiator of the 
calcium-sensing receptor (a family III/C GPCR), termed Sensipar, has now received FDA 
approval for use in treatment of hyperparathyroidism (Dong, 2005).  As with the current 
M1 and M4-selective allosteric potentiators, the key to achieving high selectivity for these 
receptors has been the targeting of sites that are distinct from the highly conserved 
orthosteric neurotransmitter binding site.  These advances with allosteric potentiators of 
family III/C GPCRs along with the present findings raise the possibility that discovery of 
highly selective and robust allosteric modulators of specific mAChR subtypes and other 
family I/A GPCRs will provide an exciting new approach for the discovery and 
development of novel research tools and therapeutic agents that target this important class 
of signaling proteins.  However, discovery of these compounds also raises the question of 
whether allosteric modulators may have broad activity across other GPCRs by interacting 
at potentially promiscuous allosteric sites.  The present finding that novel mAChR PAMs 
have no major activities across multiple targets in a large panel radioligand binding 
screen was encouraging, but does not address this critical question.  The finding that 
these compounds had no allosteric modulator activity across a panel of other family A 
GPCR subtypes is exciting and suggests that they are not likely to have activity at a site 
that is shared across multiple GPCRs.  While it is impossible to rule out activity at other 
unidentified targets, these data suggest that it may be possible to achieve higher subtype 
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selectivity across a range of receptors than has been possible with many orthosteric 
ligands. 
Interestingly, the M1 and M4 PAMs reported here increase affinity of ACh for the 
orthosteric site.  This is similar to previous reports of allosteric modulators of GPCRs 
acting by altering affinity of ligands at the orthosteric site; the magnitude of binding 
cooperativity or the shift in orthosteric agonist affinity is referred to as the alpha factor 
(Christopoulos and Kenakin, 2002).  However, while M4 PAM VU10010 apparently acts 
in part by increasing ACh affinity, the magnitude of this effect was only a 14-fold 
increase in ACh affinity whereas VU10010 induced an almost 50-fold shift in the ACh 
concentration response curve for activating calcium mobilization, Chapter IIIA (Shirey 
et al., 2008).  Thus, effects on agonist binding cannot fully account for the allosteric 
potentiator activity measured in the functional assay; potentiation by this compound must 
also increase efficacy and coupling to downstream effectors.  The present data suggest 
that VU10010 acts by both increasing ACh affinity and activation of G proteins and 
downstream signaling pathways.  Studies of the effects of VU10010 on [35S]GTPγS 
binding in cells expressing rat M4 revealed a 10-fold shift in ACh potency; this value is 
close to the calculated shift in ACh affinity at the orthosteric site, suggesting that the 
increase in ACh affinity could account for the shift in ACh potency by increasing G 
protein activation.  However, VU10010 also increased the maximal ACh-induced 
[35S]GTPγS binding response, suggesting that this potentiator increases the efficiency of 
M4 coupling to G proteins.  These two factors together likely contribute to the robust shift 
in ACh potency for inducing calcium mobilization relative to more modest shift observed 
in ACh affinity.  In contrast, radioligand binding studies examining the effect of BQCA 
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on M1 receptor affinity for ACh revealed that the fold-shift decrease in ACh Ki induced 
by BQCA was around 30-fold, whereas the shift in the functional calcium response was 
21-fold (Shirey et al., 2009).  The increase in affinity for agonist could therefore fully 
account for the potentiation of calcium mobilization by M1.  This demonstrates the 
possibility that different allosteric modulators may induce varying degrees of receptor 
affinity for orthosteric agonists and downstream effector signaling. 
A notion that complicates interpretation of selectivity data as discussed above is 
the possibility of binding of an allosteric modulator to an off-target GPCR without a 
detectable functional consequence.  Because radioligands that bind to allosteric sites of 
mAChRs and other GPCRs have not yet been developed (with the exception of mGluR5), 
it is difficult to assess binding at these sites using traditional equilibrium experiments.  It 
is possible, however to determine if allosteric ligands affect the affinity of orthosteric site 
ligands.  For example, VU10010 and BQCA did not compete for orthosteric [3H]-NMS 
binding but induced a leftward shift in the ACh competition curve (Chapters IIIA and 
IV, (Shirey et al., 2008)).  While VU10010 did not compete for [3H]-NMS binding in 
membranes from cells expressing any mAChR subtype, its effects on ACh affinity at off-
target receptor subtypes were not determined.  This will be one critical experiment that 
should be performed with novel allosteric modulators to assess their binding to off-target 
receptors.  Another related experimental approach that may useful in screening for 
compounds that only bind to a targeted mAChR or other GPCR involves examining 
neutral allosteric binding to off-target receptors or receptor subtypes.  With the newly 
available panel of allosteric modulators (and in the case of M1, allosteric agonists such as 
TBPB) of mAChRs, it is now possible to detect neutral allosteric binding to these 
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receptors.  This is an important area of exploration as no neutral allosteric modulators 
have been reported for mAChRs to date. 
 Discovery of selective allosteric modulators of mAChRs provides an 
unprecedented opportunity to develop a more detailed understanding of the functional 
roles of these receptors in neural circuits that are heavily modulated by cholinergic 
innervation.  One of the most important roles of cholinergic systems in the CNS is 
modulation of transmission through the hippocampal formation, a limbic structure that 
plays a critical role in learning and memory that is thought to be important for cholinergic 
regulation of cognitive function.  Activation of mAChRs in the hippocampus induces a 
marked reduction of transmission at both excitatory glutamatergic and inhibitory 
GABAergic synapses by presynaptic reduction of neurotransmitter release (Valentino and 
Dingledine, 1981; Bilkey and Goddard, 1985; Fernandez de Sevilla and Buno, 2003).   
Multiple mAChR subtypes are expressed in the hippocampus, and evidence suggests that 
both M2 and M4 are localized in presynaptic terminals where they could regulate 
excitatory and inhibitory synaptic transmission (Levey et al., 1995; Rouse et al., 1999; 
Rouse et al., 2000a).  In addition, evidence suggests that activation of postsynaptic 
mAChRs on hippocampal pyramidal cells that express M1 and M4 could reduce synaptic 
transmission in the hippocampus by inducing release of endocannabinoids that activate 
presynaptic CB1 cannabinoid receptors (Ohno-Shosaku et al., 2003).  Thus, the specific 
mAChR subtypes involved in regulating transmission at these important synapses is not 
clear.  The finding that VU10010 potentiates effects of mAChR agonists on excitatory 
but not inhibitory synaptic transmission provides strong evidence that M4 is one of the 
mAChR subtypes responsible for regulating transmission at glutamatergic synapses in the 
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hippocampus but is not likely to be involved in regulation of transmission at inhibitory 
synapses in this brain region (Chapter IIIA, (Shirey et al., 2008)).  This selective 
regulation of excitatory synaptic transmission is a first critical step in developing a 
detailed understanding of the roles of M4 in modulating hippocampal function.   Although 
a growing body of literature implicates M1 receptors in many of the excitatory 
postsynaptic effects of mAChR activation and in long-term plasticity (both LTP and 
LTD) in the hippocampus and cortex, many of these studies have relied on compounds 
that are not subtype selective or on studies employing knockout mice where 
compensatory mechanisms can complicate data interpretation.  In future studies, it will be 
critical to take advantage of these novel selective allosteric potentiators to further 
investigate the roles of M1 and M4 in hippocampus as well as other cortical and basal 
ganglia structures where mAChRs have been postulated to play a critical 
neuromodulatory role.  For instance, if the M1 receptor subtype does mediate the 
excitatory postsynaptic effects of muscarinic agonists (depolarization, blockade of spike 
frequency adaptation and afterhyperpolarization currents, etc.), these effects of CCh 
should be blocked by the selective M1 antagonist VU0255035 and should be mimicked 
by M1 agonists. Likewise, M1 agonists and PAMs should induce or modulate 
hippocampal LTP and LTD if this receptor subtype is responsible for the effects of CCh 
and ACh on these forms of long-term plasticity. 
 The M1 receptor has long been viewed as an exciting potential target for 
increasing cognitive function in patients suffering from AD and other CNS disorders 
(Wess et al., 2007; Fisher, 2008; Langmead et al., 2008a; Caccamo et al., 2009).  Despite 
major efforts to develop highly selective M1 orthosteric agonists over the past two 
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decades, this receptor has proven intractable using traditional approaches, thus preventing 
M1 agonists from advancing to clinical use for treatment of AD and other disorders.  
Also, lack of agents that selectively activate this receptor has made it impossible to 
develop a full understanding of the functional effects of selectively increasing M1 
receptor activity in the CNS.  Studies with BQCA, along with the new M1-selective 
antagonist VU0255035 (Sheffler et al., 2009), provide important support for the 
hypothesis that the M1 receptor may increase activation of the PFC and may enhance 
PFC-dependent cognitive function (Anagnostaras et al., 2003).  Non-selective mAChR 
agonists, such as CCh, induce an inward current in PFC pyramidal cells, and the present 
data (Chapter IV) provide strong evidence that this response is mediated by activation of 
the M1 receptor.  In addition, activation of the M1 receptor increases the frequency of 
spontaneous excitatory synaptic events in mPFC layer V pyramidal cells.  While the 
source of glutamatergic afferents giving rise to these sEPSCs has not been established, 
this is consistent with the hypothesis that the M1 receptor plays an important role in 
increasing excitability and excitatory drive to mPFC pyramidal cells.  It is also unclear 
thus far whether depolarization of glutamatergic pyramidal cells in cortical circuits 
underlies the increase in sEPSCs induced by CCh, or if these are two separate and 
unrelated phenomena.      
 Interestingly, mAChR activation induces direct excitatory effects in hippocampal 
CA1 pyramidal cells that are similar to those observed in mPFC pyramidal cells.  
However, while CA1 pyramidal cells express high levels of the M1 receptor (Levey et al., 
1991), previous studies suggest that the M1 receptor is not the mAChR subtype 
responsible for some of the excitatory effects on these cells (Rouse et al., 2000a).  Thus, 
221 
 
the precise physiological roles of the M1 receptor are likely to vary in different brain 
regions and neuronal populations.  The finding that M1 receptor activation has excitatory 
effects and increases excitatory synaptic activity in mPFC pyramidal cells is interesting in 
the context of the recent finding that M1 receptor knockout mice display clear deficits in 
PFC-dependent learning (Anagnostaras et al., 2003), whereas hippocampal-dependent 
learning is largely unaffected in M1 receptor knockout mice (Anagnostaras et al., 2003) 
and in animals treated with the M1 receptor- selective antagonist VU0255035 (Sheffler et 
al., 2009).  
 One of the most important implications of these studies is that they raise the 
possibility that highly selective M1 receptor PAMs may provide a novel approach for 
treatment of AD and other CNS disorders that involve impaired cholinergic signaling.  
Clinical studies using both direct and indirect-acting muscarinic agonists have reported 
improvements in both cognitive function and behavioral disturbances (i.e. hallucinations, 
delusions, outbursts, and paranoia) observed in AD patients (Bodick et al., 1997b; 
Cummings et al., 2001).  If M1 receptor activation is responsible for, or plays an 
important role in, these effects of nonselective cholinergic agents, M1 receptor PAMs 
could provide a viable approach to symptomatic treatment of AD.   Furthermore, in 
addition to potential efficacy in reducing symptoms in AD patients, recent studies suggest 
that mAChR activation could reduce accumulation of toxic Aβ protein, thereby providing 
additional disease modifying effects.  For instance, the muscarinic agonist AF102B was 
shown to decrease production of the amyloidogenic peptide Aβ42 in the cerebral spinal 
fluid of AD patients (Nitsch et al., 2000).  Furthermore, preclinical studies with a related 
mAChR agonist, AF267B suggest that mAChR activation increases non-amyloidogenic 
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processing and prevents Aβ formation (Caccamo et al., 2006).  While these earlier 
mAChR agonists are not selective for the M1 receptor relative to other mAChR subtypes, 
more recent studies revealed that the M1 receptor-selective agonist, TBPB, has similar 
effects in PC12 cells (Jones et al., 2008).   
 The present finding that BQCA reverses deficits in compound discrimination 
reversal learning in a transgenic mouse model of AD provides exciting support for the 
hypothesis that highly selective M1 receptor PAMs may provide efficacy in treatment of 
at least some domains of cognitive function in AD (Chapter IV).  Furthermore, the 
finding that BQCA promotes non-amyloidogenic APP processing suggests that these 
agents could also reduce amyloid burden.  In future studies, it will be important to fully 
explore the effects of BQCA in animal models that reflect other domains of cognitive 
function that are impaired in AD patients.  For instance it is possible that M1 receptor-
selective PAMs will have robust efficacy in improving PFC-dependent learning, but have 
lesser effects on hippocampal-dependent learning.  A mouse model of AD with 
impairments in hippocampal-dependent memory tasks could be used to test whether 
BQCA could restore performance in the Morris water maze or in other forms of spatial 
memory that require intact hippocampal functioning.  Also, other types of cognitive 
function may involve different mAChR subtypes and be differentially affected by 
selective activators of the M1 receptor versus selective PAMs of other mAChR subtypes, 
such as the recently reported M4 and M5 receptor-selective PAMs (Brady 2008; Chan 
2008; Shirey 2008; Bridges 2009).  Interestingly, the high subtype-selectivity of BQCA 
may prove to be important for achieving maximal effects in increasing non-
amyloidogenic APP processing.  Previous studies suggest that activation of M2 and/or M4 
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mAChR subtypes may have an antagonistic effect on the non-amyloidogenic APP 
processing shown to be promoted by M1 receptor activation (Farber et al., 1995).  Thus, 
in addition to reducing the adverse effect profile, it is possible that selective activation of 
the M1 receptor may provide greater efficacy in regulating APP processing.   
 In addition to implications for AD, the electrophysiology studies reveal 
interesting findings that may provide important insights related to the potential roles of 
mAChRs in regulating PFC function.  For instance, when added alone, BQCA induced a 
slight inward current and a slight increase in sEPSC frequency (Chapter IV, (Shirey et 
al., 2009)).  This suggests that there may be a low tonic level of M1 receptor activity or a 
low level of endogenous acetylcholine in slices that can be potentiated by BQCA.  
Furthermore, it was interesting to find that CCh induced a small reduction in sEPSC 
frequency when added in the presence of a saturating concentration of the selective M1 
antagonist, VU0255035.  This suggests that activation of another mAChR subtype can 
reduce sEPSC frequency and that this effect is unmasked when the M1 receptor is 
selectively blocked.  To test the hypothesis that this inhibitory effect is mediated by the 
M4 receptor subtype, the selective M4 PAM, VU0152100, could be used alone and in 
combination with a low concentration of CCh.  If this hypothesis were correct, I would 
expect to see a decrease in sEPSCs in the presence of VU0152100 and CCh.  
Interestingly, while effects of CCh on sEPSC frequency were dramatically reduced in M1 
receptor knockout mice, CCh did induce a small effect in slices from these animals.  This 
suggests that another mAChR subtype may be capable of eliciting this response and 
could partially compensate for genetic deletion of the M1 receptor.  Importantly, the 
effect of the highly selective M1 receptor PAM, BQCA, was eliminated in M1 receptor 
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knockout mice, suggesting that the effects of this compound are fully dependent on 
activation of the M1 receptor.  Discovery of new mAChR subtype-selective ligands for 
multiple mAChR subtypes over the last year will allow for a better understanding of the 
roles of mAChR subtypes in regulating PFC function. 
 Recent clinical and animal studies raise the possibility that mAChR agonists may 
provide a novel approach for treatment of schizophrenia (Felder et al., 2001; Langmead 
et al., 2008a; Conn et al., 2009b).  For decades, the prevailing theory behind the etiology 
of schizophrenia has been that excessive dopaminergic neurotransmission in the central 
nervous system is the major contributing factor underlying this severe psychiatric illness. 
This so-called dopamine hyperfunction hypothesis is based primarily on the observation 
that stimulation of the endogenous dopamine system (e.g. with amphetamine or cocaine) 
often leads to transient psychotic symptoms in healthy individuals (Bymaster et al., 2002; 
Raedler et al., 2007).  Furthermore, all clinically relevant antipsychotic drugs, both 
typical and atypical, possess significant antagonist activity at D2 dopamine receptors 
(D2Rs) (Carlsson, 1988; Bymaster et al., 2002; Raedler et al., 2007).  Thus, the majority 
of the efforts to discover novel therapeutic agents for the treatment of schizophrenia have 
been aimed at developing therapies that result in some level of D2R blockade or a 
combination of blockade of D2Rs and other monoamine receptors.  Nevertheless, D2R 
antagonists are only partially effective in treating schizophrenia, in that they only 
improve the positive symptoms associated with the disease, despite the fact that the 
negative and cognitive symptoms also markedly impact the quality of life for 
schizophrenic patients.  In addition, these therapies also are often poorly tolerated 
because of numerous side effects including sedation, weight gain, sexual dysfunction, 
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diabetes and Parkinson’s disease-like symptoms.  Furthermore, greater than 25% of 
schizophrenia patients do not respond to these dopamine-based therapies.  Thus, while it 
is evident that dopamine does play a prominent role in the pathogenesis and treatment of 
schizophrenia, the dopamine hyperfunction hypothesis of schizophrenia fails to account 
for all aspects of this disorder. It is increasingly evident that other neurotransmitter 
systems are likely involved.  Based on this, it is unlikely that exclusive focus on 
discovery and development of antagonists of D2Rs and other monoamine receptors will 
provide fundamental breakthroughs in the standard of treatment of schizophrenia patients 
relative to current therapies.   
 In recent years the mAChRs, namely M1 and M4, have emerged as potential novel 
targets for the treatment of schizophrenia.  This is based on clinical studies demonstrating 
efficacy of mAChR agonists in treatment of positive symptoms in schizophrenia patients, 
as well as multiple animal studies suggesting that mAChR agonists could be useful in 
treatment of cognitive dysfunction in schizophrenia patients (Bymaster et al., 2002).  A 
growing body of evidence from clinical and animal studies involving pharmacological 
manipulations, post mortem tissue analysis, and brain imaging is consistent with this 
hypothesis (Raedler et al., 2007).  Furthermore, Shekhar and colleagues (Shekhar et al., 
2008) recently reported that the M1/M4 receptor–preferring agonist xanomeline induced a 
robust improvement in positive and negative symptoms, as well as some measures of 
cognitive function, in schizophrenic patients.  While recent advances suggesting potential 
utility of mAChR activators in treatment of schizophrenia have been exciting, there have 
been few selective pharmacological tools available to fully explore this emerging 
muscarinic hypothesis of schizophrenia.  Unfortunately, previous attempts to develop 
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traditional orthosteric agonists that are highly selective for individual mAChR subtypes 
have been unsuccessful.   
The recent discovery and optimization of highly selective positive allosteric 
modulators of M1 and M4 provides a major advance in establishing a new approach for 
developing highly selective activators of these receptors.  The data presented provide 
further support for the ability to achieve high subtype selectivity by targeting allosteric 
sites and provide exciting new data demonstrating that highly selective M4 PAMs have 
robust activity in at least one animal model that is similar to effects previously described 
for the non-selective orthosteric mAChR agonist, xanomeline (Stanhope et al., 2001).  
The finding that VU0152099 and VU0152100 mimic effects of xanomeline in an animal 
model that has been used to predict antipsychotic activity (Brady et al., 2008) is 
especially promising in light of clinical studies demonstrating the clinical efficacy of 
xanomeline in schizophrenia patients.  This raises the exciting possibility that selective 
activation of M4 may provide a novel approach for the treatment of some symptoms 
associated with schizophrenia.  Based on animal studies, it is likely that both M1 and M4 
receptors may be important for clinical efficacy in this patient population (Felder et al., 
2001; Gerber et al., 2001; Miyakawa et al., 2001; Marino and Conn, 2002; Messer, 
2002b; Anagnostaras et al., 2003; Bymaster et al., 2003b; Tzavara et al., 2004; Brady et 
al., 2008; Langmead et al., 2008a; Shirey et al., 2008).  Availability of BQCA along with 
the systemically active M4 receptor-selective PAM, VU0152100, should make it possible 
to evaluate the effects of selective activation of each of these mAChR subtypes as well as 
co-administration of both BQCA and VU0152100 in a range of animal models that may 
be relevant to the antipsychotic effects of xanomeline.    
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 In addition to their potential relevance for schizophrenia, mAChRs also are 
thought to regulate motor function by exerting effects on dopaminergic transmission in 
the basal ganglia (Pisani et al., 2007; Raedler et al., 2007).  For instance, multiple 
electrophysiology studies with M4 knockout mice have led to the suggestion that 
activation of the M4 mAChR may oppose some actions of dopaminergic neurons on 
striatal motor function (Calabresi et al., 1998; Sanchez-Lemus and Arias-Montano, 
2006).  Again, the lack of highly selective activators of M4 has made it impossible to test 
this hypothesis directly.  Also, previous studies with traditional orthosteric muscarinic 
agonists bypass the action of endogenous ACh in the basal ganglia and do not provide 
information about the effects of endogenous acetylcholine on motor activity.  The finding 
that highly selective M4 potentiators reverse amphetamine-induced hyperlocomotor 
activity in rats provides exciting new evidence in support of the hypothesis that 
endogenous ACh plays an important role in regulating dopaminergic control of motor 
function.  Because these compounds do not activate M4 directly, but selectively increase 
responses of M4 to endogenous ACh, this provides direct evidence that this response can 
be modulated by endogenous ACh acting on M4 receptors.  In addition, this raises the 
possibility that selective M4 modulators could provide a novel approach to treatment of 
other disorders involving altered dopaminergic function in the basal ganglia, including 
Parkinson’s disease and dystonia.  Ongoing studies in the Conn lab are in fact examining 
the efficacy of M4 PAMS in animal models of these diseases. 
 In conclusion, the recent development of compounds that selectively activate or 
modulate individual mAChRs provides an exciting new opportunity to begin to answer 
questions about the role of these receptors in normal and pathological CNS function.  
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These tools will also allow the further validation of individual mAChR subtypes as 
therapeutic targets for a variety of disorders including AD and schizophrenia.  One 
important aspect of research will include the elucidation of various signaling cascades 
activated by different classes of orthosteric and allosteric ligands.  Preliminary data from 
our lab and others suggests that allosteric agonists of the M1 receptor like TBPB (Jones et 
al., 2008) do not induce β-arrestin recruitment or activate mPFC neurons in the same 
manner as CCh; it will be important to determine whether specific signaling pathways 
like these and ERK1/2 activation are necessary for the therapeutically beneficial effects 
of mAChR activation.  One way to assess the involvement of β-arrestin recruitment in the 
CCh-induced activation of mPFC neurons would be to perform recordings of sEPSCs in 
the presence of CCh using mice lacking the β-arrestin protein.  If this signaling molecule 
is required for the muscarinic activation of mPFC layer V neurons, this effect would 
likely be absent or altered in the β-arrestin knockout mice.  An alternate strategy could 
involve the use of a β-arrestin blocking peptide or antibody in the recording pipet in 
experiments with wildtype mice or rats.  Likewise, a selective, cell permeable MEK 
inhibitor could be used in the recording bath to determine if ERK1/2 phosphorylation is 
required for CCh-induced increase in sEPSCs.   If these experiments yielded data that 
support the involvement of these signaling proteins, this would be one possible 
explanation for the lack of effect of M1 allosteric agonists like TBPB and VU0184670 on 
mPFC neurons since these compounds do not appear to induce β-arrestin recruitment. 
 It will also be interesting to examine the efficacy of PAMs in animal models of 
diseases that involve degeneration of cholinergic nuclei.  Because postsynaptic mAChR 
expression remains largely intact despite the loss of cholinergic input, it has been 
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hypothesized that activation of these remaining postsynaptic receptors will alleviate many 
of the cognitive impairments associated with cholinergic decline (Caccamo et al., 2009).  
While this may be true for direct-acting agonists, it may not be possible to achieve 
therapeutic efficacy using allosteric potentiators that do not directly activate mAChRs.  
Depending on the level of disease progression and cholinergic degeneration, allosteric 
compounds could display a varying array of efficacies.  The recent development of 
selective M1 activators that are suitable for use in clinical trials with patients suffering 
from AD will also allow researchers and clinicians to determine the disease-modifying 
potential of these compounds.  Although initial studies indicating that the M1-preferring 
agonist AF102B decreased levels of Aβ in CSF of AD patients (Nitsch et al., 2000), it 
remains to be seen if sustained, selective M1 activation will have any effect on disease 
progression or pathology in brain tissue of this patient population. 
 Because the M1/M4-preferring agonist xanomeline lacked true subtype selectivity 
and caused dose-limiting side effect associated with activation of peripheral M3 receptors 
(Shekhar et al., 2008), clinical trial assessing the ability of this drug to significantly 
improve the symptoms of schizophrenia were somewhat limited.  However, a growing 
body of literature including studies using knockout mice and initial studies with 
VU0152100, TBPB, and BQCA support the hypothesis that M1 and M4 receptors show 
great promise as therapeutic targets for diseases involving cognitive impairment such as 
AD and schizophrenia.  Whether drugs that selectively activate these receptors will 
provide a more tolerable side-effect profile than that of AChE inhibitors or xanomeline 
remains to be seen.  It will also be critical to determine if selective activation of M1 or M4 
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alone will be sufficient to improve symptoms of schizophrenia in the same manner as 
xanomeline. 
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